Test Summary Sheet for:

8054B Postmortem, Expanded with NPS, Blood (Forensic)

The following test codes are contained in this document:

1. 8054B Postmortem, Expanded with NPS, Blood (Forensic)
2. 50000B Acetaminophen Confirmation, Blood (Forensic)
3. 52250B Alcohols and Acetone Confirmation, Blood (Forensic)
4. 52143B Alfentanil and Sufentanil Confirmation, Blood (Forensic)
5. 52168B Amitriptyline and Metabolite Confirmation, Blood (Forensic)
6. 52239B Amoxapine Confirmation, Blood (Forensic)
7. 52485B Amphetamines Confirmation, Blood (Forensic)
8. 52416B Aripiprazole Confirmation, Blood (Forensic)
9. 52007B Atomoxetine Confirmation, Blood (Forensic)
10. 50011B Barbiturates Confirmation, Blood (Forensic)
11. 52365B Bath Salts Confirmation, Blood (Forensic)
12. 52367B Bath Salts Confirmation, Blood (Forensic)
13. 50012B Benzodiazepines Confirmation, Blood (Forensic)
14. 52443B Benztropine Confirmation, Blood (Forensic)
15. 52245B Brompheniramine Confirmation, Blood (Forensic)
16. 52011B Bupivacaine Confirmation, Blood (Forensic)
17. 52012B Bupropion and Metabolite Confirmation, Blood (Forensic)
18. 52444B Buspirone Confirmation, Blood (Forensic)
19. 52198B Cannabinoids Confirmation, Blood (Forensic)
20. 52015B Carbamazepine and Metabolite Confirmation, Blood (Forensic)
21. 52017B Carisoprodol and Metabolite Confirmation, Blood (Forensic)
22. 52440B Chlorpheniramine Confirmation, Blood (Forensic)
23. 52272B Chlorpromazine Confirmation, Blood (Forensic)
24. 52482B Citalopram Confirmation, Blood (Forensic)
25. 52274B Clomipramine and Metabolite Confirmation, Blood (Forensic)
26. 52435B Clonidine Confirmation, Blood (Forensic)

27. 52023B Clozapine and Metabolite Confirmation, Blood (Forensic)
28. 50014B Cocaine and Metabolites Confirmation, Blood (Forensic)
29. 52445B Cyclobenzaprine Confirmation, Blood (Forensic)
30. 52451B D/L Methorphan, Dextrorphan & Levorphanol Confirmation, Blood (Forensic)
31. 52487B Designer Benzodiazepines Confirmation, Blood (Forensic)
32. 52488B Designer Opioids Confirmation (2017 Scope), Blood
33. 52028B Dicyclomine Confirmation, Blood (Forensic)
34. 52447B Diltiazem Confirmation, Blood (Forensic)
35. 52441B Diphenhydramine Confirmation, Blood (Forensic)
36. 52034B Donepezil Confirmation, Blood (Forensic)
37. 52278B Doxepin and Metabolite Confirmation, Blood (Forensic)
38. 52285B Doxylamine Confirmation, Blood (Forensic)
39. 52036B Duloxetine Confirmation, Blood (Forensic)
40. 52038B Eszopiclone / Zopiclone Confirmation, Blood (Forensic)
41. 0173B Ethanol Re-Check - Post Mortem, Blood
42. 52484B Fentanyl and Acetyl Fentanyl Confirmation, Blood (Forensic)
43. 52047B Flecainide Confirmation, Blood (Forensic)
44. 52048B Flunitrazepam and Metabolites Confirmation, Blood (Forensic)
45. 52287B Fluoxetine and Metabolite Confirmation, Blood (Forensic)
46. 52468B Fluphenazine Confirmation, Blood (Forensic)
47. 52049B Fluvoxamine Confirmation, Blood (Forensic)
48. 52438B Glimepiride Confirmation, Blood (Forensic)
49. 52052B Guaifenesin Confirmation, Blood (Forensic)
50. 52320B Hallucinogens and Stimulants Confirmation 2 (Qualitative), Blood
51. 52053B Haloperidol Confirmation, Blood (Forensic)
52. 52442B Hydroxyzine Confirmation, Blood (Forensic)
53. 52405B Hypoglycemics Confirmation, Blood (Forensic)
54. 52418B Iloperidone Confirmation, Blood (Forensic)
55. 52276B Imipramine and Metabolite Confirmation, Blood (Forensic)
56. 52414B Ipecac Use Markers Confirmation, Blood (Forensic)
57. 52058B Ketamine and Metabolite Confirmation, Blood (Forensic)
58. 52065B LSD Confirmation, Blood (Forensic)
59. 52420B Lacosamide Confirmation, Blood (Forensic)
60. 52059B Lamotrigine Confirmation, Blood (Forensic)
61. 52060B Levetiracetam Confirmation, Blood (Forensic)
62. 52496B Loperamide and Metabolite Confirmation, Blood (Forensic)
63. 52064B Loxapine Confirmation, Blood (Forensic)
64. 52412B MDMA / Methedrone Confirmation (Qualitative), Blood (Forensic)
65. 52434B MDMA Confirmation, Blood (Forensic)

66. 52270B Maprotiline Confirmation, Blood (Forensic)
67. 52421B Memantine Confirmation, Blood (Forensic)
68. 52068B Meperidine and Metabolite Confirmation, Blood (Forensic)
69. 52072B Mescaline Confirmation, Blood (Forensic)
70. 52422B Metaxalone Confirmation, Blood (Forensic)
71. 50015B Methadone and Metabolite Confirmation, Blood (Forensic)
72. 52073B Methaqualone Confirmation, Blood (Forensic)
73. 52430B Methcathinone Confirmation (Qualitative), Blood (Forensic)
74. 52076B Methocarbamol Confirmation, Blood (Forensic)
75. 52079B Methylphenidate and Metabolite Confirmation, Blood (Forensic)
76. 52083B Mexiletine Confirmation, Blood (Forensic)
77. 52303B Mirtazapine Confirmation, Blood (Forensic)
78. 52489B Mitragynine Confirmation, Blood
79. 52387B NBOMe Confirmation (Qualitative), Blood
80. 52497B Naltrexone and Metabolite - Free (Unconjugated) Confirmation, Blood (Forensic)
81. 52406B Naproxen Confirmation, Blood (Forensic)
82. 52088B Nifedipine Confirmation, Blood (Forensic)
83. 52091B Olanzapine Confirmation, Blood (Forensic)
84. 50016B Opiates - Free (Unconjugated) Confirmation, Blood (Forensic)
85. 52289B Orphenadrine Confirmation, Blood (Forensic)
86. 52093B Oxcarbazepine/Eslicarbazepine Acetate as Metabolite Confirmation, Blood (Forensic)
87. 52432B PMA Confirmation (Qualitative), Blood (Forensic)
88. 52096B Paroxetine Confirmation, Blood (Forensic)
89. 52423B Perphenazine Confirmation, Blood (Forensic)
90. 50017B Phencyclidine Confirmation, Blood (Forensic)
91. 52291B Pheniramine Confirmation, Blood (Forensic)
92. 52105B Phenytoin Confirmation, Blood (Forensic)
93. 52373B Piperazine Designer Drugs Confirmation, Blood (Forensic)
94. 52106B Primidone, Phenobarbital and PEMA Confirmation, Blood (Forensic)
95. 52469B Prochlorperazine Confirmation, Blood (Forensic)
96. 52446B Promazine Confirmation, Blood (Forensic)
97. 52456B Promethazine Confirmation, Blood (Forensic)
98. 50018B Propoxyphene and Metabolite Confirmation, Blood (Forensic)
99. 52431B Psilocin Confirmation (Qualitative), Blood (Forensic)
100. 52327B Pyrrolidinophenone Confirmation, Blood
101. 52112B Quetiapine Confirmation, Blood (Forensic)
102. 52148B Quinidine Confirmation, Blood (Forensic)
103. 52424B Ramelteon and Metabolite Confirmation, Blood (Forensic)

104.	52436B	Risperidone and Metabolite Confirmation, Blood (Forensic)
105.	50001B	Salicylate Confirmation, Blood (Forensic)
106.	52116B	Sertraline and Desmethylsertraline Confirmation, Blood (Forensic)
107.	52437B	Sildenafil and Metabolite Confirmation, Blood (Forensic)
108.	52403B	Strychnine Confirmation, Blood (Forensic)
109.	52328B	Substituted Cathinone Panel, Blood
110.	52499B	Suvorexant Confirmation, Blood (Forensic)
111.	5971B	Synthetic Cannabinoids Confirmation Panel 1 (Qualitative), Blood
112.	5970B	Synthetic Cannabinoids Confirmation Panel 2 (Qualitative), Blood
113.	5960B	Synthetic Cannabinoids Confirmation, Blood (Forensic)
114.	52407B	Synthetic Opioids - Free (Unconjugated) Confirmation, Blood (Forensic)
115.	52425B	Tadalafil Confirmation, Blood (Forensic)
116.	52426B	Tapentadol - Free Confirmation, Blood (Forensic)
117.	52427B	Tetrahydrozoline Confirmation, Blood (Forensic)
118.	52121B	Theophylline Confirmation, Blood (Forensic)
119.	52283B	Thioridazine and Metabolite Confirmation, Blood (Forensic)
120.	52125B	Tiletamine Confirmation, Blood (Forensic)
121.	52127B	Topiramate Confirmation, Blood (Forensic)
122.	52128B	Tramadol and Metabolite Confirmation, Blood (Forensic)
123.	52295B	Trazodone Confirmation, Blood (Forensic)
124.	52470B	Trifluoperazine Confirmation, Blood (Forensic)
125.	52415B	Trihexyphenidyl Confirmation, Blood (Forensic)
126.	52280B	Trimipramine and Metabolite Confirmation, Blood (Forensic)
127.	52297B	Triprolidine Confirmation, Blood (Forensic)
128.	52428B	Vardenafil and Metabolite Confirmation, Blood (Forensic)
129.	52132B	Venlafaxine and Metabolite Confirmation, Blood (Forensic)
130.	52298B	Verapamil Confirmation, Blood (Forensic)
131.	52135B	Xylazine Confirmation, Blood (Forensic)
132.	52136B	Yohimbine Confirmation, Blood (Forensic)
133.	52137B	Zaleplon Confirmation, Blood (Forensic)
134.	52429B	Ziprasidone Confirmation, Blood (Forensic)
135.	52138B	Zolazepam Confirmation, Blood (Forensic)
136.	52139B	Zolpidem Confirmation, Blood (Forensic)
137.	52140B	Zonisamide Confirmation, Blood (Forensic)

1. 8054B Postmortem, Expanded with NPS, Blood (Forensic)

Scope of Analysis:	*** For complete listing, contact Client Support at 800.522.6671 ***
Method(s):	Headspace Gas Chromatography (GC)
	Enzyme-Linked Immunosorbent Assay (ELISA)
	High Performance Liquid Chromatography/Tandem Mass Spectrometry QTRAP (LC-MS/MS QTRAP)
	High Performance Liquid Chromatography/Time of Flight-Mass Spectrometry (LC/TOF-MS)
Purpose:	Forensic Analysis; Exclusion Screen; This test is New York State approved.
Category:	Hypnotic, Sedative, Cardiovascular, Antihistamine, Decongestant, Anesthetic, Analgesic, Anesthetic, Skeletal Muscle Relaxant, Synthetic Cannabinoid, Sleep Aid, Bronchodilator, Anesthetic (Local), Analgesic, Muscle Relaxant, Stimulant, Phosphodiesterase #5 Inhibitor, Poison, Oral Hypoglycemic Agent, Expectorant, Cognitive Adjuvant, Cocaine Cutting Agent, Calcium Channel Blocker, Anxiolytic, Tranquilizer, Antiparkinson, Anesthetic, Opioid Analgesic, Alzheimers Drug, Cannabinoid, Antihypertensive, Antihistamine, Antihistamine, Anxiolytic, Antifungal, Anticoagulant, Pesticide, Stimulant, Anorexogenic, Anxiolytic, Sedative, Antipsychotic (Neuroleptic), Anti-Impotence Drug, Antiemetic, Antipsychotic, Antiarrhythmic, Inactive Metabolite, Occular Vasoconstrictor, Erectile Dysfunction, Anxiolytic, Antidepressant, Anticonvulsant, Antiepileptic, Analgesic, Centrally Acting Analgesic, Analgesic, Anti-Inflammatory, Narcotic Analgesic, Muscle Relaxant, Hypnotic, Sedative, Volatile, Bronchodilator, Stimulant, Antitussive, Antipsychotic, Antiemetic, Triazole Antifungal, Anticonvulsant, Therapeutic opioid, Hallucinogen, Environmental/Occupation Toxin, Emetic, Decongestant, Stimulant, Antimalarial, Anticholinergic, Plant alkaloid, NPS
Specimen Requirements:	10 mL Blood
Minimum Volume:	8.05 mL
Special Handling:	Collect sample using alcohol free skin preparation.
Specimen Container:	Gray top tube (Sodium Fluoride / Potassium Oxalate), Lavender top tube (EDTA)
Transport Temperature:	Refrigerated
Light Protection:	Yes
Rejection Criteria:	Not received Light Protected. Glass container. Green top tube (Sodium Heparin).
Known Interference(s):	Furanyl Fentanyl [LC/TOF-MS]: Azithromycin
Stability:	Room Temperature: Undetermined
	Refrigerated: Undetermined
	Frozen (-20 °C): Undetermined

If this test contains multiple compounds, the reported stability reflects that which is least stable. Stability may vary among compounds included in the test and may be dependent upon matrix, pH, collection tube, and storage temperature. Negative results should be interpreted with caution. For more information on stability of a specific compound please contact the laboratory.

NOTE: If the test contains multiple compounds samples received at room temperature will not be rejected.

Method: Enzyme-Linked Immunosorbent Assay (ELISA)

Set-Up Days / TAT: Monday-Saturday 2 days (after set-up)

CPT Code: 80307

Compound Name / Alias	Units	RL
Salicylates	mcg/mL	120
Cannabinoids	ng/mL	10
Barbiturates	mcg/mL	0.04

Method: Headspace Gas Chromatography (GC)

Set-Up Days / TAT: Monday-Friday 4 days (after set-up)

CPT Code: 80307

Compound Name / Alias	Units	RL
Ethanol Ethyl Alcohol	mg/dL	10
Reference Comment Ethyl alcohol (ethanol, drinking alcohol) is a central nervous system depressant and can cause effects such as impaired judgment, reduced alertness and impaired muscular coordination. Ethanol can also be a product of decomposition or degradation of biological samples.		
Blood Alcohol Concentration (BAC)	g/100 mL	0.01
Methanol Methyl Alcohol	mg/dL	5.0
Reference Comment Endogenous blood levels of methanol from metabolic and dietary sources are approximately 0.15 mg/dL. Exposure to 800 ppm methanol for 8 hours produced a maximum average blood methanol concentration of 3.1 mg/dL.		
Isopropanol Isopropyl Alcohol	mg/dL	5.0
Reference Comment Three workers exposed to 191 - 200 ppm isopropanol in air had blood isopropanol concentrations <1 mg/dL; acetone levels were 4 - 16 mg/dL during the exposure. After a sponge bath with isopropanol, one adult had a blood isopropanol concentration of 10 mg/dL. In a study of 31 isopropanol deaths, postmortem blood concentrations ranged from 10 to 250 mg/dL (mean, 140 mg/dL) and acetone blood concentrations ranged from 40 - 300 mg/dL (mean, 170 mg/dL).		
Acetone	mg/dL	5.0
Reference Comment Reported normal endogenous acetone levels in blood are up to 3 mg/dL. Levels associated with diabetic or fasting ketoacidosis range from 10 - 70 mg/dL. After exposure to 100 and 500 ppm acetone for 2 hr, reported blood acetone concentrations peaked at 2 and 10 mg/dL, respectively. A blood level of 250 mg/dL was reported in an individual who became lethargic following ingestion of acetone.		

Method: High Performance Liquid Chromatography/Tandem Mass Spectrometry QTRAP (LC-MS/MS QTRAP)

Set-Up Days / TAT: Monday Wednesday 3 days (after set-up)

CPT Code: 80307

Compound Name / Alias	Units	RL
PX1 (S)-N-(1-amino-1-oxo-3-phenylpropan-2-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide; 5F- APP-PICA; SRF-30	ng/mL	0.1
Reference Comment This analyte has demonstrated instability under certain storage conditions which may be dependent upon matrix, pH, collection tube, and storage temperature. Negative results should be interpreted with caution.		

Compound Name / Alias	Units	RL
PX2 (R)-N-(1-amino-1-oxo-3-phenylpropan-2-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide; 5F-APP-PINACA; FU-PX	ng/mL	0.2
Reference Comment This analyte has demonstrated instability under certain storage conditions which may be dependent upon matrix, pH, collection tube, and storage temperature. Negative results should be interpreted with caution.		
AB-FUBINACA N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide	ng/mL	1.0
5F-ADBICA N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide	ng/mL	1.0
5F-ADB-PINACA N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(5-Fluoropentyl)-1H-indazole-3-carboxamide	ng/mL	1.0
Reference Comment This analyte has demonstrated instability under certain storage conditions which may be dependent upon matrix, pH, collection tube, and storage temperature. Negative results should be interpreted with caution.		
ADB-FUBINACA N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide	ng/mL	1.0
AB-PINACA N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide	ng/mL	0.2
5F-PB-22 1-(5-fluoropentyl)-8-quinolinyl ester-1H-indole-3-carboxylic acid; 5F-QUPIC	ng/mL	0.1
5F-AMB 5F-AMP; N-[[1-(5-fluoropentyl)-1H-indazol-3-yl]carbonyl]-L-valine, methyl ester	ng/mL	0.1
Reference Comment This analyte has demonstrated instability under certain storage conditions which may be dependent upon matrix, pH, collection tube, and storage temperature. Negative results should be interpreted with caution.		
FUB-AMB AMB-FUBINACA; methyl (1-(4-fluorobenzyl)-1H-indazole-3-carbonyl)-L-valinate	ng/mL	0.1
Reference Comment This analyte has demonstrated instability under certain storage conditions which may be dependent upon matrix, pH, collection tube, and storage temperature. Negative results should be interpreted with caution.		
CUMYL-THPINACA methyl (1-(cyclohexylmethyl)-1H-indole-3-carbonyl)-L-valinate	ng/mL	0.1
FUB-PB-22 quinolin-8-yl-1-(4-fluorobenzyl)-1H-indole-3-carboxylate	ng/mL	0.1

Compound Name / Alias	Units	RL
5F-ADB 5F-MDMB-PINACA; methyl (R)-2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate	ng/mL	0.2
ADBICA N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indole-3-carboxamide	ng/mL	1.0
ADB-PINACA N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide	ng/mL	0.2
AM-2201 5F-JWH-018; [1-(5-fluoropentyl)-1H-indol-3-yl]-1-naphthalenyl-methanone	ng/mL	0.1
AB-CHMINACA N-[(1S)-1-(Aminocarbonyl)-2-methylpropyl]-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide	ng/mL	1.0
MDMB-FUBINACA 1-methoxy-3,3-dimethyl-1-oxobutan-2-yl 1-(cyclohexylmethyl)-1H-indazole-3-carboxylate; MO-AMB	ng/mL	0.1
FUB-JWH-018 (1-(4-fluorobenzyl)-1H-indol-3-yl)(naphthalen-1-yl)methanone	ng/mL	0.2
APP-CHMINACA (PX3) N-[(1S)-2-amino-2-oxo-1-(phenylmethyl)ethyl]-1-(cyclohexylmethyl)-1H-Indazole-3-carboxamide; PX3	ng/mL	0.2
5F-MN-18 1-(5-fluoropentyl)-N-1-naphthalenyl-1H-indazole-3-carboxamide	ng/mL	0.1
ADB-CHMINACA MAB-CHMINACA; N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide	ng/mL	0.1
THJ-2201 (1-(5-fluoropentyl)-1H-indazol-3-yl)(naphthalen-1-yl)methanone; 5-fluoro THJ-018; AM2201 indazole analog; Fluoropentyl-JWH-018 indazole	ng/mL	0.1
AMB AMP; methyl (1-pentyl-1H-indazole-3-carbonyl)-L-valinate	ng/mL	0.1
MMB-CHMICA FUB-MDMB; MDMB-Bz-F; methyl (S)-2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate	ng/mL	0.1

Compound Name / Alias	Units	RL
XLR-11 (1-(5-fluoropentyl)-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone; 5F-UR-144	ng/mL	0.2
FUB-144 (1-(4-fluorobenzyl)-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone; FUB-UR-144	ng/mL	0.1
NM-2201 CBL-2201; naphthalen-1-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate	ng/mL	0.1
5F-APICA 5F-JWH-018 Adamantyl Carboxamide; N-(1-adamantyl)-1-(5-fluoropentyl-1H-indole-3-carboxamide; STS-135	ng/mL	1.0
JWH-018 (1-pentyl-1H-indol-3-yl)-1-naphthalenyl-methanone; AM-678	ng/mL	0.1
MMB-CHMINACA (MDMB-CHMICA) methyl (S)-2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3,3-dimethylbutanoate	ng/mL	0.1
MA-CHMINACA AMB-CHMINACA; AMB-N-methylcyclohexyl analog; MAB-AB-CHMINACA; methyl (1-(cyclohexylmethyl)-1H-indazole-3-carbonyl)-L-valinate	ng/mL	0.2
5F-AB-001 1-(5-Fluoropentyl)-3-(1-adamantoyl)indole; 5F-JWH-018 Adamantyl Analog; AM2201 adamantyl analog **Reference Comment** This analyte has demonstrated instability under certain storage conditions which may be dependent upon matrix, pH, collection tube, and storage temperature. Negative results should be interpreted with caution.	ng/mL	1.0
JWH-122 (4-methyl-1-naphthalenyl)(1-pentyl-1H-indol-3-yl)-methanone	ng/mL	0.1
MDMB-CHMINACA N-[[1-(cyclohexylmethyl)-1H-indazol-3-yl]carbonyl]-3-methyl-L-valine, methyl ester	ng/mL	0.1
MO-CHMINACA N-(1-methyl-1-phenylethyl)-1-[(tetrahydro-2H-pyran-4-yl)methyl]-1H-indazole-3-carboxamide	ng/mL	0.1
5F-APINACA (5F-AKB-48) N-(1-adamantyl)-1-(5-Fluropentyl)-1H-indazole-3-carboxamide	ng/mL	2.0

Compound Name / Alias	Units	RL
THJ-018 1-naphthalenyl(1-pentyl-1H-indazol-3-yl)-methanone; JWH-018 indazole analog	ng/mL	0.1
UR-144 1-pentyl-3-[1-(2,2,3,3-tetramethylcyclopropyl)]indole; KM-X1	ng/mL	0.2
EG-2201 (9-(5-fluoropentyl)-9H-carbazol-3-yl)(naphthalen-1-yl)methanone	ng/mL	0.2
FUB-AKB-48 AKB-48 N-(4-fluorobenzyl) analog; N-((3s,5s,7s)-adamantan-1-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide	ng/mL	0.2
APICA 2NE1; JWH-018 Adamantyl Carboxamide; N-(1-adamantyl)-1-pentyl-1H-indole-3-carboxamide; SDB-001	ng/mL	0.2
MDMB-CHMCZCA EGMB-CHMINACA; methyl (S)-2-(9-(cyclohexylmethyl)-9H-carbazole-3-carboxamido)-3,3-dimethylbutanoate	ng/mL	0.1
APINACA (AKB-48) N-(1-adamantyl)-1-pentyl-1H-indazole-3-carboxamide	ng/mL	1.0

Method: **High Performance Liquid Chromatography/Time of Flight-Mass Spectrometry (LC/TOF-MS)**

Set-Up Days / TAT: Monday-Friday 4 days (after set-up)

CPT Code: 80307

Compound Name / Alias	Units	RL
3-Fluorophenmetrazine 3-FPM	ng/mL	5.0
3-MeO-PCP 3-Methoxy-Phencyclidine	ng/mL	5.0
4-ANPP Despropionyl fentanyl	ng/mL	0.1
4-MeO-PCP 4-Methoxy-Phencyclidine	ng/mL	5.0
4-Methoxybutyryl Fentanyl	ng/mL	0.1
6-Beta-Naltrexol - Free Naltrexone Metabolite	ng/mL	10
6-Monoacetylmorphine	ng/mL	2.0

Compound Name / Alias	Units	RL
7-Amino Clonazepam Clonazepam Metabolite	ng/mL	10
7-Amino Flunitrazepam Flunitrazepam Metabolite	ng/mL	5.0
9-Hydroxyrisperidone Risperidone Metabolite	ng/mL	5.0
10-Hydroxycarbazepine Licarbazepine; Oxcarbazepine/Eslicarbazepine Acetate Metabolite	mcg/mL	3.0
25B-NBOMe 2C-B-NBOMe	ng/mL	1.0
25C-NBOMe 2C-C-NBOMe	ng/mL	1.0
25H-NBOMe 2C-H-NBOMe	ng/mL	1.0
25I-NBOMe 2C-I-NBOMe	ng/mL	1.0
Acetaminophen Phenacetin Metabolite	mcg/mL	20
Acetyl Fentanyl	ng/mL	0.5
Reference Comment Acryl fentanyl is known to have limited stability in blood which may be dependent upon pH, collection tube, and storage temperature. Negative results should be interpreted with caution.		
Acryl Fentanyl	ng/mL	0.1
AH-7921 Doxylam	ng/mL	0.2
Alfentanil Alfenta®	ng/mL	10
Alpha-Hydroxyalprazolam Alprazolam Metabolite	ng/mL	20
alpha-Methyl Fentanyl	ng/mL	0.1
alpha-PVP alpha-Pyrrolidinovalerophenone; alpha-pyrrolidinopentiophenone	ng/mL	2.0

Compound Name / Alias	Units	RL
Alprazolam Xanax®	ng/mL	10
Amitriptyline Elavil®; Endep®	ng/mL	50
Amoxapine Asendin®	ng/mL	50
Amphetamine Benzphetamine Metabolite	ng/mL	10
Aripiprazole Abilify®	ng/mL	50
Atomoxetine Strattera®	ng/mL	100
Atropine d,l-Hyoscyamine **Reference Comment** The reported qualitative result for this substance was based upon a single analysis only. If confirmation testing is required please contact the laboratory.	ng/mL	1000
Benzoylecgonine Cocaine Degradation Product	ng/mL	100
Benztropine Cogentin®	ng/mL	100
Beta-hydroxythiofentanyl	ng/mL	0.5
Bromazepam	ng/mL	5.0
Brompheniramine Dimetane; Dimetapp	ng/mL	10
Bupivacaine Marcaine®	mcg/mL	0.1
Buprenorphine	ng/mL	1.0
Bupropion Wellbutrin®	ng/mL	25
Buspirone BuSpar®	ng/mL	25
Butorphanol Stadol®	ng/mL	2.0

Compound Name / Alias	Units	RL
Butylone	ng/mL	10
Butyryl Fentanyl / Isobutyryl Fentanyl Butyr-fentanyl/Isobutyr-fentanyl	ng/mL	0.1
BZP 1-Benzylpiperazine	ng/mL	10
Caffeine No-Doz **Reference Comment** The reported qualitative result for this substance was based upon a single analysis only. If confirmation testing is required please contact the laboratory.	mcg/mL	0.2
Carbamazepine Tegretol®	mcg/mL	0.2
Carbamazepine-10,11-Epoxide	mcg/mL	1.0
Carfentanil Wildnil®	ng/mL	0.1
Carisoprodol Soma®	mcg/mL	0.2
Cephaeline Ipecac Syrup Constituent	ng/mL	5.0
Chlordiazepoxide Librium®	ng/mL	50
Chlorpheniramine Chlor-Trimeton®	ng/mL	10
Chlorpromazine Thorazine®	ng/mL	20
Citalopram / Escitalopram Celexa® / Lexapro®	ng/mL	100
Clephedrone 4-chloromethcathinone, 4-CMC **Reference Comment** Clephedrone is known to have limited stability in blood which may be dependent upon pH, collection tube, and storage temperature. Negative results should be interpreted with caution.	ng/mL	50
Clobazam Frisium®; Urbanyl®	ng/mL	50
Clomipramine Anafranil®	ng/mL	50

Compound Name / Alias	Units	RL
Clonazepam Klonopin®	ng/mL	10
Clonazolam	ng/mL	5.0
Clonidine Catapres®	ng/mL	5.0
Clozapine Clozaril®	ng/mL	50
Cocaethylene Cocaine/Ethanol By-Product	ng/mL	20
Cocaine	ng/mL	20
Codeine	ng/mL	10
Cotinine Nicotine Metabolite **Reference Comment** The reported qualitative result for this substance was based upon a single analysis only. If confirmation testing is required please contact the laboratory.	ng/mL	200
Cyclobenzaprine Flexeril®	ng/mL	20
Delorazepam Chlordesmethyldiazepam; Cloxazolam metabolite	ng/mL	5.0
Desalkylflurazepam Flurazepam Metabolite	ng/mL	10
Deschloroetizolam	ng/mL	2.0
Desipramine Imipramine Metabolite; Norpramin®; Pertofrane®	ng/mL	50
Desmethylclomipramine Clomipramine Metabolite	ng/mL	50
Desmethyldoxepin Doxepin Metabolite	ng/mL	25
Desmethylloperamide Loperamide Metabolite	ng/mL	5.0
Desmethylsertraline Norsertraline; Sertraline Metabolite	ng/mL	20

Compound Name / Alias	Units	RL
Desmethyltrimipramine Trimipramine Metabolite	ng/mL	50
Dextro / Levo Methorphan	ng/mL	50
Dextrorphan / Levorphanol Levo-Dromoran®	ng/mL	100
Diazepam Valium®	ng/mL	25
Dibutylone bk-DMBDB	ng/mL	10
Diclazepam	ng/mL	20
Dicyclomine Bentyl®	ng/mL	100
Dihydrocodeine / Hydrocodol	ng/mL	10
Diltiazem Cardizem®	ng/mL	100
Diphenhydramine Benadryl®	ng/mL	50
Donepezil Aricept®	ng/mL	10
Doxepin Sinequan®	ng/mL	25
Doxylamine Unisom®	ng/mL	50
Duloxetine Cymbalta®	ng/mL	100
EDDP Methadone Metabolite	ng/mL	50
Emetine Ipecac	ng/mL	5.0
Ephedrine	ng/mL	250
Estazolam ProSom®	ng/mL	10

Compound Name / Alias	Units	RL
Eszopiclone / Zopiclone Imovane®; Lunesta®	ng/mL	10
Ethylone	ng/mL	10
Etizolam	ng/mL	10
Etomidate Amidate®	mcg/mL	0.1
Reference Comment Etomidate is a non-barbiturate hypnotic without analgesic activity. It is especially used in patients with cardiovascular problems since it has few effects on this system. IV administration of etomidate produces rapid hypnosis, which lasts approximately 3 to 5 minutes. The reported qualitative result for this substance was based upon a single analysis only. If confirmation testing is required please contact the laboratory.		
Fentanyl Duragesic®; Sublimaze®	ng/mL	1.0
Flecainide Ecrinal®; Tambocor®	mcg/mL	0.25
Flubromazepam	ng/mL	20
Flubromazolam	ng/mL	5.0
Flunitrazepam Rohypnol®	ng/mL	5.0
Fluoxetine Prozac®	ng/mL	50
Fluphenazine Prolixin®	ng/mL	5.0
Flurazepam Dalmane®	ng/mL	10
Fluvoxamine Luvox®	ng/mL	250
Furanyl Fentanyl	ng/mL	0.1
Reference Comment Substance(s) known to interfere with the identity and/or quantity of the reported result: Azithromycin.		
Glimepiride Amaryl®	ng/mL	100

Compound Name / Alias	Units	RL
Glipizide Glucotrol®	mcg/mL	0.1
Glyburide Micronase®	mcg/mL	0.1
Guaifenesin Glyceryl Guaiacolate	mcg/mL	5.0
Haloperidol Haldol®	ng/mL	10
Hydrocodone	ng/mL	10
Hydromorphone	ng/mL	2.0
Hydroxybupropion Bupropion Metabolite	ng/mL	100
Hydroxyethylflurazepam Flurazepam Metabolite	ng/mL	10
Hydroxytriazolam Triazolam Metabolite	ng/mL	5.0
Hydroxyzine Vistaril®	ng/mL	25
Ibuprofen Advil®; Motrin®; Nuprin® **Reference Comment** The reported qualitative result for this substance was based upon a single analysis only. If confirmation testing is required please contact the laboratory.	mcg/mL	50
Iloperidone Fanapta®; Fanapt®; Zomaril®	ng/mL	10
Imipramine Tofranil®	ng/mL	25
Itraconazole Sporanox® **Reference Comment** The reported qualitative result for this substance was based upon a single analysis only. If confirmation testing is required please contact the laboratory.	mcg/mL	1.0
Ketamine Ketalar®	ng/mL	10
Ketoconazole Nizoral® **Reference Comment** The reported qualitative result for this substance was based upon a single analysis only. If confirmation testing is required please contact the laboratory.	mcg/mL	1.0

Compound Name / Alias	Units	RL
Lacosamide Vimpat®	mcg/mL	0.01
Lamotrigine Lamictal®	mcg/mL	0.2
Laudanosine Atracurium Metabolite **Reference Comment** The reported qualitative result for this substance was based upon a single analysis only. If confirmation testing is required please contact the laboratory.	ng/mL	100
Levamisole Ergamisol®; Levasole® **Reference Comment** The reported qualitative result for this substance was based upon a single analysis only. If confirmation testing is required please contact the laboratory.	mcg/mL	0.25
Levetiracetam Keppra®	mcg/mL	5.0
Lidocaine Xylocaine® **Reference Comment** The reported qualitative result for this substance was based upon a single analysis only. If confirmation testing is required please contact the laboratory.	mcg/mL	0.2
Loperamide Imodium	ng/mL	5.0
Lorazepam Ativan®	ng/mL	5.0
Loxapine Loxitane®	ng/mL	50
LSD Lysergic Acid Diethylamide	ng/mL	2.0
Maprotiline Ludiomil®	ng/mL	100
mCPP 1-(3-Chlorophenyl)Piperazine; Nefazodone metabolite; Trazodone metabolite	ng/mL	50
MDA 3,4-Methylenedioxyamphetamine; Adam; MDMA Metabolite	ng/mL	10
MDEA 3,4-methylenedioxyethamphetamine; Eve	ng/mL	10
MDMA 3,4-Methylenedioxymethamphetamine; Ecstasy	ng/mL	10

Compound Name / Alias	Units	RL
MDPV Methylenedioxypyrovalerone	ng/mL	10
Meclonazepam	ng/mL	5.0
Memantine Axura®; Ebixa®; Namenda®	ng/mL	10
Meperidine Demerol®	mcg/mL	0.1
Mephedrone 4-methylmethcathinone	ng/mL	10
Meprobamate Carisoprodol Metabolite	mcg/mL	1.0
Mescaline 3,4,5-Trimethoxyphenethylamine; Peyote	mcg/mL	0.01
Mesoridazine Serentil®	ng/mL	100
Metaxalone Skelaxin®	mcg/mL	0.25
Methadone Dolophine®	ng/mL	50
Methamphetamine Benzphetamine Metabolite	ng/mL	10
Methaqualone Quaalude	mcg/mL	0.2
Methcathinone	ng/mL	10
Methocarbamol Robaxin®	mcg/mL	5.0
Methoxetamine	ng/mL	2.0
Methoxphenidine MXP	ng/mL	5.0
Methylone	ng/mL	10

Reference Comment

Methylone is known to have limited stability in
blood which may be dependent upon pH, collection tube,
and storage temperature.
Negative results should be interpreted with caution.

v.18

Compound Name / Alias	Units	RL
Methylphenidate Ritalin®	ng/mL	10
Metoclopramide Reglan® **Reference Comment** Metoclopramide is a substituted benzamide used for a variety of gastrointestinal disturbances, especially for the management of gastric motility disorders, esophageal reflux and for the prevention of cancer chemotherapeutic-induced emesis. For gastric motility disorders and esophageal reflux, metoclopramide is administered in divided doses up to 40 to 50 mg daily for anti-emetic purposes, a dose of 2 mg/Kg (approximately 1 mg in a 155 lb adult) is administered 30 min before anti-neoplastic administration and at 2 hr intervals thereafter. The reported qualitative result for this substance was based upon a single analysis only. If confirmation testing is required please contact the laboratory.	ng/mL	10
Mexiletine Mexitil®	mcg/mL	0.5
Midazolam Versed®	ng/mL	5.0
Mirtazapine Remeron®	ng/mL	25
Mitragynine Kratom	ng/mL	10
Monoethylglycinexylidide (MEGX) Lidocaine Metabolite **Reference Comment** The reported qualitative result for this substance was based upon a single analysis only. If confirmation testing is required please contact the laboratory.	mcg/mL	0.2
Morphine	ng/mL	10
MPHP 4'-methyl-alpha-Pyrrolidinohexiophenone	ng/mL	10
MT-45 IC-6	ng/mL	1.0
N-Ethyl Pentylone	ng/mL	10
Nalbuphine Nubain®	ng/mL	2.0
Naloxone Narcan® **Reference Comment** The reported qualitative result for this substance was based upon a single analysis only. If confirmation testing is required please contact the laboratory.	ng/mL	1.0

Compound Name / Alias	Units	RL
Naltrexone Depade®; ReVia®; Trexan®; Vivitrol®	ng/mL	1.0
Naproxen Naprosyn®	mcg/mL	50
Nicotine	ng/mL	100
Reference Comment The reported qualitative result for this substance was based upon a single analysis only. If confirmation testing is required please contact the laboratory.		
Nifedipine Procardia®	ng/mL	10
Norbuprenorphine - Free Buprenorphine Metabolite	ng/mL	2.0
Norclozapine Clozapine Metabolite	ng/mL	25
Nordiazepam Chlordiazepoxide Metabolite	ng/mL	20
Norfentanyl Fentanyl Metabolite	ng/mL	1.0
Norflunitrazepam Flunitrazepam Metabolite	ng/mL	20
Norfluoxetine Fluoxetine Metabolite	ng/mL	100
Norketamine Ketamine Metabolite	ng/mL	20
Normeperidine Meperidine Metabolite	mcg/mL	0.1
Norpropoxyphene Propoxyphene Metabolite	mcg/mL	0.25
Norpseudoephedrine	ng/mL	250
Nortriptyline Amitriptyline Metabolite; Aventyl®; Pamelor®	ng/mL	50
O-Desmethyltramadol Tramadol Metabolite	ng/mL	25
O-Desmethylvenlafaxine Desvenlafaxine; Pristiq®; Venlafaxine Metabolite	ng/mL	50

Compound Name / Alias	Units	RL
Olanzapine Zyprexa®	ng/mL	5.0
Orphenadrine Flexon; Norflex	ng/mL	50
ortho-Fluorofentanyl	ng/mL	0.1
Oxazepam Diazepam Metabolite	ng/mL	20
Oxycodone OxyContin®; Roxicodone®	ng/mL	10
Oxymorphone	ng/mL	2.0
para-Fluorobutyryl Fentanyl / FIBF 4F-butyryl fentanyl/4F-isobutyryl fentanyl; para-Fluoroisobutyryl Fentanyl (FIBF)	ng/mL	0.1
para-Fluorofentanyl	ng/mL	0.1
Paroxetine Paxil®	ng/mL	20
Pentedrone	ng/mL	2.0
Reference Comment Pentedrone is known to have limited stability in blood which may be dependent upon pH, collection tube, and storage temperature. Negative results should be interpreted with caution.		
Pentylone	ng/mL	10
Reference Comment Pentylone is known to have limited stability in blood which may be dependent upon pH, collection tube, and storage temperature. Negative results should be interpreted with caution.		
Perphenazine Trilafon®	ng/mL	5.0
Phenazepam	ng/mL	10
Phencyclidine Angel Dust; PCP; Sherm	ng/mL	5.0
Pheniramine	ng/mL	10
Phenylpropanolamine	ng/mL	250

Compound Name / Alias	Units	RL
Phenytoin Dilantin®	mcg/mL	1.0
PMA para-methoxyamphetamine	ng/mL	10
Primidone Mysoline®	mcg/mL	2.5
Prochlorperazine Compazine®	ng/mL	10
Promazine Sparine®	ng/mL	50
Promethazine Phenergan®	ng/mL	5.0
Propoxyphene Darvon®	mcg/mL	0.25
Pseudoephedrine	ng/mL	250
Psilocin 4-OH-DMT; 4-hydroxy-dimethyltryptamine	ng/mL	10
Pyrazolam	ng/mL	5.0
Quetiapine Seroquel®	ng/mL	100
Quinidine Conquinine	ng/mL	200
Quinine Qualaquin®; Quindan®; Quinimax®	ng/mL	200

Reference Comment

Quinine is derived from the bark of the cinchona tree. It has been used in the past as an antimalarial, but is more commonly used today to treat muscle cramps. It is also used as a flavoring agent in tonic water and as a cutting agent adulterant in illicit heroin.
Quinine may contribute to symptoms of cinchonism which are reversible upon discontinuation of treatment. Symptoms may include vomiting, diarrhea, abdominal pain, cardiac arrhythmias, prolonged QT intervals, vasodilation and sweating. Central nervous system (CNS) effects include headache, vertigo, tinnitus, deafness, blindness, and blurred vision.
The reported qualitative result for this substance was based upon a single analysis only. If confirmation testing is required please contact the laboratory.

Ramelteon Rozerem®	ng/mL	1.0

Compound Name / Alias	Units	RL
Risperidone Risperdal®	ng/mL	5.0
Sertraline Zoloft®	ng/mL	10
Sildenafil Viagra®	ng/mL	50
Strychnine	ng/mL	10
Sufentanil Sufenta®	ng/mL	1.0
Suvorexant Belsomra	ng/mL	20
Tadalafil Cialis®	ng/mL	50
Tapentadol	ng/mL	10
Temazepam Diazepam Metabolite; Normison®	ng/mL	20
Tetrahydrozoline Murine Tears Plus®; Tetryzoline; Tyzine®; Visine®	ng/mL	1.0
TFMPP 3-Trifluoromethylphenylpiperazine	ng/mL	10
Theophylline Aminophylline	mcg/mL	8.0
Thioridazine Mellaril®	ng/mL	10
Tiletamine Telazol®	mcg/mL	0.1
Topiramate Topamax®	ng/mL	500
Tramadol Ultram®; Ultrex®	ng/mL	20
Trazodone Desyrel®	mcg/mL	0.1
Triazolam Halcion®	ng/mL	5.0

Compound Name / Alias	Units	RL
Trifluoperazine Stelazine®	ng/mL	5.0
Trihexyphenidyl	ng/mL	5.0
Trimipramine Surmontil®	ng/mL	50
Triprolidine Actidil®	ng/mL	10
U-47700 U-4	ng/mL	0.2
U-50488	ng/mL	0.2
Valeryl Fentanyl	ng/mL	0.5
Vardenafil Levitra®	ng/mL	50
Venlafaxine Effexor®	ng/mL	50
Verapamil Calan®; Isoptin®	ng/mL	20
Voriconazole UK-109,496; Vfend®; Vfend® I.V. **Reference Comment** The reported qualitative result for this substance was based upon a single analysis only. If confirmation testing is required please contact the laboratory.	mcg/mL	1.0
Warfarin Coumadin **Reference Comment** The reported qualitative result for this substance was based upon a single analysis only. If confirmation testing is required please contact the laboratory.	mcg/mL	0.25
Xylazine Rompun®	mcg/mL	0.005
Yohimbine	ng/mL	10
Zaleplon Sonata®	ng/mL	10
Ziprasidone Geodon®; Zeldox®	ng/mL	10
Zolazepam Flupyrazapon®	mcg/mL	0.1

Compound Name / Alias	Units	RL
Zolpidem Ambien®	ng/mL	10
Zonisamide Zonegran®	mcg/mL	0.25

Scope Statement

Associated Confirmation Tests

[Acetaminophen]	50000B	Acetaminophen Confirmation, Blood (Forensic)
[Ethanol]	52250B	Alcohols and Acetone Confirmation, Blood (Forensic)
[Alfentanil & Metabolite-reflex]	52143B	Alfentanil and Sufentanil Confirmation, Blood (Forensic)
[Amitriptyline & Metab-reflex]	52168B	Amitriptyline and Metabolite Confirmation, Blood (Forensic)
[Amoxapine]	52239B	Amoxapine Confirmation, Blood (Forensic)
[Amphetamines-reflex]	52485B	Amphetamines Confirmation, Blood (Forensic)
[Aripiprazole]	52416B	Aripiprazole Confirmation, Blood (Forensic)
[Atomoxetine]	52007B	Atomoxetine Confirmation, Blood (Forensic)
[Barbiturates]	50011B	Barbiturates Confirmation, Blood (Forensic)
[Bath Salts-reflex]	52367B	Bath Salts Confirmation, Blood (Forensic)
[Bath Salts-reflex]	52365B	Bath Salts Confirmation, Blood (Forensic)
[Benzodiazepines-reflex]	50012B	Benzodiazepines Confirmation, Blood (Forensic)
[Benztropine]	52443B	Benztropine Confirmation, Blood (Forensic)
[Brompheniramine]	52245B	Brompheniramine Confirmation, Blood (Forensic)
[Bupivacaine]	52011B	Bupivacaine Confirmation, Blood (Forensic)
[Bupropion & Metabolite-reflex]	52012B	Bupropion and Metabolite Confirmation, Blood (Forensic)
[Buspirone]	52444B	Buspirone Confirmation, Blood (Forensic)
[Cannabinoids]	52198B	Cannabinoids Confirmation, Blood (Forensic)
[Carbamazepines-reflex]	52015B	Carbamazepine and Metabolite Confirmation, Blood (Forensic)
[Carisoprodol/Meprobamate -refl]	52017B	Carisoprodol and Metabolite Confirmation, Blood (Forensic)
[Chlorpheniramine]	52440B	Chlorpheniramine Confirmation, Blood (Forensic)
[Chlorpromazine]	52272B	Chlorpromazine Confirmation, Blood (Forensic)
[Citalopram / Escitalopram]	52482B	Citalopram Confirmation, Blood (Forensic)
[Clomipramine & Metab-reflex]	52274B	Clomipramine and Metabolite Confirmation, Blood (Forensic)
[Clonidine]	52435B	Clonidine Confirmation, Blood (Forensic)
[Clozapine & Metabolite-reflex]	52023B	Clozapine and Metabolite Confirmation, Blood (Forensic)
[Cocaine and Metabolites-reflex]	50014B	Cocaine and Metabolites Confirmation, Blood (Forensic)
[Cyclobenzaprine]	52445B	Cyclobenzaprine Confirmation, Blood (Forensic)
[Dextro - Levo - Methorphan]	52451B	D/L Methorphan, Dextrorphan & Levorphanol Confirmation, Blood (Forensic)
[Designer Benzo - reflex]	52487B	Designer Benzodiazepines Confirmation, Blood (Forensic)
[Designer Opioids - reflex]	52488B	Designer Opioids Confirmation (2017 Scope), Blood
[Dicyclomine]	52028B	Dicyclomine Confirmation, Blood (Forensic)
[Diltiazem]	52447B	Diltiazem Confirmation, Blood (Forensic)
[Diphenhydramine]	52441B	Diphenhydramine Confirmation, Blood (Forensic)
[Donepezil]	52034B	Donepezil Confirmation, Blood (Forensic)
[Doxepin & Metabolite-reflex]	52278B	Doxepin and Metabolite Confirmation, Blood (Forensic)
[Doxylamine]	52285B	Doxylamine Confirmation, Blood (Forensic)
[Duloxetine]	52036B	Duloxetine Confirmation, Blood (Forensic)
[Eszopiclone / Zopiclone]	52038B	Eszopiclone / Zopiclone Confirmation, Blood (Forensic)
[Ethanol]	0173B	Ethanol Re-Check - Post Mortem, Blood
[Fentanyl & Metabolites-reflex]	52484B	Fentanyl and Acetyl Fentanyl Confirmation, Blood (Forensic)
[Flecainide]	52047B	Flecainide Confirmation, Blood (Forensic)
[Flunitrazepam-reflex]	52048B	Flunitrazepam and Metabolites Confirmation, Blood (Forensic)
[Fluoxetine & Metabolite-reflex]	52287B	Fluoxetine and Metabolite Confirmation, Blood (Forensic)
[Fluphenazine]	52468B	Fluphenazine Confirmation, Blood (Forensic)
[Fluvoxamine]	52049B	Fluvoxamine Confirmation, Blood (Forensic)
[Glimepiride]	52438B	Glimepiride Confirmation, Blood (Forensic)
[Guaifenesin]	52052B	Guaifenesin Confirmation, Blood (Forensic)
[Hallucinogen &Stimulant 4-refl]	52320B	Hallucinogens and Stimulants Confirmation 2 (Qualitative), Blood
[Haloperidol]	52053B	Haloperidol Confirmation, Blood (Forensic)
[Hydroxyzine]	52442B	Hydroxyzine Confirmation, Blood (Forensic)
[Hypoglycemic-reflex]	52405B	Hypoglycemics Confirmation, Blood (Forensic)
[Iloperidone]	52418B	Iloperidone Confirmation, Blood (Forensic)
[Imipramine & Metabolite-reflex]	52276B	Imipramine and Metabolite Confirmation, Blood (Forensic)
[Ipecac Use Markers-reflex]	52414B	Ipecac Use Markers Confirmation, Blood (Forensic)
[Ketamine & Metabolite-reflex]	52058B	Ketamine and Metabolite Confirmation, Blood (Forensic)

[LSD]	52065B	LSD Confirmation, Blood (Forensic)
[Lacosamide]	52420B	Lacosamide Confirmation, Blood (Forensic)
[Lamotrigine]	52059B	Lamotrigine Confirmation, Blood (Forensic)
[Levetiracetam]	52060B	Levetiracetam Confirmation, Blood (Forensic)
[Loperamide & Metab-reflex]	52496B	Loperamide and Metabolite Confirmation, Blood (Forensic)
[Loxapine]	52064B	Loxapine Confirmation, Blood (Forensic)
[MDMA / Methedrone-reflex]	52412B	MDMA / Methedrone Confirmation (Qualitative), Blood (Forensic)
[MDMA]	52434B	MDMA Confirmation, Blood (Forensic)
[Maprotiline]	52270B	Maprotiline Confirmation, Blood (Forensic)
[Memantine]	52421B	Memantine Confirmation, Blood (Forensic)
[Meperidine & Metabolite-reflex]	52068B	Meperidine and Metabolite Confirmation, Blood (Forensic)
[Mescaline]	52072B	Mescaline Confirmation, Blood (Forensic)
[Metaxalone]	52422B	Metaxalone Confirmation, Blood (Forensic)
[Methadone & Metabolite-reflex]	50015B	Methadone and Metabolite Confirmation, Blood (Forensic)
[Methaqualone]	52073B	Methaqualone Confirmation, Blood (Forensic)
[Methcathinone]	52430B	Methcathinone Confirmation (Qualitative), Blood (Forensic)
[Methocarbamol]	52076B	Methocarbamol Confirmation, Blood (Forensic)
[Methylphenidate]	52079B	Methylphenidate and Metabolite Confirmation, Blood (Forensic)
[Mexiletine]	52083B	Mexiletine Confirmation, Blood (Forensic)
[Mirtazapine]	52303B	Mirtazapine Confirmation, Blood (Forensic)
[Mitragynine]	52489B	Mitragynine Confirmation, Blood
[NBOMe-reflex]	52387B	NBOMe Confirmation (Qualitative), Blood
[Naltrexone & Metab-reflex]	52497B	Naltrexone and Metabolite - Free (Unconjugated) Confirmation, Blood (Forensic)
[Nonsteroidal-reflex]	52406B	Naproxen Confirmation, Blood (Forensic)
[Nifedipine]	52088B	Nifedipine Confirmation, Blood (Forensic)
[Olanzapine]	52091B	Olanzapine Confirmation, Blood (Forensic)
[Opiates - Free-reflex]	50016B	Opiates - Free (Unconjugated) Confirmation, Blood (Forensic)
[Orphenadrine]	52289B	Orphenadrine Confirmation, Blood (Forensic)
[10-Hydroxycarbazepine]	52093B	Oxcarbazepine/Eslicarbazepine Acetate as Metabolite Confirmation, Blood (Forensic)
[PMA]	52432B	PMA Confirmation (Qualitative), Blood (Forensic)
[Paroxetine]	52096B	Paroxetine Confirmation, Blood (Forensic)
[Perphenazine]	52423B	Perphenazine Confirmation, Blood (Forensic)
[Phencyclidine]	50017B	Phencyclidine Confirmation, Blood (Forensic)
[Pheniramine]	52291B	Pheniramine Confirmation, Blood (Forensic)
[Phenytoin]	52105B	Phenytoin Confirmation, Blood (Forensic)
[Designer Drugs-reflex]	52373B	Piperazine Designer Drugs Confirmation, Blood (Forensic)
[Primidone]	52106B	Primidone, Phenobarbital and PEMA Confirmation, Blood (Forensic)
[Prochlorperazine]	52469B	Prochlorperazine Confirmation, Blood (Forensic)
[Promazine]	52446B	Promazine Confirmation, Blood (Forensic)
[Promethazine]	52456B	Promethazine Confirmation, Blood (Forensic)
[Propoxyphene-reflex]	50018B	Propoxyphene and Metabolite Confirmation, Blood (Forensic)
[Psilocin]	52431B	Psilocin Confirmation (Qualitative), Blood (Forensic)
[MPHP]	52327B	Pyrrolidinophenone Confirmation, Blood
[Quetiapine]	52112B	Quetiapine Confirmation, Blood (Forensic)
[Quinidine]	52148B	Quinidine Confirmation, Blood (Forensic)
[Ramelteon]	52424B	Ramelteon and Metabolite Confirmation, Blood (Forensic)
[Risperidone-reflex]	52436B	Risperidone and Metabolite Confirmation, Blood (Forensic)
[Salicylates]	50001B	Salicylate Confirmation, Blood (Forensic)
[Sertraline-reflex]	52116B	Sertraline and Desmethylsertraline Confirmation, Blood (Forensic)
[Sildenafil]	52437B	Sildenafil and Metabolite Confirmation, Blood (Forensic)
[Strychnine]	52403B	Strychnine Confirmation, Blood (Forensic)
[Hallucinogen &Stimulant 3-refl]	52328B	Substituted Cathinone Panel, Blood
[Suvorexant]	52499B	Suvorexant Confirmation, Blood (Forensic)
[Synthetic Cannabs 1-reflex]	5971B	Synthetic Cannabinoids Confirmation Panel 1 (Qualitative), Blood
[Synthetic Cannabs 2-reflex]	5970B	Synthetic Cannabinoids Confirmation Panel 2 (Qualitative), Blood
[Synthetic Cannabinoids-reflex]	5960B	Synthetic Cannabinoids Confirmation, Blood (Forensic)
[Opiates (Low Dose)-reflex]	52407B	Synthetic Opioids - Free (Unconjugated) Confirmation, Blood (Forensic)
[Tadalafil]	52425B	Tadalafil Confirmation, Blood (Forensic)
[Tapentadol]	52426B	Tapentadol - Free Confirmation, Blood (Forensic)
[Tetrahydrozoline]	52427B	Tetrahydrozoline Confirmation, Blood (Forensic)
[Theophylline]	52121B	Theophylline Confirmation, Blood (Forensic)
[Thioridazine & Metab-reflex]	52283B	Thioridazine and Metabolite Confirmation, Blood (Forensic)
[Tiletamine]	52125B	Tiletamine Confirmation, Blood (Forensic)
[Topiramate]	52127B	Topiramate Confirmation, Blood (Forensic)
[Tramadol & Metabolite-reflex]	52128B	Tramadol and Metabolite Confirmation, Blood (Forensic)
[Trazodone]	52295B	Trazodone Confirmation, Blood (Forensic)
[Trifluoperazine]	52470B	Trifluoperazine Confirmation, Blood (Forensic)
[Trihexyphenidyl]	52415B	Trihexyphenidyl Confirmation, Blood (Forensic)

Associated Confirmation Tests

[Trimipramine & Metab-reflex]	52280B	Trimipramine and Metabolite Confirmation, Blood (Forensic)
[Triprolidine]	52297B	Triprolidine Confirmation, Blood (Forensic)
[Vardenafil]	52428B	Vardenafil and Metabolite Confirmation, Blood (Forensic)
[Venlafaxine-reflex]	52132B	Venlafaxine and Metabolite Confirmation, Blood (Forensic)
[Verapamil]	52298B	Verapamil Confirmation, Blood (Forensic)
[Xylazine]	52135B	Xylazine Confirmation, Blood (Forensic)
[Yohimbine]	52136B	Yohimbine Confirmation, Blood (Forensic)
[Zaleplon]	52137B	Zaleplon Confirmation, Blood (Forensic)
[Ziprasidone]	52429B	Ziprasidone Confirmation, Blood (Forensic)
[Zolazepam]	52138B	Zolazepam Confirmation, Blood (Forensic)
[Zolpidem]	52139B	Zolpidem Confirmation, Blood (Forensic)
[Zonisamide]	52140B	Zonisamide Confirmation, Blood (Forensic)

2. 50000B Acetaminophen Confirmation, Blood (Forensic)

Scope of Analysis: Acetaminophen
Method(s): High Performance Liquid Chromatography(HPLC)
Purpose: Confirmation of positive Screen; This test is New York State approved.
Category: Analgesic
Specimen Requirements: 1 mL Blood
Minimum Volume: 0.4 mL
Special Handling: None
Specimen Container: NMS Labs has no experimental or literature-based data regarding the choice of specific specimen collection containers for this test.
Transport Temperature: Refrigerated
Light Protection: Not Required
Rejection Criteria: None
Known Interference(s): N/A
Stability: Room Temperature: 1 month(s)
Refrigerated: 1 month(s)
Frozen (-20 °C): 1 month(s)

Method: High Performance Liquid Chromatography(HPLC)

Set-Up Days / TAT: Monday Thursday 3 days (after set-up)
CPT Code: 80329

Compound Name / Alias	Units	RL
Acetaminophen Tylenol®	mcg/mL	0.5

Reference Comment
Usual therapeutic range (Following one gram): 5 - 20 mcg/mL. Hepatic damage may occur if concentration is greater than 120 mcg/mL at 4 hours or greater than 50 mcg/mL at 12 hours after ingestion.

3. 52250B Alcohols and Acetone Confirmation, Blood (Forensic)

Scope of Analysis: Acetone; Ethanol; Isopropanol; Methanol
Method(s): Headspace Gas Chromatography (GC)
Purpose: Confirmation of positive Screen; This test is New York State approved.
Category: Hypnotic, Sedative, Volatile, Environmental/Occupation Toxin
Specimen Requirements: 1 mL Blood
Minimum Volume: 0.5 mL
Special Handling: Collect sample using alcohol free skin preparation.

Specimen Container: Gray top tube (Sodium Fluoride / Potassium Oxalate)
Transport Temperature: Refrigerated
Light Protection: Not Required
Rejection Criteria: None
Known Interference(s): N/A
Stability: Room Temperature: 7 day(s)
Refrigerated: 1 month(s)
Frozen (-20 °C): 8 month(s)

Method: Headspace Gas Chromatography (GC)

Set-Up Days / TAT: Monday-Friday 4 days (after set-up)
CPT Code: 80320

Compound Name / Alias	Units	RL
Ethanol Ethyl Alcohol	mg/dL	10
Methanol Methyl Alcohol	mg/dL	5.0
Isopropanol Isopropyl Alcohol	mg/dL	5.0
Acetone	mg/dL	5.0

Associated Confirmation Tests

[Ethanol]	0173B	Ethanol Re-Check - Post Mortem, Blood

4. 52143B Alfentanil and Sufentanil Confirmation, Blood (Forensic)

Scope of Analysis: Alfentanil; Sufentanil
Method(s): High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)
Purpose: Confirmation of positive Screen; This test is New York State approved.
Category: Anesthetic, Opioid Analgesic
Specimen Requirements: 2 mL Blood
Minimum Volume: 0.7 mL
Special Handling: None
Specimen Container: Lavender top tube (EDTA)
Transport Temperature: Refrigerated
Light Protection: Not Required
Rejection Criteria: None
Known Interference(s): N/A
Stability: Room Temperature: 1 month(s)
Refrigerated: 1 month(s)
Frozen (-20 °C): 3 month(s)

Method: High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

Set-Up Days / TAT: Monday-Friday 7 days (after set-up)
CPT Code: 80354

Compound Name / Alias	Units	RL
Alfentanil Alfenta®	ng/mL	0.1
Reference Comment Following an intravenous injection of 50 mcg/kg to two subjects, a mean plasma concentration of 540 ng/mL was reported at 1 minute, decreasing to 38 ng/mL at 1 hour.		
Sufentanil Sufenta®	ng/mL	0.1
Reference Comment Following I.V. administration of 30 mcg Sufentanil/kg for surgical analgesia, mean peak plasma levels range from 36 - 43 ng/mL and decline to 0.33 ng/mL at 23 hours. Terminal plasma elimination half-life occurs at 2 hours post dose.		

5. 52168B Amitriptyline and Metabolite Confirmation, Blood (Forensic)

Scope of Analysis:	Amitriptyline; Nortriptyline
Method(s):	Gas Chromatography (GC)
Purpose:	Confirmation of positive Screen; This test is New York State approved.
Category:	Antidepressant
Specimen Requirements:	2 mL Blood
Minimum Volume:	0.7 mL
Special Handling:	None
Specimen Container:	NMS Labs has no experimental or literature-based data regarding the choice of specific specimen collection containers for this test.
Transport Temperature:	Refrigerated
Light Protection:	Not Required
Rejection Criteria:	None
Known Interference(s):	N/A
Stability:	Room Temperature: 14 day(s) Refrigerated: 14 day(s) Frozen (-20 °C): 12 month(s)

Method:

Set-Up Days / TAT: N/A

CPT Code: 80362, 80376

Method: Gas Chromatography (GC)

Set-Up Days / TAT: Monday-Friday 3 days (after set-up)

CPT Code: 80355

Compound Name / Alias	Units	RL
Amitriptyline Elavil®; Endep®	ng/mL	20
Nortriptyline Amitriptyline Metabolite; Aventyl®; Pamelor®	ng/mL	20
Reference Comment Nortriptyline is a metabolite of Amitriptyline and is also available as an independent therapeutic agent. When Amitriptyline is the administered drug: Usual therapeutic range for the total of Amitriptyline plus Nortriptyline: 80 - 250 ng/mL. When Nortriptyline is the administered drug: Usual therapeutic range: 50 - 150 ng/mL.		

6. 52239B Amoxapine Confirmation, Blood (Forensic)

Scope of Analysis:	Amoxapine
Method(s):	Gas Chromatography (GC)
Purpose:	Confirmation of positive Screen; This test is New York State approved.
Category:	Antidepressant
Specimen Requirements:	2 mL Blood
Minimum Volume:	0.7 mL
Special Handling:	None
Specimen Container:	NMS Labs has no experimental or literature-based data regarding the choice of specific specimen collection containers for this test.
Transport Temperature:	Refrigerated
Light Protection:	Not Required
Rejection Criteria:	None
Known Interference(s):	N/A
Stability:	Room Temperature: 7 day(s) Refrigerated: 14 day(s) Frozen (-20 °C): 10 month(s)

Method: Gas Chromatography (GC)

Set-Up Days / TAT: Tuesday Thursday 3 days (after set-up)

CPT Code: 80335

Compound Name / Alias	Units	RL
Amoxapine Asendin®	ng/mL	20

Reference Comment

Reported serum concentrations following a 300 mg daily regimen ranged from 17 - 93 ng/mL.

The ratio of whole blood concentration to serum or plasma concentration is unknown for this analyte.

7. 52485B Amphetamines Confirmation, Blood (Forensic)

Scope of Analysis:	Amphetamine; Ephedrine; MDA; MDEA; Methamphetamine; Norpseudoephedrine; Phentermine; Phenylpropanolamine; Pseudoephedrine
Method(s):	High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)
Purpose:	Confirmation of positive Screen; This test is New York State approved.
Category:	Antihistamine, Decongestant, Stimulant, Appetite Suppressant, Stimulant, Anorexogenic, Bronchodilator, Stimulant, Decongestant, Stimulant
Specimen Requirements:	1 mL Blood
Minimum Volume:	0.3 mL
Special Handling:	None
Specimen Container:	Lavender top tube (EDTA)
Transport Temperature:	Refrigerated
Light Protection:	Not Required
Rejection Criteria:	None
Known Interference(s):	N/A
Stability:	Room Temperature: 16 day(s) Refrigerated: 16 day(s) Frozen (-20 °C): 16 day(s)

Method: **High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)**

Set-Up Days / TAT: Monday-Friday 7 days (after set-up)

CPT Code: 80326, 80359

Compound Name / Alias	Units	RL
Ephedrine	ng/mL	5.0

Reference Comment

A single 24 mg oral dose resulted in a peak plasma concentration of approximately 100 ng/mL.

During chronic daily oral therapy with 15 mg (3 times daily), a plasma level of 95 ng/mL was reported at 4 hours, and 65 ng/mL at 6 hours after one 15 mg dose.

Pseudoephedrine	ng/mL	5.0

Reference Comment

Following a 60 mg oral dose (immediate-release tablet or syrup), mean peak plasma concentrations of 180 to 360 ng/mL were reported at 3 hours.

Following a 120 mg oral dose (controlled-release capsule), mean peak plasma concentrations of 265 to 315 ng/mL were reported.

Chronic administration of 360 mg/day (of a controlled-release preparation) resulted in mean steady-state plasma concentrations between 500 and 640 ng/mL over a 10-day period.

Phenylpropanolamine Norephedrine; PPA	ng/mL	5.0

Reference Comment

Phenylpropanolamine is a drug as well as the metabolite of Ephedrine.

Following a single 50 mg oral dose (immediate-release tablet), the mean peak plasma concentration was 180 ng/mL at 1 to 2 hours.

Following a single 150 mg oral dose (sustained-release preparation), the mean peak plasma concentration was 280 ng/mL at 6 hours.

Norpseudoephedrine Cathine	ng/mL	5.0

Reference Comment

Norpseudoephedrine is a metabolite of Pseudoephedrine.

Amphetamine	ng/mL	5.0

Reference Comment

Amphetamine is a drug as well as the metabolite of Methamphetamine.

Therapeutic Range (treatment of Narcolepsy or Attention Deficit Disorder) with doses between 10 and 30 mg daily: Mean peak plasma concentrations between 35 and 110 ng/mL.

Phentermine Adipex-P®; Ionamin®; Pro-Fast®	ng/mL	5.0

Reference Comment

A single 26 mg/70 kg oral dose produced a mean peak blood concentration of 90 ng/mL at 4 hours, declining to 30 ng/mL after 40 hours.

Adults receiving 30 mg daily oral doses for 2 weeks achieved a mean steady-state plasma concentration of 360 ng/mL (range 180 to 510 ng/mL).

Compound Name / Alias	Units	RL
Methamphetamine	ng/mL	5.0

Reference Comment

Benzphetamine is rapidly metabolized to Amphetamine and Methamphetamine.

This test reports Methamphetamine as the total of the undifferentiated d and l enantiomers. The ratio of these enantiomers is important in determining whether the source of Methamphetamine is from over the counter medications, prescribed medication or controlled substances.
Call lab for further information on d to l enantiomer ratio determination.

MDA 3,4-Methylenedioxyamphetamine; Adam; MDMA Metabolite	ng/mL	5.0

Reference Comment

MDA is a metabolite of MDMA and methylenedioxyethylamphetamine (MDEA) and is abused for its central nervous system stimulant and hallucinogenic properties.
The peak concentration of the MDA metabolite following a 110 mg dose of MDMA was reported as 28 ng/mL at 4 hours.

The blood to plasma ratio of MDA is approximately 1.2 - 1.3

MDEA 3,4-methylenedioxyethamphetamine; Eve	ng/mL	5.0

Reference Comment

A single oral 140 mg dose given to 6 adults produced peak plasma concentrations that averaged 260 ng/mL at 2.2 hours.

8. 52416B Aripiprazole Confirmation, Blood (Forensic)

Scope of Analysis:	Aripiprazole
Method(s):	High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)
Purpose:	Confirmation of positive Screen; This test is New York State approved.
Category:	Antipsychotic
Specimen Requirements:	1 mL Blood
Minimum Volume:	0.3 mL
Special Handling:	None
Specimen Container:	Gray top tube (Sodium Fluoride / Potassium Oxalate)
Transport Temperature:	Refrigerated
Light Protection:	Not Required
Rejection Criteria:	None
Known Interference(s):	N/A
Stability:	Room Temperature: 30 day(s) Refrigerated: 30 day(s) Frozen (-20 °C): 30 day(s)

Method: High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

Set-Up Days / TAT:	Friday 3 days (after set-up)
CPT Code:	80342

v.18

Compound Name / Alias	Units	RL
Aripiprazole Abilify®	ng/mL	20

Reference Comment

Steady-state plasma levels in adults following a daily regimen have been reported as:
5 mg - 70 to 126 ng/mL
10 mg - 109 to 216 ng/mL
15 mg - 206 to 278 ng/mL
20 mg - 212 to 574 ng/mL
30 mg - 320 to 585 ng/mL.

9. 52007B Atomoxetine Confirmation, Blood (Forensic)

Scope of Analysis: Atomoxetine
Method(s): Gas Chromatography/Mass Spectrometry (GC/MS)
Purpose: Confirmation of positive Screen; This test is New York State approved.
Category: Antidepressant
Specimen Requirements: 5 mL Blood
Minimum Volume: 2.1 mL
Special Handling: None
Specimen Container: Gray top tube (Sodium Fluoride / Potassium Oxalate)
Transport Temperature: Refrigerated
Light Protection: Not Required
Rejection Criteria: None
Known Interference(s): N/A
Stability: Room Temperature: 7 day(s)
Refrigerated: 30 day(s)
Frozen (-20 °C): 6 month(s)

Method: Gas Chromatography/Mass Spectrometry (GC/MS)

Set-Up Days / TAT: Tuesday Thursday 3 days (after set-up)
CPT Code: 80338

Compound Name / Alias	Units	RL
Atomoxetine Strattera®	ng/mL	20

Reference Comment

No reference data available.

10. 50011B Barbiturates Confirmation, Blood (Forensic)

Scope of Analysis: Amobarbital; Butabarbital; Butalbital; Pentobarbital; Phenobarbital; Secobarbital
Method(s): Gas Chromatography/Mass Spectrometry (GC/MS)
Purpose: Confirmation of positive Screen; This test is New York State approved.
Category: Hypnotic, Sedative, Anticonvulsant, Sedative
Specimen Requirements: 2 mL Blood
Minimum Volume: 0.7 mL
Special Handling: None
Specimen Container: Lavender top tube (EDTA)
Transport Temperature: Refrigerated
Light Protection: Not Required

Rejection Criteria: None

Known Interference(s): N/A

Stability: Room Temperature: 14 day(s)

Refrigerated: 14 day(s)

Frozen (-20 °C): 14 day(s)

Method: Gas Chromatography/Mass Spectrometry (GC/MS)

Set-Up Days / TAT: Tuesday Thursday 3 days (after set-up)

CPT Code: 80345

Compound Name / Alias	Units	RL
Butabarbital Butisol Sodium	mcg/mL	0.2
Reference Comment Plasma concentrations of 2 - 3 mcg/mL produce sedation and plasma concentrations of 25 mcg/mL produce sleep in most patients. Plasma concentrations of greater than 30 mcg/mL may produce coma and plasma concentrations in excess of 50 mcg/mL are potentially lethal.		
Butalbital	mcg/mL	0.2
Reference Comment A single oral 100 mg dose resulted in a mean peak blood concentration of 2.1 mcg/mL (range, 1.7 - 2.6 mcg/mL) at 2 hours, with a decline to 1.5 mcg/mL (range, 1.3 - 1.7 mcg/mL) by 24 hours. Potentially toxic at plasma concentrations greater than 10 mcg/mL.		
Amobarbital	mcg/mL	0.2
Reference Comment Following a single oral administration of 120 mg, serum concentrations peaked at about 1.8 mcg/mL at 2 hours, and declined slowly thereafter with a half-life of approximately 24 hours. Potentially toxic at plasma concentrations greater than 9 mcg/mL.		
Pentobarbital	mcg/mL	0.2
Reference Comment Peak serum concentrations of 1.2 - 3.1 mcg/mL were produced 0.5 - 2.0 hours after a 100 mg oral dose and peak serum concentrations of 3 mcg/mL were produced 6 min. following a 100 mg IV dose. Potentially toxic at blood concentrations greater than 10 mcg/mL.		
Secobarbital Seconal®	mcg/mL	0.2
Reference Comment A 3.3 mg/kg oral dose (approx. 230 mg/70 kg) produced a mean peak blood concentration of 2.0 mcg/mL (range, 1.8 - 2.2 mcg/mL) at 3 hours, diminishing to 1.3 mcg/mL by 20 hours and 0.8 mcg/mL by 40 hours. Potentially toxic at blood concentrations greater than 8 mcg/mL.		
Phenobarbital Luminal®	mcg/mL	0.2
Reference Comment Serum/plasma concentrations of 10 - 30 mcg/mL are generally considered desirable when given as an anticonvulsant. A blood/plasma ratio of 0.81 has been reported.		

11. 52365B Bath Salts Confirmation, Blood (Forensic)

Scope of Analysis:	MDPV; Mephedrone; Methylone
Method(s):	High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)
Purpose:	Confirmation of positive Screen; This test is New York State approved.
Category:	NPS
Specimen Requirements:	1 mL Blood
Minimum Volume:	0.4 mL
Special Handling:	None
Specimen Container:	Gray top tube (Sodium Fluoride / Potassium Oxalate)
Transport Temperature:	Refrigerated
Light Protection:	Not Required
Rejection Criteria:	Received Room Temperature.
Known Interference(s):	N/A
Stability:	Room Temperature: 1 day(s) Refrigerated: 7 day(s) Frozen (-20 °C): 30 day(s)

Method: High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

Set-Up Days / TAT: Monday 3 days (after set-up)

CPT Code: 80371

Compound Name / Alias	Units	RL
Mephedrone 4-MMC; 4-methyl-N-methcathinone; 4-methylmethcathinone	ng/mL	10

Reference Comment

Mephedrone is a psychoactive phenethylamine derivative that is structurally related to methcathinone and amphetamine. It is abused for its perceived 'ecstasy like' effects of euphoria, excitement, and alertness.

Reported adverse effects include peripheral vasoconstriction resulting in a bruised appearance on the arms and legs, loss of appetite, poor concentration, increased heart rate, sweating with an odor, and dilation of the pupils.

In two fatalities where mephedrone intoxication was determined to be the cause of death blood concentrations were 22000 ng/mL and 3300 ng/mL.

MDPV 1-(1,3-benzodioxol-5-yl)-2-pyrrolidin-1-ylpentan-1-one; MDPK; Methylenedioxypyrovalerone	ng/mL	10

Reference Comment

MDPV is a synthetic stimulant drug reported to have effects similar to methylphenidate at low doses and cocaine at high doses. Desired outcomes following use include increased energy and sociability, increased concentration, psychedelic effects and sexual stimulation.

Reported adverse effects include insomnia, severe agitation/anxiety, panic attacks, kidney pain, stomach cramps, tachycardia, hypertension, dilated pupils, headache, tinnitus and peripheral neuropathies and dizziness. Use of MDPV has been linked to the popular 'Designer Drug' movement and may be present in products sold as 'Legal High' or 'Bath Salts' for recreational purposes. The drug is usually taken orally, but can also be insufflated or vaporized.

Blood concentrations in 17 fatalities were 10 - 5000 ng/mL. Blood concentrations in 9 cases of drivers exhibiting signs of impairment were 6 - 360 ng/ml; other impairing drugs were often found in conjunction with MDPV.

Compound Name / Alias	Units	RL
Methylone 3,4-methylenedioxy-N-methylcathinone; bk-MDMA	ng/mL	5.0

Reference Comment

Methylone is a methylenedioxy beta keto amphetamine, or cathinone stimulant drug. It is the beta-keto analog of MDMA. Its use has been linked to the popular 'Designer Drug' movement, and may be present in products sold as 'Legal High' or 'Bath Salts' for recreational purposes. Methylone acts as an inhibitor of dopamine, norepinephrine, and serotonin reuptake and may have stimulating effects on the central nervous system. The drug is usually taken orally, but can also be insufflated or vaporized.

Euphoria, agitation, sweating, nausea, vomiting, dilated pupils, seizures, hyponatremia and confusion were reported in two cases after the use of bath salt products found to contain methylone. Other substances may have been present.

Four fatalities attributed to this drug had methylone heart blood concentrations of 60 - 1100 ng/mL; concentrations in femoral blood in three fatalities were 560, 840, and 3300 ng/mL.

Methylone is known to have limited stability in blood which may be dependent upon pH, collection tube, and storage temperature; results should be interpreted with caution.

12. 52367B Bath Salts Confirmation, Blood (Forensic)

Scope of Analysis:	Methoxetamine; Pentedrone; alpha-PVP
Method(s):	High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)
Purpose:	Confirmation of positive Screen; This test is New York State approved.
Category:	NPS
Specimen Requirements:	1 mL Blood
Minimum Volume:	0.4 mL
Special Handling:	None
Specimen Container:	Gray top tube (Sodium Fluoride / Potassium Oxalate)
Transport Temperature:	Refrigerated
Light Protection:	Not Required
Rejection Criteria:	Received Room Temperature.
Known Interference(s):	N/A
Stability:	Room Temperature: 1 day(s) Refrigerated: 30 day(s) Frozen (-20 °C): 30 day(s)

If this test contains multiple compounds, the reported stability reflects that which is least stable. Stability may vary among compounds included in the test and may be dependent upon matrix, pH, collection tube, and storage temperature. Negative results should be interpreted with caution. For more information on stability of a specific compound please contact the laboratory.

NOTE: If the test contains multiple compounds samples received at room temperature will not be rejected.

Method:	High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)
Set-Up Days / TAT:	Monday 3 days (after set-up)
CPT Code:	80371

Compound Name / Alias	Units	RL
alpha-PVP alpha-Pyrrolidinovalerophenone; alpha-pyrrolidinopentiophenone	ng/mL	2.0

Reference Comment

Alpha-Pyrrolidinovalerophenone (alpha-PVP) is a psychoactive stimulant that is structurally related to pyrovalerone and MDPV. The compound has been sold on the internet as a designer drug for the intention of recreational drug use in the form of tablets or powders to be taken orally or insufflated, respectively. It is abused for its perceived 'ecstasy like' effects of euphoria, excitement and alertness. It is claimed that alpha-PVP improves productivity, wakefulness, motivation, locomotion and endurance. In general, psychoactive stimulants have temporary effects on the psychoneurotic system. In addition, they seem to have a much higher tendency to cause side effects such as paranoia, hallucinations, and schizophrenic or psychosis like symptoms.
Serum concentrations in 2 fatalities were 410 and 1500 ng/mL. A serum concentration in a case where the individual presented to the ED with visual hallucinations, psychotic symptoms, tachycardia, and rhabdomyolysis was 235 ng/mL; other impairing drugs were often found in conjuction with Alpha PVP.
The blood to plasma ratio for alpha-PVP is not known.

Pentedrone	ng/mL	2.0

Reference Comment

Pentedrone is a beta keto amphetamine or cathinone that is chemically related to mephedrone. It is a stimulant drug that was first reported in 2010. Its use has been linked to the popular 'Designer Drug' movement and may be present in products sold as 'Legal Highs' or 'Bath Salts' for recreational purposes. The drug is usually taken orally, but can also be insufflated or vaporized.

Pentedrone is known to have limited stability in blood which may be dependent upon pH, collection tube, and storage temperature. Results should be interpreted with caution.

Methoxetamine	ng/mL	2.0

Reference Comment

Methoxetamine is a psychoactive compound that is structurally related to ketamine and reported to have similar effects. Ketamine is a DEA Schedule III rapidly acting general anesthetic that is chemically related to phencyclidine (PCP). The effects of ketamine include profound analgesia, normal or enhanced skeletal muscle tone and cardiovascular and respiratory stimulation. Reactions manifested by hallucinations, delirium, irrational behavior and/or dream-like states may be seen with use of ketamine and, presumably, methoxetamine. The use of methoxetamine has been linked to the popular 'Designer Drug' movement and this substance may be present in products sold as 'Legal Highs' or 'Bath Salts' for recreational purposes.

Blood concentrations of 130 - 490 ng/g (approximately 130 - 510 ng/mL) have been reported following acute ingestion of methoxetamine. In one fatality a concentration of 8600 ng/g (approximately 9000 ng/mL) was reported.

13. 50012B Benzodiazepines Confirmation, Blood (Forensic)

Scope of Analysis:	7-Amino Clonazepam; Alpha-Hydroxyalprazolam; Alprazolam; Chlordiazepoxide; Clobazam; Clonazepam; Desalkylflurazepam; Diazepam; Estazolam; Flurazepam; Hydroxyethylflurazepam; Hydroxytriazolam; Lorazepam; Midazolam; Nordiazepam; Oxazepam; Temazepam; Triazolam
Method(s):	High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)
Purpose:	Confirmation of positive Screen; This test is New York State approved.
Category:	Hypnotic, Sedative, Anxiolytic, Tranquilizer, Anxiolytic, Sedative, Anticonvulsant, Antiepileptic
Specimen Requirements:	1 mL Blood
Minimum Volume:	0.3 mL
Special Handling:	None
Specimen Container:	Lavender top tube (EDTA)
Transport Temperature:	Refrigerated
Light Protection:	Not Required
Rejection Criteria:	None
Known Interference(s):	N/A
Stability:	Room Temperature: 14 day(s) Refrigerated: 14 day(s) Frozen (-20 °C): 14 day(s)

Method: High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

Set-Up Days / TAT: Monday-Friday 7 days (after set-up)

CPT Code: 80347

Compound Name / Alias	Units	RL
Diazepam Valium®	ng/mL	20
Reference Comment Therapeutic range: 100 - 1000 ng/mL.		
Nordiazepam Chlordiazepoxide Metabolite	ng/mL	20
Reference Comment Psychiatric patients taking chronic diazepam doses ranging from 2 to 55 mg daily had steady state plasma concentrations of nordiazepam averaging 390 ng/mL (range 26 to 1600 ng/mL). The blood to plasma ratio of nordiazepam is 0.6.		
Oxazepam Serax®	ng/mL	20
Reference Comment When used as a drug, the therapeutic plasma concentration: 200 - 1400 ng/mL. Potentially toxic greater than 2000 ng/mL. As a metabolite of Diazepam, low concentrations may be observed. In one study, following chronic daily doses of about 70 mg of Diazepam, the steady-state serum concentrations were 50 - 400 ng Oxazepam/mL.		
Temazepam Diazepam Metabolite; Normison®	ng/mL	20
Reference Comment When used as a drug, peak plasma concentrations range from 200 - 1100 ng/mL within 1.5 hours post-dose. As a metabolite of Diazepam, low concentrations may be observed. In one study, following chronic daily doses of about 70 mg of Diazepam, the steady-state serum concentrations were 100 - 600 ng Temazepam/mL.		

Compound Name / Alias	Units	RL
Clobazam Frisium®; Urbanyl®	ng/mL	20
Reference Comment Following a single 20 mg oral dose, the mean peak plasma concentration: 465 ng/mL (range, 220 - 710 ng/mL) after 1.7 hours. Following a single 40 mg oral dose, the mean peak plasma concentration: 730 ng/mL at 2.5 hours. The plasma concentration decreased to 360 ng/mL at 12 hours, 180 ng/mL at 48 hours and 17 ng/mL at 96 hours.		
Chlordiazepoxide Librium®	ng/mL	20
Reference Comment Therapeutic range: 400 - 2000 ng/mL.		
Lorazepam Ativan®	ng/mL	5.0
Reference Comment Therapeutic range: 50 - 240 ng/mL.		
Clonazepam Klonopin®	ng/mL	2.0
Reference Comment Therapeutic range: 10 - 75 ng/mL. Toxic: Greater than 100 ng/mL.		
7-Amino Clonazepam Clonazepam Metabolite	ng/mL	5.0
Reference Comment Plasma concentrations following chronic therapy with 6 mg/day of Clonazepam: 20 - 140 ng/mL.		
Alprazolam Xanax®	ng/mL	5.0
Reference Comment Therapeutic range: 10 - 100 ng/mL. Potentially toxic at greater than 100 ng/mL.		
Alpha-Hydroxyalprazolam Alprazolam Metabolite	ng/mL	5.0
Reference Comment Alpha-Hydroxyalprazolam has approximately 66% of the pharmacological activity of Alprazolam.		
Midazolam Versed®	ng/mL	5.0
Reference Comment Peak plasma levels following a single 12.5 mg IM dose: approximately 200 ng/mL within 45 minutes of dose. Following a single 75 mcg/kg IV dose over 1 minute: 320 ng/mL at 0.25 hours 250 ng/mL at 0.5 hours 210 ng/mL at 1 hour 140 ng/mL at 2 hours 80 ng/mL at 4 hours 40 ng/mL at 6 hours 20 ng/mL at 8 hours.		
Triazolam Halcion®	ng/mL	2.0
Reference Comment Following a single 0.25 mg oral dose, the mean plasma concentration: 3.0 ng/mL (range, 2.3 - 3.7 ng/mL) within 1.5 hours. Following a single 0.5 mg oral dose, the mean plasma concentration: 4.4 ng/mL (range, 1.7 - 9.4 ng/mL) within 4 hours.		

Compound Name / Alias	Units	RL
Hydroxytriazolam Triazolam Metabolite	ng/mL	5.0
Reference Comment Hydroxytriazolam has 50 to 100% of the pharmacological activity of Triazolam.		
Hydroxyethylflurazepam Flurazepam Metabolite	ng/mL	5.0
Reference Comment The mean peak plasma concentration following a 30 mg oral dose of Flurazepam was 18 ng Hydroxyethylflurazepam/mL at 1 hour post dose.		
Desalkylflurazepam Flurazepam Metabolite	ng/mL	5.0
Reference Comment The mean peak plasma concentration following a 30 mg oral dose of Flurazepam was 23 ng Desalkylflurazepam/mL at 12 hours post dose.		
Flurazepam Dalmane®	ng/mL	2.0
Reference Comment The mean peak plasma concentration following a 30 mg oral dose was 2.1 ng/mL at 1 hour post dose, but was undetectable at subsequent times.		
Estazolam ProSom®	ng/mL	5.0
Reference Comment The mean peak plasma concentration following a 1 mg oral dose was 55 ng/mL (range, 40 - 70 ng/mL). The mean peak plasma concentration following a 2 mg oral dose was 98 ng/mL (range, 75 - 140 ng/mL).		

14. 52443B Benztropine Confirmation, Blood (Forensic)

Scope of Analysis:	Benztropine
Method(s):	High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)
Purpose:	Confirmation of positive Screen; This test is New York State approved.
Category:	Anticholinergic
Specimen Requirements:	1 mL Blood
Minimum Volume:	0.4 mL
Special Handling:	None
Specimen Container:	Lavender top tube (EDTA)
Transport Temperature:	Refrigerated
Light Protection:	Not Required
Rejection Criteria:	None
Known Interference(s):	N/A
Stability:	Room Temperature: 30 day(s) Refrigerated: 30 day(s) Frozen (-20 °C): 30 day(s)

Method: High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

Set-Up Days / TAT:	Monday Wednesday Friday 3 days (after set-up)
CPT Code:	80375

Compound Name / Alias	Units	RL
Benztropine Cogentin®	ng/mL	1.0
Reference Comment Reported therapeutic range in plasma: Approximately 80 - 120 ng/mL after daily 4 mg oral dose. Toxicities reported at levels greater than 100 ng/mL in serum.		

15. 52245B Brompheniramine Confirmation, Blood (Forensic)

Scope of Analysis:	Brompheniramine
Method(s):	Gas Chromatography (GC)
Purpose:	Confirmation of positive Screen; This test is New York State approved.
Category:	Antihistamine
Specimen Requirements:	2 mL Blood
Minimum Volume:	0.7 mL
Special Handling:	None
Specimen Container:	NMS Labs has no experimental or literature-based data regarding the choice of specific specimen collection containers for this test.
Transport Temperature:	Refrigerated
Light Protection:	Not Required
Rejection Criteria:	None
Known Interference(s):	N/A
Stability:	Room Temperature: Undetermined Refrigerated: Undetermined Frozen (-20 °C): Undetermined

Method: Gas Chromatography (GC)

Set-Up Days / TAT:	Tuesday Thursday 3 days (after set-up)
CPT Code:	80375

Compound Name / Alias	Units	RL
Brompheniramine Dimetane; Dimetapp	ng/mL	40

Reference Comment

Therapeutic range: 5 - 15 ng/mL.
Toxic: Greater than 500 ng/mL.

16. 52011B Bupivacaine Confirmation, Blood (Forensic)

Scope of Analysis:	Bupivacaine
Method(s):	Gas Chromatography (GC)
Purpose:	Confirmation of positive Screen; This test is New York State approved.
Category:	Anesthetic
Specimen Requirements:	1 mL Blood
Minimum Volume:	0.4 mL
Special Handling:	None
Specimen Container:	NMS Labs has no experimental or literature-based data regarding the choice of specific specimen collection containers for this test.
Transport Temperature:	Refrigerated
Light Protection:	Not Required
Rejection Criteria:	None
Known Interference(s):	N/A
Stability:	Room Temperature: Undetermined Refrigerated: Undetermined Frozen (-20 °C): Undetermined

Method: Gas Chromatography (GC)

Set-Up Days / TAT:	Tuesday 3 days (after set-up)
CPT Code:	80375

Compound Name / Alias	Units	RL
Bupivacaine Marcaine®	mcg/mL	0.1

Reference Comment

Following a single 150 mg peridural blocking dose:
Up to 1.1 mcg/mL.

17. 52012B Bupropion and Metabolite Confirmation, Blood (Forensic)

Scope of Analysis:	Bupropion; Hydroxybupropion
Method(s):	High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)
Purpose:	Confirmation of positive Screen; This test is New York State approved.
Category:	Antidepressant
Specimen Requirements:	1 mL Blood
Minimum Volume:	0.3 mL
Special Handling:	None
Specimen Container:	Lavender top tube (EDTA)
Transport Temperature:	Refrigerated
Light Protection:	Not Required
Rejection Criteria:	Received Room Temperature.
Known Interference(s):	N/A
Stability:	Room Temperature: Not Stable Refrigerated: 7 day(s) Frozen (-20 °C): 1 month(s)

Method: High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

Set-Up Days / TAT:	Wednesday Sunday 2 days (after set-up)
CPT Code:	80338

Compound Name / Alias	Units	RL
Bupropion Wellbutrin®	ng/mL	10

Reference Comment

Maximum antidepressant response was observed at trough plasma concentrations of 50 - 100 ng/mL bupropion with virtually no response below 25 ng/mL.

Reported average bupropion peak plasma concentrations:
Adults: Single 100 mg IR - 120 +/- 10 ng/mL (Males);
150 +/- 10 ng/mL (Females)
Adults: Single 200 mg IR -220 +/- 20 ng/mL (Males);
270 +/- 20 ng/mL (Females)
Adults: Single 150 mg SR – 140 +/- 20 ng/mL
Juveniles: 100 mg/day SR for 2 weeks - 25 +/- 8 ng/mL
Juveniles: 200 mg/day SR for 2 weeks - 53 +/- 22 ng/mL

The ratio of whole blood concentration to serum or plasma concentration is unknown for this analyte.

Specimens must be kept frozen. If specimens are not kept frozen, this may cause lower or negative values.

Hydroxybupropion Bupropion Metabolite	ng/mL	100

Reference Comment

8 adults (Age 22-42) taking thrice daily 100 mg normal release bupropion for 2 weeks had an average peak plasma concentration of 1000 +/- 70 ng/mL hydroxybupropion.

Juvenile patients taking once daily, extended release bupropion for two weeks had the following peak plasma concentrations:
100 mg/day (n = 11), 450 +/- 210 ng/mL hydroxybupropion
200 mg/day (n = 8), 710 +/- 350 ng/mL hydroxybupropion

The ratio of whole blood concentration to serum or plasma concentration is unknown for this analyte.

18. 52444B Buspirone Confirmation, Blood (Forensic)

Scope of Analysis:	Buspirone
Method(s):	High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)
Purpose:	Confirmation of positive Screen; This test is New York State approved.
Category:	Anxiolytic
Specimen Requirements:	1 mL Blood
Minimum Volume:	0.4 mL
Special Handling:	Peak serum levels are recommended when monitoring patients because the level in the blood drops so rapidly that many negative results are found at the trough. The peak occurs at 40 to 90 minutes post dose.
Specimen Container:	Lavender top tube (EDTA)
Transport Temperature:	Refrigerated
Light Protection:	Not Required
Rejection Criteria:	None
Known Interference(s):	N/A
Stability:	Room Temperature: 30 day(s) Refrigerated: 1 month(s) Frozen (-20 °C): 1 month(s)

Method: High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

Set-Up Days / TAT: Monday Wednesday Friday 3 days (after set-up)

CPT Code: 80375

Compound Name / Alias	Units	RL
Buspirone BuSpar®	ng/mL	0.5

Reference Comment

Peak plasma levels of 1 - 6 ng/mL have been observed
40 to 90 minutes after a single oral dose of 20 mg.

19. 52198B Cannabinoids Confirmation, Blood (Forensic)

Scope of Analysis:	11-Hydroxy Delta-9 THC; Delta-9 Carboxy THC; Delta-9 THC
Method(s):	High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)
Purpose:	Confirmation of positive Screen; This test is New York State approved.
Category:	Cannabinoid
Specimen Requirements:	1 mL Blood
Minimum Volume:	0.45 mL
Special Handling:	None
Specimen Container:	Gray top tube (Sodium Fluoride / Potassium Oxalate)
Transport Temperature:	Refrigerated
Light Protection:	Not Required
Rejection Criteria:	None
Known Interference(s):	N/A
Stability:	Room Temperature: 30 day(s) Refrigerated: 30 day(s) Frozen (-20 °C): 3 month(s)

Method: **High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)**

Set-Up Days / TAT: Monday-Friday 3 days (after set-up)

CPT Code: 80349

Compound Name / Alias	Units	RL
11-Hydroxy Delta-9 THC Active Metabolite	ng/mL	1.0
Reference Comment 11-Hydroxy Delta-9 THC is an active intermediate metabolite of tetrahydrocannabinol (THC) the active component of marijuana. Usual peak levels: Less than 10% of THC levels after smoking.		
Delta-9 Carboxy THC Inactive Metabolite	ng/mL	5.0
Reference Comment Usual peak levels in Serum for 1.75% or 3.55% THC marijuana cigarettes: 10 - 101 ng/mL about 32 to 240 minutes after beginning smoking, with a slow decline. Usually not detectable after passive inhalation.		
Delta-9 THC Active Ingredient of Marijuana	ng/mL	0.5
Reference Comment THC concentrations in blood are usually about one-half of serum/plasma concentrations. Usual peak levels in serum for 1.75% or 3.55% THC marijuana cigarettes: 50 - 270 ng/mL at 6 to 9 minutes after beginning smoking, decreasing to less than 5 ng/mL by 2 hrs.		

20. 52015B Carbamazepine and Metabolite Confirmation, Blood (Forensic)

Scope of Analysis: Carbamazepine; Carbamazepine-10,11-Epoxide

Method(s): High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

Purpose: Confirmation of positive Screen; This test is New York State approved.

Category: Anticonvulsant, Antiepileptic

Specimen Requirements: 1 mL Blood

Minimum Volume: 0.25 mL

Special Handling: None

Specimen Container: Gray top tube (Sodium Fluoride / Potassium Oxalate)

Transport Temperature: Refrigerated

Light Protection: Not Required

Rejection Criteria: None

Known Interference(s): N/A

Stability: Room Temperature: 30 day(s)

Refrigerated: 30 day(s)

Frozen (-20 °C): 24 month(s)

Method: **High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)**

Set-Up Days / TAT: Monday Wednesday Friday 3 days (after set-up)

CPT Code: 80156

Compound Name / Alias	Units	RL
Carbamazepine-10,11-Epoxide Carbamazepine Metabolite	mcg/mL	0.2
Reference Comment Carbamazepine-10,11-Epoxide has anticonvulsant activity similar to the parent drug. The expected range following chronic therapeutic doses (5.3 - 20 mg/kg) of Carbamazepine: 0.2 - 2.0 mcg Carbamazepine-10,11-Epoxide/mL.		

Compound Name / Alias	Units	RL
Carbamazepine Tegretol®	mcg/mL	0.2

Reference Comment

Usual antiepileptic range: 4 - 12 mcg/mL.
Toxic: Greater than 15 mcg/mL.

21. 52017B Carisoprodol and Metabolite Confirmation, Blood (Forensic)

Scope of Analysis:	Carisoprodol; Meprobamate
Method(s):	Gas Chromatography/Mass Spectrometry (GC/MS)
Purpose:	Confirmation of positive Screen; This test is New York State approved.
Category:	Muscle Relaxant
Specimen Requirements:	2 mL Blood
Minimum Volume:	0.7 mL
Special Handling:	None
Specimen Container:	Lavender top tube (EDTA)
Transport Temperature:	Refrigerated
Light Protection:	Not Required
Rejection Criteria:	None
Known Interference(s):	N/A
Stability:	Room Temperature: 21 day(s) Refrigerated: 21 day(s) Frozen (-20 °C): 21 day(s)

Method: Gas Chromatography/Mass Spectrometry (GC/MS)

Set-Up Days / TAT:	Monday Thursday 3 days (after set-up)
CPT Code:	80369

Compound Name / Alias	Units	RL
Carisoprodol Soma®	mcg/mL	0.2

Reference Comment

Following a 350 mg oral dose of carisoprodol, peak plasma concentrations averaged 2.1 mcg/mL in 1 hour.
Following a 700 mg oral dose of carisoprodol, peak plasma concentrations averaged 3.5 mcg/mL in 0.8 hour.

Meprobamate Carisoprodol Metabolite	mcg/mL	1.0

Reference Comment

Usual therapeutic range: 10 - 30 mcg/mL.

22. 52440B Chlorpheniramine Confirmation, Blood (Forensic)

Scope of Analysis:	Chlorpheniramine
Method(s):	High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)
Purpose:	Confirmation of positive Screen; This test is New York State approved.
Category:	Antihistamine
Specimen Requirements:	1 mL Blood
Minimum Volume:	0.4 mL
Special Handling:	None
Specimen Container:	Gray top tube (Sodium Fluoride / Potassium Oxalate)
Transport Temperature:	Refrigerated
Light Protection:	Not Required

Rejection Criteria: None
Known Interference(s): N/A
Stability: Room Temperature: 1 month(s)
Refrigerated: 1 month(s)
Frozen (-20 °C): 6 month(s)

Method: High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

Set-Up Days / TAT: Monday Wednesday Thursday Friday 3 days (after set-up)
CPT Code: 80375

Compound Name / Alias	Units	RL
Chlorpheniramine Chlor-Trimeton®	ng/mL	10

Reference Comment
Peak concentrations of 10 ng/mL chlorpheniramine were obtained 3 hours following single oral administration of 8 mg. Toxic effects have been reported in adults at concentrations greater than 400 ng/mL in serum. The blood to plasma ratio of chlorpheniramine is approximately 1.2.

23. 52272B Chlorpromazine Confirmation, Blood (Forensic)

Scope of Analysis: Chlorpromazine
Method(s): Gas Chromatography (GC)
Purpose: Confirmation of positive Screen; This test is New York State approved.
Category: Antiemetic, Antipsychotic
Specimen Requirements: 2 mL Blood
Minimum Volume: 0.7 mL
Special Handling: None
Specimen Container: NMS Labs has no experimental or literature-based data regarding the choice of specific specimen collection containers for this test.
Transport Temperature: Refrigerated
Light Protection: Not Required
Rejection Criteria: None
Known Interference(s): N/A
Stability: Room Temperature: 7 day(s)
Refrigerated: 14 day(s)
Frozen (-20 °C): 12 month(s)

Method: Gas Chromatography (GC)

Set-Up Days / TAT: Tuesday Thursday 3 days (after set-up)
CPT Code: 80342

Compound Name / Alias	Units	RL
Chlorpromazine Thorazine®	ng/mL	20

Reference Comment
Optimal antipsychotic concentrations: 150 - 300 ng/mL.

24. 52482B Citalopram Confirmation, Blood (Forensic)

Scope of Analysis: Citalopram / Escitalopram
Method(s): High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)
Purpose: Confirmation of positive Screen; This test is New York State approved.

Category:	Antidepressant
Specimen Requirements:	1 mL Blood
Minimum Volume:	0.4 mL
Special Handling:	None
Specimen Container:	Lavender top tube (EDTA)
Transport Temperature:	Refrigerated
Light Protection:	Not Required
Rejection Criteria:	None
Known Interference(s):	N/A
Stability:	Room Temperature: 7 day(s) Refrigerated: 7 day(s) Frozen (-20 °C): 12 month(s)

Method: High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

Set-Up Days / TAT: Monday Wednesday Friday 3 days (after set-up)

CPT Code: 80332

Compound Name / Alias	Units	RL
Citalopram / Escitalopram Celexa® / Lexapro®	ng/mL	5.0

Reference Comment

Steady-state serum or plasma levels from patients on a daily regimen of 30 to 60 mg Citalopram: 9 - 200 ng/mL.

Steady-state peak plasma levels from patients on a regimen of 10 or 30 mg Escitalopram: 21 and 64 ng/mL, respectively, and occur at approximately 4 hours post dose.

This test is not chiral specific; therefore, citalopram and/or escitalopram may be present.

25. 52274B Clomipramine and Metabolite Confirmation, Blood (Forensic)

Scope of Analysis:	Clomipramine; Desmethylclomipramine
Method(s):	Gas Chromatography (GC)
Purpose:	Confirmation of positive Screen; This test is New York State approved.
Category:	Antidepressant
Specimen Requirements:	2 mL Blood
Minimum Volume:	0.7 mL
Special Handling:	None
Specimen Container:	NMS Labs has no experimental or literature-based data regarding the choice of specific specimen collection containers for this test.
Transport Temperature:	Refrigerated
Light Protection:	Not Required
Rejection Criteria:	None
Known Interference(s):	N/A
Stability:	Room Temperature: 14 day(s) Refrigerated: 14 day(s) Frozen (-20 °C): 24 month(s)

Method: Gas Chromatography (GC)

Set-Up Days / TAT: Tuesday Thursday 3 days (after set-up)

CPT Code: 80335

Compound Name / Alias	Units	RL
Clomipramine Anafranil®	ng/mL	20
Desmethylclomipramine Clomipramine Metabolite	ng/mL	20

Reference Comment

The plasma concentrations of Clomipramine and metabolite vary widely between patients. The suggested antidepressant range for the sum of Clomipramine plus Desmethylclomipramine: 200 - 500 ng/mL plasma.

26. 52435B Clonidine Confirmation, Blood (Forensic)

Scope of Analysis: Clonidine

Method(s): High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

Purpose: Confirmation of positive Screen; This test is New York State approved.

Category: Antihypertensive

Specimen Requirements: 1 mL Blood

Minimum Volume: 0.45 mL

Special Handling: None

Specimen Container: Lavender top tube (EDTA)

Transport Temperature: Refrigerated

Light Protection: Not Required

Rejection Criteria: None

Known Interference(s): N/A

Stability: Room Temperature: 30 day(s)

Refrigerated: 30 day(s)

Frozen (-20 °C): 24 month(s)

Method: High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

Set-Up Days / TAT: Tuesday Thursday 2 days (after set-up)

CPT Code: 80375

Compound Name / Alias	Units	RL
Clonidine Catapres®	ng/mL	0.1

27. 52023B Clozapine and Metabolite Confirmation, Blood (Forensic)

Scope of Analysis: Clozapine; Norclozapine

Method(s): High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

Purpose: Confirmation of positive Screen; This test is New York State approved.

Category: Antipsychotic

Specimen Requirements: 1 mL Blood

Minimum Volume: 0.4 mL

Special Handling: None

Specimen Container: Lavender top tube (EDTA)

Transport Temperature: Refrigerated
Light Protection: Not Required
Rejection Criteria: None
Known Interference(s): N/A
Stability: Room Temperature: 30 day(s)
Refrigerated: 30 day(s)
Frozen (-20 °C): 30 day(s)

Method: High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

Set-Up Days / TAT: Tuesday Friday 3 days (after set-up)
CPT Code: 80159

Compound Name / Alias	Units	RL
Clozapine Clozaril®	ng/mL	20

Reference Comment

After typical therapeutic doses of Clozapine, plasma concentrations are reported to range from 60 - 1000 ng/mL, with average concentrations between 200 - 400 ng/mL.

At an average dose of 3.09 mg/Kg, steady-state plasma concentrations of Clozapine averaged 231 ng/mL +/- 144 ng/mL (mean +/- SD). Norclozapine concentrations averaged 84% of Clozapine.

Whole blood clozapine concentrations are approximately 10% lower than plasma concentrations where as Norclozapine blood concentrations are approximately 30% higher than plasma concentrations.

Norclozapine Clozapine Metabolite	ng/mL	20

Reference Comment

The rate of formation and biologic activity of Clozapine metabolites have not been fully elucidated. One study of patients dosed with 400 mg Clozapine daily for 4 weeks showed that patients were most likely to respond to therapy when plasma concentrations of Clozapine plus Norclozapine (limited activity) totaled at least 450 ng/mL.

28. 50014B Cocaine and Metabolites Confirmation, Blood (Forensic)

Scope of Analysis: Benzoylecgonine; Cocaethylene; Cocaine
Method(s): Gas Chromatography/Mass Spectrometry (GC/MS)
Purpose: Confirmation of positive Screen; This test is New York State approved.
Category: Stimulant
Specimen Requirements: 2 mL Blood
Minimum Volume: 0.7 mL
Special Handling: None
Specimen Container: Gray top tube (Sodium Fluoride / Potassium Oxalate)
Transport Temperature: Refrigerated
Light Protection: Not Required

Rejection Criteria: Received Room Temperature.
Known Interference(s): N/A
Stability: Room Temperature: 1 day(s)
Refrigerated: 7 day(s)
Frozen (-20 °C): Undetermined

Method: Gas Chromatography/Mass Spectrometry (GC/MS)

Set-Up Days / TAT: Monday Wednesday Friday 3 days (after set-up)
CPT Code: 80353

Compound Name / Alias	Units	RL
Cocaine	ng/mL	20
Reference Comment Following oral or nasal intake of 2 mg/kg: Up to 200 ng/mL.		
Cocaethylene Cocaine/Ethanol By-Product	ng/mL	20
Benzoylecgonine Cocaine Degradation Product	ng/mL	50

29. 52445B Cyclobenzaprine Confirmation, Blood (Forensic)

Scope of Analysis: Cyclobenzaprine
Method(s): High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)
Purpose: Confirmation of positive Screen; This test is New York State approved.
Category: Muscle Relaxant
Specimen Requirements: 1 mL Blood
Minimum Volume: 0.4 mL
Special Handling: None
Specimen Container: Lavender top tube (EDTA)
Transport Temperature: Refrigerated
Light Protection: Not Required
Rejection Criteria: None
Known Interference(s): N/A
Stability: Room Temperature: 30 day(s)
Refrigerated: 1 month(s)
Frozen (-20 °C): 1 month(s)

Method: High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

Set-Up Days / TAT: Monday Wednesday Friday 3 days (after set-up)
CPT Code: 80369

Compound Name / Alias	Units	RL
Cyclobenzaprine Flexeril®	ng/mL	1.0
Reference Comment Reported therapeutic range in plasma: approximately 4 - 40 ng/mL		

30. 52451B D/L Methorphan, Dextrorphan & Levorphanol Confirmation, Blood (Forensic)

Scope of Analysis:	Dextro / Levo Methorphan; Dextrorphan / Levorphanol
Method(s):	High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)
Purpose:	Confirmation of positive Screen; This test is New York State approved.
Category:	Narcotic Analgesic, Antitussive
Specimen Requirements:	1 mL Blood
Minimum Volume:	0.3 mL
Special Handling:	None
Specimen Container:	Gray top tube (Sodium Fluoride / Potassium Oxalate), Lavender top tube (EDTA)
Transport Temperature:	Refrigerated
Light Protection:	Not Required
Rejection Criteria:	None
Known Interference(s):	N/A
Stability:	Room Temperature: 29 day(s) Refrigerated: 29 day(s) Frozen (-20 °C): 29 day(s)

Method:

Set-Up Days / TAT: N/A

CPT Code: 80362, 80376

Method: High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

Set-Up Days / TAT: Monday Wednesday Friday 3 days (after set-up)

CPT Code: 80332, 80336, 80338

Compound Name / Alias	Units	RL
Dextrorphan / Levorphanol Levo-Dromoran®	ng/mL	2.0

Reference Comment

Reported therapeutic levels range from
4 - 28 ng/mL plasma.

Note: This method cannot differentiate between levorphanol and its stereoisomer dextrorphan (dextromethorphan metabolite).

Dextro / Levo Methorphan	ng/mL	5.0

Reference Comment

Mean peak following a single 20 mg oral dose: approximately 2 ng/mL.
Peak plasma levels on the 7th day of a 30 mg q.i.d. regimen: 2.4 ng/mL (range 0.5 - 5.9) in 14 extensive metabolizers;
207 ng/mL (range 182 - 231) in 2 poor metabolizers.

This test is not chiral specific; therefore, Dextromethorphan and/or Levomethorphan may be present.

31. 52487B Designer Benzodiazepines Confirmation, Blood (Forensic)

Scope of Analysis:	Bromazepam; Clonazolam; Delorazepam; Deschloroetizolam; Diclazepam; Etizolam; Flubromazepam; Flubromazolam; Meclonazepam; Phenazepam; Pyrazolam
Method(s):	High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)
Purpose:	Confirmation of positive Screen; This test is New York State approved.
Category:	NPS

Specimen Requirements:	2 mL Blood
Minimum Volume:	0.7 mL
Special Handling:	None
Specimen Container:	Gray top tube (Sodium Fluoride / Potassium Oxalate), Lavender top tube (EDTA)
Transport Temperature:	Refrigerated
Light Protection:	Not Required
Rejection Criteria:	Received Room Temperature.
Known Interference(s):	Flubromazepam [LC-MS/MS]: Chlordiazepoxide, Midazolam
	Flubromazolam [LC-MS/MS]: Oxazepam
	Meclonazepam [LC-MS/MS]: Oxazepam
	Phenazepam [LC-MS/MS]: Nordiazepam
	Pyrazolam [LC-MS/MS]: Oxazepam
Stability:	Room Temperature: 2 day(s)
	Refrigerated: 14 day(s)
	Frozen (-20 °C): 30 day(s)

Method: High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

Set-Up Days / TAT:	Wednesday 3 days (after set-up)
CPT Code:	80346

Compound Name / Alias	Units	RL
Bromazepam	ng/mL	5.0

Reference Comment

Bromazepam is a benzodiazepine drug that is used as a novel psychoactive substance.
It is reported to have CNS depressant properties and shares anticonvulsant, muscle relaxant, hypnotic, anxiolytic and sedative effects with other benzodiazepines. It is not approved for use in the United States, but is available in some other countries.

Average peak plasma concentrations following a single 3 mg, 6 mg and 12 mg dose were reported to be 10 ng/mL at 8 hours, 83 ng/mL at 2 hours and 130 ng/mL at 1-4 hours after dosing, respectively. Chronic oral administration of 9 mg daily resulted in an steady-state plasma concentrations of 81-150 ng/mL (Average = 120 ng/mL).
Reported half-lives are 12 - 27 hours.

The blood to serum/plasma ratio is not known.

Clonazolam	ng/mL	5.0

Reference Comment

Clonazolam is a benzodiazepine that is used as a novel psychoactive substance.
It is reported to have CNS depressant properties and shares anticonvulsant, muscle relaxant, hypnotic, anxiolytic and sedative effects with other benzodiazepines. It is not marketed for use as a pharmaceutical product in any country.

Pyrazolam	ng/mL	5.0

Reference Comment

Pyrazolam is a benzodiazepine that is used as a novel psychoactive substance.
It is reported to have CNS depressant properties and shares anticonvulsant, muscle relaxant, hypnotic, anxiolytic and sedative effects with other benzodiazepines. It is not marketed for use as a pharmaceutical product in any country.

The peak serum concentration following a single 1 mg oral dose was reported to be approximately 50 ng/mL at 3 hours. Pyrazolam may be detected in serum for at least 4 days after use.
The reported half-life is 17 hours.

The blood to serum/plasma ratio is not known.

Substance(s) known to interfere with the identity and/or quantity of the reported result: Oxazepam.

Compound Name / Alias	Units	RL
Meclonazepam	ng/mL	5.0

Reference Comment

Meclonazepam is a benzodiazepine that is used as a novel psychoactive substance.
It is reported to have CNS depressant properties and shares anticonvulsant, muscle relaxant, hypnotic, anxiolytic and sedative effects with other benzodiazepines. It is not marketed for use as a pharmaceutical product in any country.

Substance(s) known to interfere with the identity and/or quantity of the reported result: Oxazepam.

Flubromazepam	ng/mL	20

Reference Comment

Flubromazepam is a benzodiazepine that is used as a novel psychoactive substance.
It is reported to have CNS depressant properties and shares anticonvulsant, muscle relaxant, hypnotic, anxiolytic and sedative effects with other benzodiazepines. It is not marketed for use as a pharmaceutical product in any country.

The peak serum concentration following a single 4 mg oral dose was reported to be 78 ng/mL at 6 hours and the half-life was reported to be 106 hours.

The blood to serum/plasma ratio is not known.

Substance(s) known to interfere with the identity and/or quantity of the reported result: Chlordiazepoxide, Midazolam.

Etizolam	ng/mL	2.0

Reference Comment

Etizolam is a benzodiazepine drug that is used as a novel psychoactive substance.
It is reported to have CNS depressant properties and shares anticonvulsant, muscle relaxant, hypnotic, anxiolytic and sedative effects with other benzodiazepines. It is not approved for use in the United States, but is available in some other countries.

Average peak plasma concentrations following a single 0.5 mg and 1 mg dose were reported to be 8.3 ng/mL and 17 - 21 ng/mL (extensive and poor metabolizers, respectively) approximately 1 hour after dosing, respectively. Chronic oral administration of 1 mg daily resulted in an average steady-state plasma concentrations of 9.3 ng/mL. Reported half-lives are 7 - 15hours.

The blood to plasma ratio is not known.

Deschloroetizolam	ng/mL	2.0

Reference Comment

Deschloroetizolam is a benzodiazepine that is used as a novel psychoactive substance.
It is reported to have CNS depressant properties and shares anticonvulsant, muscle relaxant, hypnotic, anxiolytic and sedative effects with other benzodiazepines. It is not marketed for use as a pharmaceutical product in any country.

Compound Name / Alias	Units	RL
Flubromazolam	ng/mL	2.0

Reference Comment

Flubromazolam is a benzodiazepine that is used as a novel psychoactive substance.
It is reported to have CNS depressant properties and shares anticonvulsant, muscle relaxant, hypnotic, anxiolytic and sedative effects with other benzodiazepines. It is not marketed for use as a pharmaceutical product in any country.

A serum specimen analyzed approximately 19 hours post-ingestion of a reported 3 mg dose had a Flubromazolam concentration of 59 ng/mL.

The blood to serum/plasma ratio is not known.

Substance(s) known to interfere with the identity and/or quantity of the reported result: Oxazepam.

Delorazepam Chlordesmethyldiazepam; Cloxazolam metabolite	ng/mL	5.0

Reference Comment

Delorazepam is a benzodiazepine drug that is used as a novel psychoactive substance.
It is reported to have CNS depressant properties and shares anticonvulsant, muscle relaxant, hypnotic, anxiolytic and sedative effects with other benzodiazepines. It is not approved for use in the United States, but is available in some other countries.
In addition, the pharmaceutical benzodiazepine Cloxazolam is rapidly metabolized to delorazepam.

Average peak plasma concentrations of delorazepam following a single 4 mg dose of Cloxazolam was reported to be 16 ng/mL at 2 hours and the half-life of delorazepam was reported to be 137 hours.

The blood to plasma ratio is not known.

Phenazepam	ng/mL	20

Reference Comment

Phenazepam is a benzodiazepine drug that is used as a novel psychoactive substance.
It is reported to have CNS depressant properties and shares anticonvulsant, muscle relaxant, hypnotic, anxiolytic and sedative effects with other benzodiazepines. It is not approved for use in the United States, but is available in some other countries.

Average peak plasma concentrations following a single 3 mg and 5 mg dose were reported to be 24 ng/mL and 38 ng/mL at 4 hours after dosing, respectively.
The reported half-life is 60 hours.

The blood to serum/plasma ratio is not known.

Substance(s) known to interfere with the identity and/or quantity of the reported result: Nordiazepam.

Diclazepam	ng/mL	5.0

Reference Comment

Diclazepam is a benzodiazepine that is used as a novel psychoactive substance.
It is reported to have CNS depressant properties and shares anticonvulsant, muscle relaxant, hypnotic, anxiolytic and sedative effects with other benzodiazepines. It is not marketed for use as a pharmaceutical product in any country.

The peak serum concentration following a single 1 mg oral dose was reported to be approximately 3.4 ng/mL at 3 hours. Diclazepam is metabolized to the active compounds delorazepam (chlordesmethyldiazepam), lormetazepam and lorazepam. Diclazepam may be detected in serum for at least to 4 days after use.
The reported half-life is 42 hours.

The blood to serum/plasma ratio is not known.

32. 52488B Designer Opioids Confirmation (2017 Scope), Blood

Scope of Analysis:	4-ANPP; 4-Methoxybutyryl Fentanyl; AH-7921; Acryl Fentanyl; Beta-hydroxythiofentanyl; Butyryl Fentanyl/Isobutyryl Fentanyl; Carfentanil; Furanyl Fentanyl; MT-45; U-47700; U-50488; Valeryl Fentanyl; alpha-Methyl Fentanyl; ortho-Fluorofentanyl; para-Fluorobutyryl Fentanyl/FIBF; para-Fluorofentanyl
Method(s):	High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)
Purpose:	Confirmation of positive Screen; This test is New York State approved.
Category:	NPS
Specimen Requirements:	2 mL Blood
Minimum Volume:	0.7 mL
Special Handling:	None
Specimen Container:	Gray top tube (Sodium Fluoride / Potassium Oxalate)
Transport Temperature:	Frozen
Light Protection:	Not Required
Rejection Criteria:	Received Room Temperature. Received Refrigerated.
Known Interference(s):	Butyryl Fentanyl/Isobutyryl Fentanyl [LC-MS/MS]: 3-methyl fentanyl ortho-Fluorofentanyl [LC-MS/MS]: Meta-fluorofentanyl para-Fluorofentanyl [LC-MS/MS]: Meta-fluorofentanyl
Stability:	Room Temperature: Not Stable Refrigerated: 2 day(s) Frozen (-20 °C): 14 day(s)

Method: High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

Set-Up Days / TAT: Monday Wednesday Friday 14 days (after set-up)

CPT Code: 80364

Compound Name / Alias	Units	RL
Beta-hydroxythiofentanyl	ng/mL	0.5
Reference Comment Beta-hydroxythiofentanyl is a novel non-prescription synthetic opioid.		
Carfentanil Wildnil®	ng/mL	0.1
Reference Comment Carfentanil is an opioid analgesic.		
Valeryl Fentanyl	ng/mL	0.1
Reference Comment Valeryl fentanyl is a novel non-prescription synthetic opioid.		
para-Fluorobutyryl Fentanyl/FIBF 4F-butyryl fentanyl/4F-isobutyryl fentanyl; para-Fluoroisobutyryl Fentanyl (FIBF)	ng/mL	0.1
Reference Comment Para-fluorobutyryl fentanyl and para-fluoroisobutyryl fentanyl (FIBF) are novel non-prescription synthetic opioids. This assay does not differentiate between the isomers of para-fluorobutyryl fentanyl and FIBF (para-fluoroisobutyryl fentanyl); if further testing is needed, please contact the laboratory.		
Furanyl Fentanyl Fu-F	ng/mL	0.1
Reference Comment Furanyl Fentanyl is a novel non-prescription synthetic opioid.		

Compound Name / Alias	Units	RL
ortho-Fluorofentanyl	ng/mL	0.1
Reference Comment Ortho-fluorofentanyl is a novel non-prescription synthetic opioid. Substance(s) known to interfere with the identity and/or quantity of the reported result: Meta-fluorofentanyl.		
para-Fluorofentanyl	ng/mL	0.1
Reference Comment Para-fluorofentanyl is a novel non-prescription synthetic opioid. Substance(s) known to interfere with the identity and/or quantity of the reported result: Meta-fluorofentanyl.		
4-ANPP Despropionyl fentanyl	ng/mL	0.1
Reference Comment 4-ANPP (despropionylfentanyl) is a precursor chemical used in the production of fentanyl/fentanyl related compounds and is also a fentanyl metabolite and may be a metabolite of other fentanyl-related compounds. It is considered to be pharmacologically weak.		
Butyryl Fentanyl/Isobutyryl Fentanyl Butyr-fentanyl/Isobutyr-fentanyl	ng/mL	0.1
Reference Comment Butyryl fentanyl and isobutyryl fentanyl are novel non-prescription synthetic opioids. This assay does not differentiate between the isomers of butyryl fentanyl and isobutyryl fentanyl; if further testing is needed, please contact the laboratory. Substance(s) known to interfere with the identity and/or quantity of the reported result: 3-methyl fentanyl		
Acryl Fentanyl	ng/mL	0.1
Reference Comment Acryl fentanyl is a novel non-prescription synthetic opioid. Acryl fentanyl is known to have limited stability in blood which may be dependent upon pH, collection tube, and storage temperature. Negative results should be interpreted with caution.		
4-Methoxybutyryl Fentanyl	ng/mL	0.1
Reference Comment 4-Methoxybutyryl fentanyl is a novel non-prescription synthetic opioid.		
alpha-Methyl Fentanyl	ng/mL	0.1
Reference Comment Alpha-methyl fentanyl is a novel non-prescription synthetic opioid.		
MT-45 IC-6	ng/mL	0.1
Reference Comment MT-45 is a novel non-prescription synthetic opioid.		
U-47700 U-4	ng/mL	0.2
Reference Comment U-47700 is a novel non-prescription synthetic opioid.		

Compound Name / Alias	Units	RL
AH-7921 Doxylam	ng/mL	0.2

Reference Comment

AH-7921 is a novel non-prescription synthetic opioid.

U-50488	ng/mL	0.2

Reference Comment

U-50488 is a novel non-prescription synthetic opioid.

33. 52028B Dicyclomine Confirmation, Blood (Forensic)

Scope of Analysis:	Dicyclomine
Method(s):	Gas Chromatography (GC)
Purpose:	Confirmation of positive Screen; This test is New York State approved.
Category:	Anticholinergic
Specimen Requirements:	2 mL Blood
Minimum Volume:	0.7 mL
Special Handling:	None
Specimen Container:	NMS Labs has no experimental or literature-based data regarding the choice of specific specimen collection containers for this test.
Transport Temperature:	Refrigerated
Light Protection:	Not Required
Rejection Criteria:	None
Known Interference(s):	N/A
Stability:	Room Temperature: Undetermined Refrigerated: Undetermined Frozen (-20 °C): Undetermined

Method: Gas Chromatography (GC)

Set-Up Days / TAT:	Monday 3 days (after set-up)
CPT Code:	80375

Compound Name / Alias	Units	RL
Dicyclomine Bentyl®	ng/mL	1.0

Reference Comment

Following a single 20 mg oral dose: Up to 20 ng/mL.

34. 52447B Diltiazem Confirmation, Blood (Forensic)

Scope of Analysis:	Diltiazem
Method(s):	High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)
Purpose:	Confirmation of positive Screen; This test is New York State approved.
Category:	Cardiovascular
Specimen Requirements:	1 mL Blood
Minimum Volume:	0.4 mL
Special Handling:	None
Specimen Container:	Lavender top tube (EDTA)
Transport Temperature:	Frozen
Light Protection:	Not Required

Rejection Criteria: Received Room Temperature. Received Refrigerated.

Known Interference(s): N/A

Stability: Room Temperature: Not Stable

Refrigerated: 4 day(s)

Frozen (-20 °C): 30 day(s)

Method: High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

Set-Up Days / TAT: Monday Wednesday Friday 3 days (after set-up)

CPT Code: 80375

Compound Name / Alias	Units	RL
Diltiazem Cardizem®	ng/mL	5.0

Reference Comment

Reported therapeutic range:
Approximately 50 - 300 ng/mL.

35. 52441B Diphenhydramine Confirmation, Blood (Forensic)

Scope of Analysis: Diphenhydramine

Method(s): High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

Purpose: Confirmation of positive Screen; This test is New York State approved.

Category: Antihistamine

Specimen Requirements: 1 mL Blood

Minimum Volume: 0.4 mL

Special Handling: None

Specimen Container: Gray top tube (Sodium Fluoride / Potassium Oxalate)

Transport Temperature: Refrigerated

Light Protection: Not Required

Rejection Criteria: None

Known Interference(s): N/A

Stability: Room Temperature: 1 month(s)

Refrigerated: 1 month(s)

Frozen (-20 °C): 6 month(s)

Method: High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

Set-Up Days / TAT: Monday Wednesday Thursday Friday 3 days (after set-up)

CPT Code: 80375

Compound Name / Alias	Units	RL
Diphenhydramine Benadryl®; Ingredient of Benylin and Panadol; Nytol; Unisom	ng/mL	50

Reference Comment

Usual antihistaminic/hypnotic range: 100 - 1000 ng/mL.
Toxicity reported at greater than 1000 ng/mL.

The blood to plasma concentration ratio for diphenhydramine is approximately 0.80.

36. 52034B Donepezil Confirmation, Blood (Forensic)

Scope of Analysis:	Donepezil
Method(s):	High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)
Purpose:	Confirmation of positive Screen; This test is New York State approved.
Category:	Cognitive Adjuvant
Specimen Requirements:	1 mL Blood
Minimum Volume:	0.24 mL
Special Handling:	None
Specimen Container:	Lavender top tube (EDTA)
Transport Temperature:	Refrigerated
Light Protection:	Not Required
Rejection Criteria:	None
Known Interference(s):	N/A
Stability:	Room Temperature: 30 day(s) Refrigerated: 30 day(s) Frozen (-20 °C): 30 day(s)

Method: High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

Set-Up Days / TAT: Thursday 4 days (after set-up)

CPT Code: 80375

Compound Name / Alias	Units	RL
Donepezil Aricept®	ng/mL	5.0

Reference Comment

Acetylcholinesterase inhibition (50 - 90%) has been observed at steady-state plasma concentrations between 15 - 50 ng/mL.
Steady-state levels are achieved after approximately 2 weeks of daily dosing.

37. 52278B Doxepin and Metabolite Confirmation, Blood (Forensic)

Scope of Analysis:	Desmethyldoxepin; Doxepin
Method(s):	Gas Chromatography (GC)
Purpose:	Confirmation of positive Screen; This test is New York State approved.
Category:	Antidepressant
Specimen Requirements:	2 mL Blood
Minimum Volume:	0.7 mL
Special Handling:	None
Specimen Container:	NMS Labs has no experimental or literature-based data regarding the choice of specific specimen collection containers for this test.
Transport Temperature:	Refrigerated
Light Protection:	Not Required
Rejection Criteria:	None
Known Interference(s):	N/A
Stability:	Room Temperature: 14 day(s) Refrigerated: 14 day(s) Frozen (-20 °C): 17 month(s)

Method:

Set-Up Days / TAT: N/A

CPT Code: 80362, 80376

Method: Gas Chromatography (GC)

Set-Up Days / TAT: Monday-Friday 3 days (after set-up)

CPT Code: 80335

Compound Name / Alias	Units	RL
Doxepin Sinequan® **Reference Comment** Patients on an average antidepressant dose of 113 mg Doxepin/day: 5 - 115 ng/mL	ng/mL	20
Desmethyldoxepin Doxepin Metabolite **Reference Comment** Patients on an average antidepressant dose of 113 mg Doxepin/day: 0 - 80 ng Desmethyldoxepin/mL.	ng/mL	20

38. 52285B Doxylamine Confirmation, Blood (Forensic)

Scope of Analysis: Doxylamine

Method(s): Gas Chromatography (GC)

Purpose: Confirmation of positive Screen; This test is New York State approved.

Category: Antihistamine

Specimen Requirements: 2 mL Blood

Minimum Volume: 0.7 mL

Special Handling: None

Specimen Container: NMS Labs has no experimental or literature-based data regarding the choice of specific specimen collection containers for this test.

Transport Temperature: Refrigerated

Light Protection: Not Required

Rejection Criteria: None

Known Interference(s): N/A

Stability: Room Temperature: Undetermined

Refrigerated: Undetermined

Frozen (-20 °C): Undetermined

Method:

Set-Up Days / TAT: N/A

CPT Code: 80362, 80376

Method: Gas Chromatography (GC)

Set-Up Days / TAT: Monday-Friday 3 days (after set-up)

CPT Code: 80375

Compound Name / Alias	Units	RL
Doxylamine Unisom® **Reference Comment** Following a single 25 mg oral dose: Up to 170 ng/mL.	ng/mL	100

39. 52036B Duloxetine Confirmation, Blood (Forensic)

Scope of Analysis:	Duloxetine
Method(s):	High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)
Purpose:	Confirmation of positive Screen; This test is New York State approved.
Category:	Antidepressant
Specimen Requirements:	1 mL Blood
Minimum Volume:	0.22 mL
Special Handling:	Ensure that container remains tightly sealed.
Specimen Container:	Lavender top tube (EDTA)
Transport Temperature:	Refrigerated
Light Protection:	Not Required
Rejection Criteria:	None
Known Interference(s):	N/A
Stability:	Room Temperature: 30 day(s) Refrigerated: 30 day(s) Frozen (-20 °C): 30 day(s)

Method: High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

Set-Up Days / TAT: Wednesday 3 days (after set-up)

CPT Code: 80332

Compound Name / Alias	Units	RL
Duloxetine Cymbalta®	ng/mL	30

Reference Comment

Steady-state trough plasma concentrations after
5 days of oral therapy were:
20 mg twice daily: 4 - 22 ng/mL
30 mg twice daily: 8 - 48 ng/mL
40 mg twice daily: 12 - 60 ng/mL.

40. 52038B Eszopiclone / Zopiclone Confirmation, Blood (Forensic)

Scope of Analysis:	Eszopiclone / Zopiclone
Method(s):	High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)
Purpose:	Confirmation of positive Screen; This test is New York State approved.
Category:	Sleep Aid
Specimen Requirements:	1 mL Blood
Minimum Volume:	0.4 mL
Special Handling:	None
Specimen Container:	Lavender top tube (EDTA)
Transport Temperature:	Frozen
Light Protection:	Not Required
Rejection Criteria:	Received Room Temperature. Received Refrigerated.
Known Interference(s):	N/A
Stability:	Room Temperature: Not Stable Refrigerated: Not Stable Frozen (-20 °C): 14 day(s)

Method: **High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)**

Set-Up Days / TAT: Thursday 4 days (after set-up)

CPT Code: 80368

Compound Name / Alias	Units	RL
Eszopiclone / Zopiclone Imovane®; Lunesta®	ng/mL	2.0

Reference Comment

Once daily 3 mg oral dose given to healthy adults for 7 days resulted in peak serum concentrations of 20 to 33 ng/mL.

Once daily 2 mg Eszopiclone oral dose given to elderly adults for 7 days resulted in a peak serum concentration of approximately 15 ng/mL.

This test is not chiral specific; therefore, Eszopiclone and/or Racemic Zopiclone (not approved in the US) may be present.

41. 0173B Ethanol Re-Check - Post Mortem, Blood

Scope of Analysis: N/A
Method(s): N/A
Purpose: In-House Test
Category: N/A
Specimen Requirements: 1 mL Blood
Minimum Volume: 0.25 mL
Special Handling: None
Specimen Container: N/A
Transport Temperature: N/A
Light Protection: Not Required
Rejection Criteria: None
Known Interference(s): N/A
Stability: Room Temperature: Undetermined
Refrigerated: Undetermined
Frozen (-20 °C): Undetermined

42. 52484B Fentanyl and Acetyl Fentanyl Confirmation, Blood (Forensic)

Scope of Analysis: Acetyl Fentanyl; Fentanyl; Norfentanyl
Method(s): High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)
Purpose: Confirmation of positive Screen; This test is New York State approved.
Category: Anesthetic, Opioid Analgesic, NPS
Specimen Requirements: 2 mL Blood
Minimum Volume: 0.7 mL
Special Handling: None
Specimen Container: Lavender top tube (EDTA)
Transport Temperature: Refrigerated
Light Protection: Not Required
Rejection Criteria: None

Known Interference(s): Fentanyl [LC-MS/MS]: 4-methylphenethyl acetyl fentanyl

Norfentanyl [LC-MS/MS]: Benzyl Fentanyl

Stability: Room Temperature: 30 day(s)

Refrigerated: 30 day(s)

Frozen (-20 °C): 3 month(s)

Method: High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

Set-Up Days / TAT: Monday-Friday 7 days (after set-up)

CPT Code: 80354, 80362

Compound Name / Alias	Units	RL
Fentanyl Duragesic®; Sublimaze®	ng/mL	0.1
Reference Comment Immediately following a single 2 mcg/kg I.V. dose: Up to 11 ng/mL, declining to 1 ng/mL after one hour. Following the application of a 100 mcg/hour transdermal patch, serum levels (after an initial lag time of approximately six hours) of 0.8 - 2.6 ng/mL were maintained for more than 24 hours after application. Peak plasma levels following a single oral transmucosal dose (Fentanyl Oralet) of 15 mcg/kg to children: 2 - 4 ng/mL at 20 minutes. Substance(s) known to interfere with the identity and/or quantity of the reported result: 4-methylphenethyl acetyl fentanyl		
Norfentanyl Fentanyl Metabolite	ng/mL	0.2
Reference Comment Substance(s) known to interfere with the identity and/or quantity of the reported result: Benzyl Fentanyl		
Acetyl Fentanyl	ng/mL	0.1
Reference Comment Acetyl fentanyl is a novel non-prescription synthetic opioid that has been implicated in several deaths.		

43. 52047B Flecainide Confirmation, Blood (Forensic)

Scope of Analysis: Flecainide

Method(s): High Performance Liquid Chromatography (HPLC)

Purpose: Confirmation of positive Screen; This test is New York State approved.

Category: Antiarrhythmic

Specimen Requirements: 1 mL Blood

Minimum Volume: 0.45 mL

Special Handling: None

Specimen Container: Lavender top tube (EDTA)

Transport Temperature: Refrigerated

Light Protection: Not Required

Rejection Criteria: None
Known Interference(s): N/A
Stability: Room Temperature: 14 day(s)
Refrigerated: 14 day(s)
Frozen (-20 °C): 14 day(s)

Method: High Performance Liquid Chromatography (HPLC)

Set-Up Days / TAT: Thursday 2 days (after set-up)
CPT Code: 80375

Compound Name / Alias	Units	RL
Flecainide Ecrinal®; Tambocor®	mcg/mL	0.1

Reference Comment
Therapeutic range: 0.2 - 1.0 mcg/mL.

44. 52048B Flunitrazepam and Metabolites Confirmation, Blood (Forensic)

Scope of Analysis: 7-Amino Flunitrazepam; Flunitrazepam; Norflunitrazepam
Method(s): High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)
Purpose: Confirmation of positive Screen; This test is New York State approved.
Category: Hypnotic, Sedative
Specimen Requirements: 2 mL Blood
Minimum Volume: 0.7 mL
Special Handling: None
Specimen Container: Lavender top tube (EDTA)
Transport Temperature: Refrigerated
Light Protection: Not Required
Rejection Criteria: Received Room Temperature.
Known Interference(s): N/A
Stability: Room Temperature: 2 day(s)
Refrigerated: 14 day(s)
Frozen (-20 °C): 3 month(s)

Method: High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

Set-Up Days / TAT: Monday-Friday 2 days (after set-up)
CPT Code: 80346

Compound Name / Alias	Units	RL
Flunitrazepam Rohypnol®	ng/mL	2.0

Reference Comment
Flunitrazepam is present in plasma at a concentration of approximately 1.5 ng/mL at 24 hours after a single 2 mg oral dose.

Norflunitrazepam Flunitrazepam Metabolite	ng/mL	2.0

Reference Comment
Norflunitrazepam is present in plasma at a concentration of approx. 1 ng/mL at 24 hours after a single 2 mg oral dose of Flunitrazepam.

7-Amino Flunitrazepam Flunitrazepam Metabolite	ng/mL	2.0

Reference Comment
7-Amino Flunitrazepam is present in plasma at a concentration of approx. 0.8 ng/mL at 24 hours after a single 2 mg oral dose of Flunitrazepam.

45. 52287B Fluoxetine and Metabolite Confirmation, Blood (Forensic)

Scope of Analysis:	Fluoxetine; Norfluoxetine
Method(s):	Gas Chromatography (GC)
Purpose:	Confirmation of positive Screen; This test is New York State approved.
Category:	Antidepressant
Specimen Requirements:	2 mL Blood
Minimum Volume:	0.7 mL
Special Handling:	None
Specimen Container:	Gray top tube (Sodium Fluoride / Potassium Oxalate)
Transport Temperature:	Refrigerated
Light Protection:	Not Required
Rejection Criteria:	None
Known Interference(s):	N/A
Stability:	Room Temperature: 7 day(s) Refrigerated: 14 day(s) Frozen (-20 °C): 3 month(s)

Method:

Set-Up Days / TAT: N/A

CPT Code: 80362, 80376

Method: Gas Chromatography (GC)

Set-Up Days / TAT: Monday-Friday 3 days (after set-up)

CPT Code: 80332

Compound Name / Alias	Units	RL
Fluoxetine Prozac® **Reference Comment** Daily therapy with 40 mg Fluoxetine/day: Steady-state concentration at 4 to 8 hours after dosing ranges from 91 - 302 ng/mL serum.	ng/mL	20
Norfluoxetine Fluoxetine Metabolite **Reference Comment** Daily therapy with 40 mg Fluoxetine/day: Steady-state concentration at 4 to 8 hours after dosing ranges from 72 - 258 ng/mL serum.	ng/mL	20

46. 52468B Fluphenazine Confirmation, Blood (Forensic)

Scope of Analysis:	Fluphenazine
Method(s):	High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)
Purpose:	Confirmation of positive Screen; This test is New York State approved.
Category:	Antipsychotic (Neuroleptic)
Specimen Requirements:	1 mL Blood
Minimum Volume:	0.3 mL
Special Handling:	None
Specimen Container:	Lavender top tube (EDTA)
Transport Temperature:	Refrigerated
Light Protection:	Not Required

Rejection Criteria: None

Known Interference(s): Fluphenazine [LC-MS/MS]: Trimeprazine

Stability: Room Temperature: 30 day(s)

Refrigerated: 30 day(s)

Frozen (-20 °C): 30 day(s)

Method: High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

Set-Up Days / TAT: Wednesday 3 days (after set-up)

CPT Code: 80342

Compound Name / Alias	Units	RL
Fluphenazine Permitil®; Prolixin®	ng/mL	0.5

Reference Comment

Schizophrenic patients maintained with depot injections of fluphenazine decanoate at 12.5 to 50 mg every 1 to 2 weeks had plasma fluphenazine concentrations ranging from 1 to 17 ng/mL. Healthy subjects given single oral doses of 5 mg fluphenazine had peak plasma concentrations averaging 0.6 ng/mL (SEM +/- 0.1 ng/mL).

The blood to plasma ratio for fluphenazine is approximately 1.

Substance(s) known to interfere with the identity and/or quantity of the reported result: Trimeprazine

47. 52049B Fluvoxamine Confirmation, Blood (Forensic)

Scope of Analysis: Fluvoxamine

Method(s): Gas Chromatography (GC)

Purpose: Confirmation of positive Screen; This test is New York State approved.

Category: Antidepressant

Specimen Requirements: 3 mL Blood

Minimum Volume: 1.2 mL

Special Handling: None

Specimen Container: NMS Labs has no experimental or literature-based data regarding the choice of specific specimen collection containers for this test.

Transport Temperature: Refrigerated

Light Protection: Not Required

Rejection Criteria: None

Known Interference(s): N/A

Stability: Room Temperature: 14 day(s)

Refrigerated: 14 day(s)

Frozen (-20 °C): 6 month(s)

Method: Gas Chromatography (GC)

Set-Up Days / TAT: Tuesday 3 days (after set-up)

CPT Code: 80332

Compound Name / Alias	Units	RL
Fluvoxamine Luvox®	ng/mL	10

Reference Comment

Steady-state plasma levels following a daily regimen of 150 to 300 mg/day: 78 - 920 ng/mL (mean of 510).

48. 52438B Glimepiride Confirmation, Blood (Forensic)

Scope of Analysis:	Glimepiride
Method(s):	High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)
Purpose:	Confirmation of positive Screen; This test is New York State approved.
Category:	Oral Hypoglycemic Agent
Specimen Requirements:	1 mL Blood
Minimum Volume:	0.3 mL
Special Handling:	None
Specimen Container:	Lavender top tube (EDTA)
Transport Temperature:	Refrigerated
Light Protection:	Not Required
Rejection Criteria:	None
Known Interference(s):	N/A
Stability:	Room Temperature: 28 day(s) Refrigerated: 28 day(s) Frozen (-20 °C): 24 month(s) Frozen (-70 °C): 3 month(s)

Method: High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

Set-Up Days / TAT: Monday Thursday 3 days (after set-up)

CPT Code: 80375

Compound Name / Alias	Units	RL
Glimepiride Amaryl®; Avandaryl®; Duetact®	ng/mL	25

Reference Comment

Peak plasma concentrations of approximately 60 - 340 ng/mL were achieved 2 - 3 hours after administration of 4 mg of glimepiride.

The blood to plasma ratio of Glimepiride is not known.

49. 52052B Guaifenesin Confirmation, Blood (Forensic)

Scope of Analysis:	Guaifenesin
Method(s):	High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)
Purpose:	Confirmation of positive Screen; This test is New York State approved.
Category:	Expectorant
Specimen Requirements:	1 mL Blood
Minimum Volume:	0.25 mL
Special Handling:	None
Specimen Container:	Gray top tube (Sodium Fluoride / Potassium Oxalate)
Transport Temperature:	Refrigerated
Light Protection:	Not Required

Rejection Criteria: Received Room Temperature.

Known Interference(s): N/A

Stability: Room Temperature: 1 day(s)

Refrigerated: 7 day(s)

Frozen (-20 °C): 24 month(s)

Method: High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

Set-Up Days / TAT: Monday Wednesday Friday 3 days (after set-up)

CPT Code: 80375

Compound Name / Alias	Units	RL
Guaifenesin Glyceryl Guaiacolate	mcg/mL	0.2

Reference Comment

Following a single 600 mg oral dose:
Peak blood concentrations averaged
1.4 mcg/mL at 15 minutes post dose.
Half-life in blood: 60 minutes.

50. 52320B Hallucinogens and Stimulants Confirmation 2 (Qualitative), Blood

Scope of Analysis: 3-Fluorophenmetrazine; 3-MeO-PCP; 4-MeO-PCP; Clephedrone; Methoxphenidine

Method(s): Gas Chromatography/Mass Spectrometry (GC/MS)

Purpose: Confirmation of positive Screen; This test is New York State approved.

Category: NPS

Specimen Requirements: 3 mL Blood

Minimum Volume: 1.2 mL

Special Handling: None

Specimen Container: Gray top tube (Sodium Fluoride / Potassium Oxalate), Lavender top tube (EDTA)

Transport Temperature: Frozen

Light Protection: Not Required

Rejection Criteria: Received Room Temperature. Received Refrigerated.

Known Interference(s): N/A

Stability: Room Temperature: Not Stable

Refrigerated: 2 day(s)

Frozen (-20 °C): 7 day(s)

Method: Gas Chromatography/Mass Spectrometry (GC/MS)

Set-Up Days / TAT: Thursday 5 days (after set-up)

CPT Code: 80371

Compound Name / Alias	Units	RL
3-Fluorophenmetrazine 3-FPM	ng/mL	5.0

Reference Comment

3-Fluorophenmetrazine is a stimulant that is closely related to phenmetrazine and has been sold online as a novel psychoactive substance.

3-MeO-PCP 3-Methoxy-Phencyclidine	ng/mL	10

Reference Comment

3-Methoxyphencyclidine (3-MeO-PCP) is a designer drug that is structurally similar to phencyclidine (PCP) and has been described as having effects similar to those of PCP. Phencyclidine is a dangerous dissociative anesthetic. No studies have been performed to evaluate the pharmacological effects of 3-MeO-PCP.

Compound Name / Alias	Units	RL
4-MeO-PCP 4-Methoxy-Phencyclidine	ng/mL	10
Reference Comment 4-Methoxyphencyclidine (4-MeO-PCP) is a designer drug that is structurally similar to phencyclidine (PCP) and has been described as having effects similar to those of PCP. Phencyclidine is a dangerous dissociative anesthetic. No studies have been performed to evaluate the pharmacological effects of 4-MeO-PCP.		
Clephedrone 4-chloromethcathinone, 4-CMC	ng/mL	50
Reference Comment Clephedrone is a substituted cathinone sold as a novel psychoactive substance. Due to its structural similarities to other cathinones such as mephedrone, clephedrone is expected to have stimulant type effects.		
Methoxphenidine MXP	ng/mL	5.0
Reference Comment Methoxphenidine is a dissociative type drug that is sold as a novel psychoactive substance. Adverse effects noted in analytically confirmed cases of methoxphenidine were similar to those reported for other dissociative substances such as ketamine and methoxetamine; these may include hallucinations, delirium, irrational behavior, and/or dream-like states, along with profound analgesia and cardiovascular stimulation.		

51. 52053B Haloperidol Confirmation, Blood (Forensic)

Scope of Analysis:	Haloperidol
Method(s):	High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)
Purpose:	Confirmation of positive Screen; This test is New York State approved.
Category:	Antipsychotic (Neuroleptic)
Specimen Requirements:	1 mL Blood
Minimum Volume:	0.4 mL
Special Handling:	None
Specimen Container:	Lavender top tube (EDTA)
Transport Temperature:	Refrigerated
Light Protection:	Not Required
Rejection Criteria:	None
Known Interference(s):	N/A
Stability:	Room Temperature: 1 month(s) Refrigerated: 1 month(s) Frozen (-20 °C): 1 month(s)

Method: High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

Set-Up Days / TAT:	Tuesday Friday 3 days (after set-up)
CPT Code:	80173

Compound Name / Alias	Units	RL
Haloperidol Haldol®	ng/mL	1.0
Reference Comment Steady-state antipsychotic plasma concentration during daily regimen of 1 to 90 mg/day: 0.5 - 120 ng/mL (mean, 6 ng/mL). Blood to plasma ratio: 0.79.		

52. 52442B Hydroxyzine Confirmation, Blood (Forensic)

Scope of Analysis:	Hydroxyzine
Method(s):	High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)
Purpose:	Confirmation of positive Screen; This test is New York State approved.
Category:	Antihistamine, Anxiolytic
Specimen Requirements:	1 mL Blood
Minimum Volume:	0.4 mL
Special Handling:	None
Specimen Container:	Gray top tube (Sodium Fluoride / Potassium Oxalate)
Transport Temperature:	Refrigerated
Light Protection:	Not Required
Rejection Criteria:	None
Known Interference(s):	N/A
Stability:	Room Temperature: 1 month(s) Refrigerated: 1 month(s) Frozen (-20 °C): 6 month(s)

Method: High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

Set-Up Days / TAT: Monday Wednesday Thursday Friday 3 days (after set-up)

CPT Code: 80375

Compound Name / Alias	Units	RL
Hydroxyzine Atarax®; Hydroxyzine Hydrochloride; Vistaril®	ng/mL	5.0

Reference Comment

The following mean peak serum or plasma concentrations of hydroxyzine have been reported:
25 mg oral dose: 43 ng/mL at 3 hours
50 mg oral dose: 70 ng/mL at 2 hours,
30 ng/mL at 6 hours, and 22 ng/mL at 12 hours
100 mg oral dose: 78 ng/mL at 4 hours
and 35 ng/mL at 8 hours
The whole blood to serum or plasma ratio is not known for hydroxyzine.

53. 52405B Hypoglycemics Confirmation, Blood (Forensic)

Scope of Analysis:	Glipizide; Glyburide
Method(s):	High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)
Purpose:	Confirmation of positive Screen; This test is New York State approved.
Category:	Oral Hypoglycemic Agent
Specimen Requirements:	1 mL Blood
Minimum Volume:	0.3 mL
Special Handling:	None
Specimen Container:	Lavender top tube (EDTA)
Transport Temperature:	Refrigerated
Light Protection:	Not Required
Rejection Criteria:	None

Known Interference(s): N/A

Stability: Room Temperature: 14 day(s)
Refrigerated: 28 day(s)
Frozen (-20 °C): 24 month(s)
Frozen (-70 °C): 3 month(s)

Method: High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

Set-Up Days / TAT: Monday Thursday 3 days (after set-up)

CPT Code: 80375

Compound Name / Alias	Units	RL
Glipizide Glibenese; Glucotrol®; Glynase	ng/mL	40

Reference Comment

Peak plasma concentrations of approximately 310 - 610 ng/mL were achieved after administration of a single 5 mg dose of both immediate and extended release formulations. Maximum concentrations were reached in approximately 1.5 - 4.5 and 3.5 - 7 hours after immediate and extended release dosing, respectively.

The blood to plasma ratio of Glipizide is not known.

Glyburide Glibenclamide; Glynase®; Micronase®; PresTab®	ng/mL	40

Reference Comment

Peak plasma concentrations of approximately 130 - 200 ng/mL following a single 5 mg dose have been reported. A group of ten diabetic patients given daily oral 2.5 mg doses for 6 weeks attained peak plasma glyburide concentrations averaging 140 ng/mL at 3 hours after the first dose and 240 ng/mL at 2.4 hours after the last dose.

The reported blood to plasma ratio of Glyburide is 0.5.

54. 52418B Iloperidone Confirmation, Blood (Forensic)

Scope of Analysis: Iloperidone

Method(s): High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

Purpose: Confirmation of positive Screen; This test is New York State approved.

Category: Antipsychotic

Specimen Requirements: 1 mL Blood

Minimum Volume: 0.4 mL

Special Handling: None

Specimen Container: Lavender top tube (EDTA)

Transport Temperature: Refrigerated

Light Protection: Not Required

Rejection Criteria: None

Known Interference(s): N/A

Stability: Room Temperature: 14 day(s)
Refrigerated: 30 day(s)
Frozen (-20 °C): 30 day(s)

Method: High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

Set-Up Days / TAT: Tuesday 3 days (after set-up)

CPT Code: 80342

Compound Name / Alias	Units	RL
Iloperidone Fanapta®; Fanapt®; Zomaril®	ng/mL	0.25

Reference Comment

Peak plasma levels of iloperidone are achieved 2 to 4 hours after ingestion. Steady-state concentrations are attained within 3 to 4 days of dosing. The mean plasma level for iloperidone ranges from 2.2 - 2.7 ng/mL following a single 3 mg dose. In one study that examined the pharmacokinetic and pharmacodynamic relationship in regard to iloperidone efficacy, maximal response in terms of therapeutic benefit was observed at plasma concentrations of 5 - 8 ng/mL.
Genetic variations may substantially influence the rate of iloperidone metabolism.

The ratio of whole blood concentration to serum or plasma concentration is unknown for this analyte.

55. 52276B Imipramine and Metabolite Confirmation, Blood (Forensic)

Scope of Analysis: Desipramine; Imipramine

Method(s): Gas Chromatography (GC)

Purpose: Confirmation of positive Screen; This test is New York State approved.

Category: Antidepressant

Specimen Requirements: 2 mL Blood

Minimum Volume: 0.7 mL

Special Handling: None

Specimen Container: NMS Labs has no experimental or literature-based data regarding the choice of specific specimen collection containers for this test.

Transport Temperature: Refrigerated

Light Protection: Not Required

Rejection Criteria: None

Known Interference(s): N/A

Stability: Room Temperature: 7 day(s)

Refrigerated: 14 day(s)

Frozen (-20 °C): 18 month(s)

Method: Gas Chromatography (GC)

Set-Up Days / TAT: Tuesday Thursday 3 days (after set-up)

CPT Code: 80335

Compound Name / Alias	Units	RL
Imipramine Tofranil®	ng/mL	20
Desipramine Imipramine Metabolite; Norpramin®; Pertofrane®	ng/mL	20

Reference Comment

Desipramine is a metabolite of Imipramine and is also available as an independent therapeutic agent.

When Imipramine is the administered drug:
Usual therapeutic range for the total of Imipramine plus Desipramine: 150 - 400 ng/mL.

When Desipramine is the administered drug:
Usual therapeutic range in outpatients on 100 to 200 mg Desipramine/day: 40 - 250 ng/mL.

56. 52414B Ipecac Use Markers Confirmation, Blood (Forensic)

Scope of Analysis:	Cephaeline; Emetine
Method(s):	High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)
Purpose:	Confirmation of positive Screen; This test is New York State approved.
Category:	Emetic
Specimen Requirements:	1 mL Blood
Minimum Volume:	0.3 mL
Special Handling:	None
Specimen Container:	NMS Labs has no experimental or literature-based data regarding the choice of specific specimen collection containers for this test.
Transport Temperature:	Refrigerated
Light Protection:	Not Required
Rejection Criteria:	None
Known Interference(s):	N/A
Stability:	Room Temperature: 7 day(s) Refrigerated: 7 day(s) Frozen (-20 °C): 7 day(s)

Method: High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

Set-Up Days / TAT: Monday-Friday 7 days (after set-up)

CPT Code: 80375

Compound Name / Alias	Units	RL
Emetine Ipecac	ng/mL	5.0
Reference Comment Emetine is absorbed after oral administration, although vomiting may remove from 10% to nearly 100% of a dose. Blood concentrations of Emetine were measurable in only 6 of 10 emergency room adult patients who received 30 mL of Ipecac syrup for treatment of drug or chemical overdose; the levels varied from 5 - 75 ng/mL within 2 hours of administration.		
Cephaeline Ipecac Syrup Constituent	ng/mL	5.0
Reference Comment No reference data available.		

57. 52058B Ketamine and Metabolite Confirmation, Blood (Forensic)

Scope of Analysis:	Ketamine; Norketamine
Method(s):	Gas Chromatography/Mass Spectrometry (GC/MS)
Purpose:	Confirmation of positive Screen; This test is New York State approved.
Category:	Hypnotic, Sedative, Anesthetic
Specimen Requirements:	2 mL Blood
Minimum Volume:	0.7 mL
Special Handling:	None
Specimen Container:	Gray top tube (Sodium Fluoride / Potassium Oxalate)
Transport Temperature:	Refrigerated
Light Protection:	Not Required

Rejection Criteria: None

Known Interference(s): N/A

Stability: Room Temperature: 14 day(s)

Refrigerated: 30 day(s)

Frozen (-20 °C): 6 month(s)

Method: Gas Chromatography/Mass Spectrometry (GC/MS)

Set-Up Days / TAT: Tuesday Thursday 3 days (after set-up)

CPT Code: 80357

Compound Name / Alias	Units	RL
Ketamine Ketalar®	ng/mL	40
Reference Comment Reported levels during anesthesia: 500 - 6500 ng/mL.		
Norketamine Ketamine Metabolite	ng/mL	40
Reference Comment The intravenous administration of 2 mg/kg of Ketamine followed by continuous infusion of 41 mcg/kg/minute produced an average steady-state plasma concentration of 2200 ng Ketamine/mL and an average peak Norketamine level of 1050 ng/mL which occurred near the end of the 3 hour infusion.		

58. 52065B LSD Confirmation, Blood (Forensic)

Scope of Analysis: LSD

Method(s): High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

Purpose: Confirmation of positive Screen; This test is New York State approved.

Category: Hallucinogen

Specimen Requirements: 1 mL Blood

Minimum Volume: 0.45 mL

Special Handling: Glass containers are not acceptable.

Specimen Container: Lavender top tube (EDTA)

Transport Temperature: Refrigerated

Light Protection: Yes

Rejection Criteria: Not received Light Protected. Glass container.

Known Interference(s): N/A

Stability: Room Temperature: 30 day(s)

Refrigerated: 30 day(s)

Frozen (-20 °C): 30 day(s)

Method: High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

Set-Up Days / TAT: Tuesday Thursday 2 days (after set-up)

CPT Code: 80323

Compound Name / Alias	Units	RL
LSD Lysergic Acid Diethylamide	ng/mL	0.1
Reference Comment No reference data available.		

59. 52420B Lacosamide Confirmation, Blood (Forensic)

Scope of Analysis:	Lacosamide
Method(s):	High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)
Purpose:	Confirmation of positive Screen; This test is New York State approved.
Category:	Anticonvulsant
Specimen Requirements:	1 mL Blood
Minimum Volume:	0.25 mL
Special Handling:	None
Specimen Container:	Lavender top tube (EDTA)
Transport Temperature:	Refrigerated
Light Protection:	Not Required
Rejection Criteria:	Received Room Temperature.
Known Interference(s):	N/A
Stability:	Room Temperature: 1 day(s) Refrigerated: 7 day(s) Frozen (-20 °C): 12 month(s)

Method: High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

Set-Up Days / TAT: Monday Thursday 3 days (after set-up)

CPT Code: 80339

Compound Name / Alias	Units	RL
Lacosamide Vimpat®	mcg/mL	0.5

Reference Comment

Peak plasma concentrations are reached 1 to 2 hours after a single oral or intravenous dose with a half-life of 13 hours.
Following a single 200 mg dose administered as a 30-minute infusion, a 60-minute infusion, or orally as a tablet to 24 male subjects, mean maximum plasma lacosamide concentrations were 5.95 +/- 1.49, 5.38 +/- 1.10 and 5.15 +/- 1.4 mcg/mL, respectively.

Mean plasma concentrations following maintenance doses:
200 mg/day: 4.99 +/- 2.51 mcg/mL;
400 mg/day: 9.35 +/- 4.22 mcg/mL;
600 mg/day: 12.46 +/- 5.60 mcg/mL.

The ratio of whole blood concentration to plasma concentration is 1.1

60. 52059B Lamotrigine Confirmation, Blood (Forensic)

Scope of Analysis:	Lamotrigine
Method(s):	High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)
Purpose:	Confirmation of positive Screen; This test is New York State approved.
Category:	Anticonvulsant, Antiepileptic
Specimen Requirements:	1 mL Blood
Minimum Volume:	0.25 mL
Special Handling:	None
Specimen Container:	Gray top tube (Sodium Fluoride / Potassium Oxalate)
Transport Temperature:	Refrigerated

Light Protection: Not Required
Rejection Criteria: None
Known Interference(s): N/A
Stability: Room Temperature: 30 day(s)
Refrigerated: 30 day(s)
Frozen (-20 °C): 24 month(s)

Method: High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

Set-Up Days / TAT: Monday Wednesday Friday 3 days (after set-up)
CPT Code: 80175

Compound Name / Alias	Units	RL
Lamotrigine Lamictal®	mcg/mL	0.2

Reference Comment
A therapeutic range of 3-14 mcg/mL has been proposed, but pharmacokinetics can vary with the administration of other antiepileptic drugs.

The blood/plasma ratio for lamotrigine is not known.

61. 52060B Levetiracetam Confirmation, Blood (Forensic)

Scope of Analysis: Levetiracetam
Method(s): High Performance Liquid Chromatography(HPLC)
Purpose: Confirmation of positive Screen; This test is New York State approved.
Category: Anticonvulsant, Antiepileptic
Specimen Requirements: 1 mL Blood
Minimum Volume: 0.25 mL
Special Handling: None
Specimen Container: NMS Labs has no experimental or literature-based data regarding the choice of specific specimen collection containers for this test.
Transport Temperature: Refrigerated
Light Protection: Not Required
Rejection Criteria: None
Known Interference(s): N/A
Stability: Room Temperature: Undetermined
Refrigerated: Undetermined
Frozen (-20 °C): Undetermined

Method: High Performance Liquid Chromatography(HPLC)

Set-Up Days / TAT: Tuesday 2 days (after set-up)
CPT Code: 80177

Compound Name / Alias	Units	RL
Levetiracetam Keppra®	mcg/mL	2.0

Reference Comment
Steady-state trough serum or plasma levels following doses of 1000 to 3000 mg/day: 3 - 37 mcg/mL.
The same dosage regimen will typically result in peak levels of 10 - 60 mcg/mL, at approximately 1.5 hours post dose.

62. 52496B Loperamide and Metabolite Confirmation, Blood (Forensic)

Scope of Analysis:	Desmethylloperamide; Loperamide
Method(s):	High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)
Purpose:	Confirmation of positive Screen; This test is New York State approved.
Category:	Inactive Metabolite, Therapeutic opioid
Specimen Requirements:	1 mL Blood
Minimum Volume:	0.45 mL
Special Handling:	None
Specimen Container:	Gray top tube (Sodium Fluoride / Potassium Oxalate)
Transport Temperature:	Refrigerated
Light Protection:	Not Required
Rejection Criteria:	None
Known Interference(s):	N/A
Stability:	Room Temperature: 14 day(s) Refrigerated: 30 day(s) Frozen (-20 °C): 30 day(s)

Method: High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

Set-Up Days / TAT: Friday 3 days (after set-up)

CPT Code: 80375

Compound Name / Alias	Units	RL
Loperamide Imodium	ng/mL	10

Reference Comment

Loperamide is a synthetic opioid derivative that has structural similarities to meperidine and diphenoxylate. It is effective against diarrhea resulting from gastroenteritis, inflammatory bowel disease, or unknown causes. It is available in tablets and capsules of 2 mg and liquids containing 1 mg/5 mL; the common dosage for adults is 4 mg several times daily until the diarrhea is controlled.

Approximately 40% of the drug is absorbed into the bloodstream after oral administration but, unlike most opioids, loperamide does not penetrate the blood-brain barrier very well. The drug is metabolized to inactive products and is eliminated through both the urine and the feces. The mean elimination half-life is approximately 10 hours.

Peak plasma concentrations occur approximately 5 hours after capsule administration and after about 2.5 hours after tablet or liquid use and common plasma concentrations are usually under 10 ng/mL.
Reported concentrations in fatalities were reported as low as 77 ng/mL blood, and other drugs may also have been present.
Adverse effects of loperamide after therapeutic doses may include dizziness, drowsiness, dry mouth and constipation. The drug does not produce typical opioid-like CNS effects except after very high doses.

Desmethylloperamide Loperamide Metabolite	ng/mL	10

Reference Comment

Desmethylloperamide is an inactive metabolite of loperamide. Plasma concentrations following therapeutic loperamide dosing are usually under 20 ng desmethylloperamide/mL.
Postmortem blood concentration in one fatality was reported at 380 ng desmethylloperamide/mL.

63. 52064B Loxapine Confirmation, Blood (Forensic)

Scope of Analysis:	Loxapine
Method(s):	High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)
Purpose:	Confirmation of positive Screen; This test is New York State approved.
Category:	Antipsychotic (Neuroleptic)
Specimen Requirements:	1 mL Blood
Minimum Volume:	0.5 mL
Special Handling:	None
Specimen Container:	Lavender top tube (EDTA)
Transport Temperature:	Refrigerated
Light Protection:	Not Required
Rejection Criteria:	None
Known Interference(s):	N/A
Stability:	Room Temperature: 30 day(s) Refrigerated: 30 day(s) Frozen (-20 °C): 6 month(s)

Method: High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

Set-Up Days / TAT: Tuesday 3 days (after set-up)

CPT Code: 80342

Compound Name / Alias	Units	RL
Loxapine Loxitane®	ng/mL	5.0

Reference Comment

With a single 30-50 mg dose (orally or intramuscularly), the plasma concentrations were 17-33 ng/mL.
With 150 mg chronic daily oral dose, the plasma concentration was 30 ng/mL.
A peak plasma concentration after a single 10 mg oral inhalation dose was 260 ng/mL.

64. 52412B MDMA / Methedrone Confirmation (Qualitative), Blood (Forensic)

Scope of Analysis:	MDMA; Methedrone
Method(s):	High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)
Purpose:	Confirmation of positive Screen; This test is New York State approved.
Category:	Stimulant, NPS
Specimen Requirements:	2 mL Blood
Minimum Volume:	1 mL
Special Handling:	None
Specimen Container:	Lavender top tube (EDTA)
Transport Temperature:	Refrigerated
Light Protection:	Not Required
Rejection Criteria:	None
Known Interference(s):	N/A
Stability:	Room Temperature: 30 day(s) Refrigerated: 30 day(s) Frozen (-20 °C): 30 day(s)

Method:	High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

Set-Up Days / TAT: Tuesday 5 days (after set-up)

CPT Code: 80359, 80371

Compound Name / Alias	Units	RL
MDMA 3,4-Methylenedioxymethamphetamine; Ecstasy	ng/mL	10
Methedrone	ng/mL	10

Reference Comment

Methedrone is a beta keto amphetamine or Cathinone stimulant entactogenic drug first reported in 2010. Its use has been linked to the popular 'Designer Drug' movement and may be present in products sold as 'Legal High' or 'Bath Salts' for recreational purposes. The drug is usually taken orally, but can also be insufflated or vaporized.

Methedrone chemically related to mephedrone.

Associated Confirmation Tests

[MDMA]	52434B	MDMA Confirmation, Blood (Forensic)

65. 52434B MDMA Confirmation, Blood (Forensic)

Scope of Analysis: MDMA

Method(s): High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

Purpose: Confirmation of positive Screen; This test is New York State approved.

Category: Stimulant

Specimen Requirements: 1 mL Blood

Minimum Volume: 0.3 mL

Special Handling: None

Specimen Container: Lavender top tube (EDTA)

Transport Temperature: Refrigerated

Light Protection: Not Required

Rejection Criteria: None

Known Interference(s): N/A

Stability: Room Temperature: 1 month(s)

Refrigerated: 1 month(s)

Frozen (-20 °C): 1 month(s)

Method:	High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

Set-Up Days / TAT: Monday-Friday 7 days (after set-up)

CPT Code: 80359

Compound Name / Alias	Units	RL
MDMA 3,4-Methylenedioxymethamphetamine; Ecstasy	ng/mL	5.0

66. 52270B Maprotiline Confirmation, Blood (Forensic)

Scope of Analysis:	Maprotiline
Method(s):	Gas Chromatography (GC)
Purpose:	Confirmation of positive Screen; This test is New York State approved.
Category:	Antidepressant
Specimen Requirements:	2 mL Blood
Minimum Volume:	0.7 mL
Special Handling:	None
Specimen Container:	NMS Labs has no experimental or literature-based data regarding the choice of specific specimen collection containers for this test.
Transport Temperature:	Refrigerated
Light Protection:	Not Required
Rejection Criteria:	None
Known Interference(s):	N/A
Stability:	Room Temperature: 14 day(s) Refrigerated: 25 day(s) Frozen (-20 °C): 12 month(s)

Method: Gas Chromatography (GC)

Set-Up Days / TAT: Tuesday Thursday 3 days (after set-up)

CPT Code: 80335

Compound Name / Alias	Units	RL
Maprotiline Ludiomil®	ng/mL	20

Reference Comment

Following daily oral doses of 50, 100 and 150 mg, the steady-state mean blood concentrations were 70, 140 and 220 ng/mL respectively.

67. 52421B Memantine Confirmation, Blood (Forensic)

Scope of Analysis:	Memantine
Method(s):	High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)
Purpose:	Confirmation of positive Screen; This test is New York State approved.
Category:	Alzheimers Drug
Specimen Requirements:	1 mL Blood
Minimum Volume:	0.24 mL
Special Handling:	None
Specimen Container:	Lavender top tube (EDTA)
Transport Temperature:	Refrigerated
Light Protection:	Not Required
Rejection Criteria:	None
Known Interference(s):	N/A
Stability:	Room Temperature: 30 day(s) Refrigerated: 30 day(s) Frozen (-20 °C): 30 day(s)

Method: High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

Set-Up Days / TAT: Thursday 4 days (after set-up)

CPT Code: 80375

Compound Name / Alias	Units	RL
Memantine Axura®; Ebixa®; Namenda®	ng/mL	10

Reference Comment

The steady state plasma concentration of memantine in 56 patients taking 5 to 45 mg daily for at least eleven days was 16 - 264 ng/mL (72 - 182 ng/mL for patients taking 20 mg daily).

68. 52068B Meperidine and Metabolite Confirmation, Blood (Forensic)

Scope of Analysis: Meperidine; Normeperidine

Method(s): Gas Chromatography (GC)

Purpose: Confirmation of positive Screen; This test is New York State approved.

Category: Analgesic, Anesthetic

Specimen Requirements: 2 mL Blood

Minimum Volume: 0.7 mL

Special Handling: None

Specimen Container: Lavender top tube (EDTA)

Transport Temperature: Refrigerated

Light Protection: Not Required

Rejection Criteria: None

Known Interference(s): N/A

Stability: Room Temperature: 7 day(s)

Refrigerated: 14 day(s)

Frozen (-20 °C): 14 day(s)

Method: Gas Chromatography (GC)

Set-Up Days / TAT: Tuesday Thursday 3 days (after set-up)

CPT Code: 80362

Compound Name / Alias	Units	RL
Meperidine Demerol®	mcg/mL	0.04
Normeperidine Meperidine Metabolite	mcg/mL	0.02

Reference Comment

Expected analgesic range: 0.1 - 0.6 mcg Meperidine/mL.
Normeperidine concentrations: Up to 0.5 mcg/mL.

69. 52072B Mescaline Confirmation, Blood (Forensic)

Scope of Analysis: Mescaline

Method(s): Gas Chromatography (GC)

Purpose: Confirmation of positive Screen; This test is New York State approved.

Category: Hallucinogen

Specimen Requirements: 3 mL Blood

Minimum Volume: 0.7 mL

Special Handling: None

Specimen Container: NMS Labs has no experimental or literature-based data regarding the choice of specific specimen collection containers for this test.

Transport Temperature: Refrigerated

Light Protection: Not Required

Rejection Criteria: None

Known Interference(s): N/A

Stability: Room Temperature: 30 day(s)
Refrigerated: 30 day(s)
Frozen (-20 °C): 30 day(s)

Method: Gas Chromatography (GC)

Set-Up Days / TAT: Wednesday 3 days (after set-up)

CPT Code: 80323

Compound Name / Alias	Units	RL
Mescaline 3,4,5-Trimethoxyphenethylamine; Peyote	mcg/mL	0.04

Reference Comment

No reference data available.

70. 52422B Metaxalone Confirmation, Blood (Forensic)

Scope of Analysis: Metaxalone

Method(s): High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

Purpose: Confirmation of positive Screen; This test is New York State approved.

Category: Muscle Relaxant

Specimen Requirements: 1 mL Blood

Minimum Volume: 0.3 mL

Special Handling: None

Specimen Container: Lavender top tube (EDTA)

Transport Temperature: Refrigerated

Light Protection: Not Required

Rejection Criteria: None

Known Interference(s): N/A

Stability: Room Temperature: 30 day(s)
Refrigerated: 30 day(s)
Frozen (-20 °C): 30 day(s)

Method: High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

Set-Up Days / TAT: Tuesday 3 days (after set-up)

CPT Code: 80369

Compound Name / Alias	Units	RL
Metaxalone Skelaxin®	mcg/mL	0.025

71. 50015B Methadone and Metabolite Confirmation, Blood (Forensic)

Scope of Analysis: EDDP; Methadone

Method(s): High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

Purpose: Confirmation of positive Screen; This test is New York State approved.

Category: Narcotic Analgesic
Specimen Requirements: 1 mL Blood
Minimum Volume: 0.3 mL
Special Handling: None
Specimen Container: Gray top tube (Sodium Fluoride / Potassium Oxalate), Lavender top tube (EDTA)
Transport Temperature: Refrigerated
Light Protection: Not Required
Rejection Criteria: None
Known Interference(s): N/A
Stability: Room Temperature: 7 day(s)
Refrigerated: 30 day(s)
Frozen (-20 °C): 30 day(s)

Method: High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

Set-Up Days / TAT: Monday Wednesday Friday 3 days (after set-up)
CPT Code: 80358

Compound Name / Alias	Units	RL
Methadone Dolophine®	ng/mL	20
Reference Comment Usual narcotic stabilization range: 50 - 1000 ng/mL.		
EDDP Methadone Metabolite	ng/mL	20

72. 52073B Methaqualone Confirmation, Blood (Forensic)

Scope of Analysis: Methaqualone
Method(s): Gas Chromatography/Mass Spectrometry (GC/MS)
Purpose: Confirmation of positive Screen; This test is New York State approved.
Category: Hypnotic, Sedative
Specimen Requirements: 2 mL Blood
Minimum Volume: 0.7 mL
Special Handling: None
Specimen Container: NMS Labs has no experimental or literature-based data regarding the choice of specific specimen collection containers for this test.
Transport Temperature: Refrigerated
Light Protection: Not Required
Rejection Criteria: None
Known Interference(s): N/A
Stability: Room Temperature: 7 day(s)
Refrigerated: 14 day(s)
Frozen (-20 °C): 12 month(s)

Method: Gas Chromatography/Mass Spectrometry (GC/MS)

Set-Up Days / TAT: Wednesday 3 days (after set-up)
CPT Code: 80368

Compound Name / Alias	Units	RL
Methaqualone Quaalude	mcg/mL	0.1
Reference Comment Reported blood levels associated with: Erratic driving: 2 - 12 mcg/mL Mild Toxicity: 2 - 16 mcg/mL Unconsciousness: Greater than 8 mcg/mL		

73. 52430B Methcathinone Confirmation (Qualitative), Blood (Forensic)

Scope of Analysis:	Methcathinone
Method(s):	High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)
Purpose:	Confirmation of positive Screen; This test is New York State approved.
Category:	NPS
Specimen Requirements:	2 mL Blood
Minimum Volume:	0.7 mL
Special Handling:	None
Specimen Container:	Lavender top tube (EDTA)
Transport Temperature:	Refrigerated
Light Protection:	Not Required
Rejection Criteria:	Received Room Temperature.
Known Interference(s):	N/A
Stability:	Room Temperature: 3 day(s) Refrigerated: 30 day(s) Frozen (-20 °C): 30 day(s)

Method: High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

Set-Up Days / TAT:	Tuesday 5 days (after set-up)
CPT Code:	80371

Compound Name / Alias	Units	RL
Methcathinone	ng/mL	10

Reference Comment

Methcathinone, a CNS-stimulant, is similar to methamphetamine in that it can reduce fatigue and block hunger. The drug can also trigger impulsive, erratic behavior by increasing the action of two neurotransmitters, norepinephrine and dopamine. At higher dosages, or with chronic use, feelings of heightened confidence, arousal, paranoia, irritability, and severe depression are exhibited.

Physical side effects include loss of appetite, profuse sweating, dehydration, elevated heart rate and body temperature, and uncontrolled shaking. Psychological effects include anxiety and irritability. Tolerance often develops rapidly as does dependence. Early withdrawal symptoms of anxiety and profuse sweating can precede convulsions, hallucinations, and severe depression.

No reference blood concentration data for this compound have been reported.

74. 52076B Methocarbamol Confirmation, Blood (Forensic)

Scope of Analysis:	Methocarbamol
Method(s):	High Performance Liquid Chromatography(HPLC)
Purpose:	Confirmation of positive Screen; This test is New York State approved.
Category:	Muscle Relaxant
Specimen Requirements:	2 mL Blood
Minimum Volume:	0.7 mL

Special Handling: None
Specimen Container: Lavender top tube (EDTA)
Transport Temperature: Refrigerated
Light Protection: Not Required
Rejection Criteria: Received Room Temperature.
Known Interference(s): N/A
Stability: Room Temperature: 5 day(s)
Refrigerated: 14 day(s)
Frozen (-20 °C): 14 day(s)

Method: High Performance Liquid Chromatography(HPLC)

Set-Up Days / TAT: Monday Wednesday Friday 3 days (after set-up)
CPT Code: 80369

Compound Name / Alias	Units	RL
Methocarbamol Robaxin®	mcg/mL	2.0

Reference Comment
Peak levels 1 to 2 hours following a single oral dose:
2 g: 26 mcg/mL
4 g: 41 mcg/mL

75. 52079B Methylphenidate and Metabolite Confirmation, Blood (Forensic)

Scope of Analysis: Methylphenidate; Ritalinic Acid
Method(s): High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)
Purpose: Confirmation of positive Screen; This test is New York State approved.
Category: Stimulant
Specimen Requirements: 1 mL Blood
Minimum Volume: 0.45 mL
Special Handling: Sample should be collected 1 to 6 hours post dose.
Specimen Container: Lavender top tube (EDTA)
Transport Temperature: Frozen
Light Protection: Not Required
Rejection Criteria: Received Room Temperature. Received Refrigerated.
Known Interference(s): N/A
Stability: Room Temperature: Not Stable
Refrigerated: Not Stable
Frozen (-20 °C): 5 month(s)

Method: High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

Set-Up Days / TAT: Tuesday 3 days (after set-up)
CPT Code: 80360

Compound Name / Alias	Units	RL
Methylphenidate Ritalin®	ng/mL	4.0
Ritalinic Acid Methylphenidate Metabolite	ng/mL	20

Reference Comment
Plasma concentrations 3 to 6 hours post-dose in children given a 10 to 15 mg oral dose of Methylphenidate: 80 - 250 ng Ritalinic Acid/mL.

76. 52083B Mexiletine Confirmation, Blood (Forensic)

Scope of Analysis:	Mexiletine
Method(s):	Gas Chromatography (GC)
Purpose:	Confirmation of positive Screen; This test is New York State approved.
Category:	Antiarrhythmic
Specimen Requirements:	2 mL Blood
Minimum Volume:	0.7 mL
Special Handling:	None
Specimen Container:	NMS Labs has no experimental or literature-based data regarding the choice of specific specimen collection containers for this test.
Transport Temperature:	Refrigerated
Light Protection:	Not Required
Rejection Criteria:	None
Known Interference(s):	N/A
Stability:	Room Temperature: 14 day(s) Refrigerated: 14 day(s) Frozen (-20 °C): 5 month(s)

Method: Gas Chromatography (GC)

Set-Up Days / TAT: Tuesday 3 days (after set-up)
CPT Code: 80375

Compound Name / Alias	Units	RL
Mexiletine Mexitil®	mcg/mL	0.05

Reference Comment
Usual antiarrhythmic range: 0.7 - 2.5 mcg/mL.

77. 52303B Mirtazapine Confirmation, Blood (Forensic)

Scope of Analysis:	Mirtazapine
Method(s):	Gas Chromatography (GC)
Purpose:	Confirmation of positive Screen; This test is New York State approved.
Category:	Antidepressant
Specimen Requirements:	2 mL Blood
Minimum Volume:	0.7 mL
Special Handling:	None
Specimen Container:	NMS Labs has no experimental or literature-based data regarding the choice of specific specimen collection containers for this test.
Transport Temperature:	Refrigerated
Light Protection:	Not Required
Rejection Criteria:	None
Known Interference(s):	N/A
Stability:	Room Temperature: 7 day(s) Refrigerated: 14 day(s) Frozen (-20 °C): 14 day(s)

Method:

Set-Up Days / TAT: N/A
CPT Code: 80362, 80376

Method: Gas Chromatography (GC)

Set-Up Days / TAT: Monday-Friday 3 days (after set-up)

CPT Code: 80335

Compound Name / Alias	Units	RL
Mirtazapine Remeron®	ng/mL	10

Reference Comment

Steady-state peak (0.7 to 4.8 hours post-dose) and trough plasma concentrations following a daily regimen:
15 mg/day: 27 - 51 ng/mL peak; 4.3 - 12 ng/mL trough
30 mg/day: 56 - 104 ng/mL peak; 11 - 25 ng/mL trough
45 mg/day: 84 - 142 ng/mL peak; 17 - 39 ng/mL trough
60 mg/day: 117 - 199 ng/mL peak; 24 - 52 ng/mL trough
75 mg/day: 137 - 225 ng/mL peak; 28 - 64 ng/mL trough

Elimination half-life: 20 to 40 hours.

78. 52489B Mitragynine Confirmation, Blood

Scope of Analysis: Mitragynine
Method(s): High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)
Purpose: Confirmation of positive Screen; This test is New York State approved.
Category: Plant alkaloid
Specimen Requirements: 2 mL Blood
Minimum Volume: 0.7 mL
Special Handling: None
Specimen Container: Gray top tube (Sodium Fluoride / Potassium Oxalate)
Transport Temperature: Refrigerated
Light Protection: Not Required
Rejection Criteria: None
Known Interference(s): N/A
Stability: Room Temperature: 7 day(s)
Refrigerated: 30 day(s)
Frozen (-20 °C): 30 day(s)

Method: High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

Set-Up Days / TAT: Tuesday Thursday 3 days (after set-up)

CPT Code: 80375

Compound Name / Alias	Units	RL
Mitragynine Kratom	ng/mL	5.0

Reference Comment

Mitragynine is an alkaloid found in the plant Kratom which originates from Asia. The leaves of the plant are consumed for their stimulant and analgesic effects and these effects are attributed to mitragynine. Plant extracts are sold for their medicinal use and may be subject to abuse. Adverse effects include seizures, coma, and death. Mitragynine blood concentrations listed in fatalities ranged from 20-600 ng/mL; other substances may have also been present.

79. 52387B NBOMe Confirmation (Qualitative), Blood

Scope of Analysis:	25B-NBOMe; 25C-NBOMe; 25H-NBOMe; 25I-NBOMe
Method(s):	High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)
Purpose:	Confirmation of positive Screen; This test is New York State approved.
Category:	NPS
Specimen Requirements:	1 mL Blood
Minimum Volume:	0.3 mL
Special Handling:	None
Specimen Container:	Lavender top tube (EDTA)
Transport Temperature:	Refrigerated
Light Protection:	Not Required
Rejection Criteria:	Received Room Temperature.
Known Interference(s):	N/A
Stability:	Room Temperature: 4 day(s) Refrigerated: 23 day(s) Frozen (-20 °C): 30 day(s)

Method: High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

Set-Up Days / TAT: Tuesday 3 days (after set-up)

CPT Code: 80371

Compound Name / Alias	Units	RL
25I-NBOMe 2C-I-NBOMe	ng/mL	0.5
Reference Comment 25I-NBOMe is a novel substituted phenethylamine with hallucinogenic and stimulant properties. Clinical features include seizures, aggression, self-harm and agitation, distortions in space and time, psychosis-like symptoms, tachycardia, hyperpyrexia, and rhabdomyolysis. Case reports of NBOMe use have included hospitalizations and deaths which indicate a substantial risk of toxicity after ingestion or insufflation of limited quantities of this substance.		
25C-NBOMe 2C-C-NBOMe	ng/mL	0.5
Reference Comment 25C-NBOMe is a novel substituted phenethylamine with hallucinogenic and stimulant properties. Clinical features include seizures, aggression, self-harm and agitation, distortions in space and time, psychosis-like symptoms, tachycardia, hyperpyrexia, and rhabdomyolysis. Case reports of NBOMe use have included hospitalizations and deaths which indicate a substantial risk of toxicity after ingestion or insufflation of limited quantities of this substance.		
25H-NBOMe 2C-H-NBOMe	ng/mL	0.5
Reference Comment 25H-NBOMe is a novel substituted phenethylamine with hallucinogenic and stimulant properties. Clinical features include seizures, aggression, self-harm and agitation, distortions in space and time, psychosis-like symptoms, tachycardia, hyperpyrexia, and rhabdomyolysis. Case reports of NBOMe use have included hospitalizations and deaths which indicate a substantial risk of toxicity after ingestion or insufflation of limited quantities of this substance.		

Compound Name / Alias	Units	RL
25B-NBOMe 2C-B-NBOMe	ng/mL	0.5

Reference Comment

25B-NBOMe is a novel substituted phenethylamine with hallucinogenic and stimulant properties. Clinical features include seizures, aggression, self-harm and agitation, distortions in space and time, psychosis-like symptoms, tachycardia, hyperpyrexia, and rhabdomyolysis. Case reports of NBOMe use have included hospitalizations and deaths which indicate a substantial risk of toxicity after ingestion or insufflation of limited quantities of this substance.

80. 52497B Naltrexone and Metabolite - Free (Unconjugated) Confirmation, Blood (Forensic)

Scope of Analysis: 6-Beta-Naltrexol - Free; Naltrexone - Free
Method(s): High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)
Purpose: Confirmation of positive Screen; This test is New York State approved.
Category: Narcotic Analgesic
Specimen Requirements: 2 mL Blood
Minimum Volume: 0.7 mL
Special Handling: None
Specimen Container: Gray top tube (Sodium Fluoride / Potassium Oxalate)
Transport Temperature: Refrigerated
Light Protection: Not Required
Rejection Criteria: None
Known Interference(s): N/A
Stability: Room Temperature: 14 day(s)
Refrigerated: 30 day(s)
Frozen (-20 °C): 3 month(s)

Method: High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

Set-Up Days / TAT: Tuesday Thursday 3 days (after set-up)
CPT Code: 80362

Compound Name / Alias	Units	RL
Naltrexone - Free Depade; ReVia; Trexan; Vivitrol	ng/mL	0.5

Reference Comment

The peak plasma concentrations at approximately one hour following a single oral dose of naltrexone were:
9 (+/- 5) ng/mL after 50 mg
20 (+/- 18) ng/mL after 100 mg
36 (+/- 20) ng/mL after 200 mg
The average peak plasma concentration of naltrexone was 28 ng/mL following four doses of 380 mg naltrexone given by depot intramuscular injection every 28 days.
The blood to plasma ratio of naltrexone is approximately 0.9.

6-Beta-Naltrexol - Free Naltrexone Metabolite	ng/mL	0.5

Reference Comment

The peak plasma concentrations of 6-beta naltrexol at approximately one hour following a single oral dose of naltrexone were:
99 (+/- 30) ng/mL after 50 mg
210 (+/- 78) ng/mL after 100 mg
440 (+/- 140) ng/mL after 200 mg
The average peak plasma concentration of 6-beta-naltrexol was 34 ng/mL following four doses of 380 mg naltrexone given by depot intramuscular injection every 28 days.
The blood to plasma ratio of 6-beta-naltrexol is approximately 0.5.

81. 52406B Naproxen Confirmation, Blood (Forensic)

Scope of Analysis:	Naproxen
Method(s):	High Performance Liquid Chromatography(HPLC)
Purpose:	Confirmation of positive Screen; This test is New York State approved.
Category:	Analgesic, Anti-Inflammatory
Specimen Requirements:	1 mL Blood
Minimum Volume:	0.4 mL
Special Handling:	None
Specimen Container:	NMS Labs has no experimental or literature-based data regarding the choice of specific specimen collection containers for this test.
Transport Temperature:	Refrigerated
Light Protection:	Not Required
Rejection Criteria:	None
Known Interference(s):	N/A
Stability:	Room Temperature: 16 day(s) Refrigerated: 16 day(s) Frozen (-20 °C): 10 month(s)

Method: High Performance Liquid Chromatography(HPLC)

Set-Up Days / TAT: Tuesday Thursday 3 days (after set-up)
CPT Code: 80330

Compound Name / Alias	Units	RL
Naproxen Naprosyn®	mcg/mL	0.3

Reference Comment
Anti-inflammatory or analgesic range: 30 - 90 mcg/mL.

82. 52088B Nifedipine Confirmation, Blood (Forensic)

Scope of Analysis:	Nifedipine
Method(s):	High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)
Purpose:	Confirmation of positive Screen; This test is New York State approved.
Category:	Antihypertensive
Specimen Requirements:	1 mL Blood
Minimum Volume:	0.5 mL
Special Handling:	None
Specimen Container:	Lavender top tube (EDTA)
Transport Temperature:	Refrigerated
Light Protection:	Yes
Rejection Criteria:	Not received Light Protected.
Known Interference(s):	N/A
Stability:	Room Temperature: 30 day(s) Refrigerated: 30 day(s) Frozen (-20 °C): 30 day(s)

Method: High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

Set-Up Days / TAT: Tuesday 3 days (after set-up)
CPT Code: 80375

Compound Name / Alias	Units	RL
Nifedipine Procardia®	ng/mL	5.0

Reference Comment

The effective daily dosage: 30 - 120 mg.
Reported therapeutic serum range: 25 - 200 ng/mL.

83. 52091B Olanzapine Confirmation, Blood (Forensic)

Scope of Analysis:	Olanzapine
Method(s):	Gas Chromatography (GC)
Purpose:	Confirmation of positive Screen; This test is New York State approved.
Category:	Antipsychotic (Neuroleptic)
Specimen Requirements:	8 mL Blood
Minimum Volume:	3.6 mL
Special Handling:	None
Specimen Container:	NMS Labs has no experimental or literature-based data regarding the choice of specific specimen collection containers for this test.
Transport Temperature:	Frozen
Light Protection:	Not Required
Rejection Criteria:	Received Room Temperature. Received Refrigerated.
Known Interference(s):	N/A
Stability:	Room Temperature: Not Stable Refrigerated: 2 day(s) Frozen (-20 °C): 14 day(s)

Method: Gas Chromatography (GC)

Set-Up Days / TAT: Tuesday 3 days (after set-up)
CPT Code: 80342

Compound Name / Alias	Units	RL
Olanzapine Zyprexa®	ng/mL	3.0

Reference Comment

Proposed therapeutic range: 5.0 - 75 ng/mL.

84. 50016B Opiates - Free (Unconjugated) Confirmation, Blood (Forensic)

Scope of Analysis:	6-Monoacetylmorphine - Free; Codeine - Free; Dihydrocodeine / Hydrocodol - Free; Hydrocodone - Free; Hydromorphone - Free; Morphine - Free; Oxycodone - Free; Oxymorphone - Free
Method(s):	High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)
Purpose:	Confirmation of positive Screen; This test is New York State approved.
Category:	Drug Metabolite, Narcotic Analgesic
Specimen Requirements:	2 mL Blood
Minimum Volume:	0.7 mL
Special Handling:	Note: Sample rejection criteria for this test is based on refrigerated conditions. While 6-MAM stability is best if frozen, positive findings are routinely found in non-frozen samples. If optimal stability is required for this analyte, freeze the specimen and order test 2276SP, 2276B or 2276U which includes Heroin Metabolites.
Specimen Container:	Gray top tube (Sodium Fluoride / Potassium Oxalate)
Transport Temperature:	Refrigerated
Light Protection:	Not Required

Rejection Criteria: None

Known Interference(s): N/A

Stability: Room Temperature: 14 day(s)

Refrigerated: 30 day(s)

Frozen (-20 °C): 30 day(s)

Method: High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

Set-Up Days / TAT: Monday-Friday 2nd Shift 4 days (after set-up)

CPT Code: 80356, 80361, 80365

Compound Name / Alias	Units	RL
Dihydrocodeine / Hydrocodol - Free Hydrocodone Metabolite	ng/mL	5.0
Reference Comment Adult therapeutic range: 72-150 ng/mL.		
Codeine - Free	ng/mL	5.0
Reference Comment Adult therapeutic range: 20-210 ng/mL.		
Morphine - Free Codeine Metabolite	ng/mL	5.0
Reference Comment Adult therapeutic range: <73 ng/mL.		
Hydrocodone - Free Vicodin®; Zohydro®	ng/mL	5.0
Reference Comment Adult therapeutic range: 6-29 ng/mL.		
6-Monoacetylmorphine - Free 6-MAM; Heroin Metabolite	ng/mL	1.0
Reference Comment 6-Monoacetylmorphine is a metabolite of heroin.		
Hydromorphone - Free Dilaudid®; Hydrocodone Metabolite	ng/mL	1.0
Reference Comment Adult therapeutic range: 5-20 ng/mL.		
Oxycodone - Free OxyContin®; Roxicodone®	ng/mL	5.0
Reference Comment Adult therapeutic range: 13-120 ng/mL.		
Oxymorphone - Free Numorphan®; Opana®; Oxycodone Metabolite	ng/mL	1.0
Reference Comment Adult therapeutic range: 3-8 ng/mL.		

85. 52289B Orphenadrine Confirmation, Blood (Forensic)

Scope of Analysis: Orphenadrine

Method(s): Gas Chromatography (GC)

Purpose: Confirmation of positive Screen; This test is New York State approved.

Category: Antihistamine

Specimen Requirements: 2 mL Blood

Minimum Volume: 0.7 mL

Special Handling: None

Specimen Container: Lavender top tube (EDTA)

Transport Temperature: Refrigerated

Light Protection: Not Required
Rejection Criteria: None
Known Interference(s): N/A
Stability: Room Temperature: 7 day(s)
Refrigerated: 14 day(s)
Frozen (-20 °C): 10 month(s)

Method:
Set-Up Days / TAT: N/A
CPT Code: 80369, 80376

Method: Gas Chromatography (GC)
Set-Up Days / TAT: Tuesday Thursday 3 days (after set-up)
CPT Code: 80369

Compound Name / Alias	Units	RL
Orphenadrine Flexon; Norflex	ng/mL	100

Reference Comment
During chronic oral muscle relaxing 300 mg/day:
100 - 200 ng/mL.

86. 52093B Oxcarbazepine/Eslicarbazepine Acetate as Metabolite Confirmation, Blood (Forensic)

Scope of Analysis: 10-Hydroxycarbazepine
Method(s): High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)
Purpose: Confirmation of positive Screen; This test is New York State approved.
Category: Anticonvulsant, Antiepileptic
Specimen Requirements: 1 mL Blood
Minimum Volume: 0.25 mL
Special Handling: None
Specimen Container: Gray top tube (Sodium Fluoride / Potassium Oxalate)
Transport Temperature: Refrigerated
Light Protection: Not Required
Rejection Criteria: None
Known Interference(s): N/A
Stability: Room Temperature: 30 day(s)
Refrigerated: 30 day(s)
Frozen (-20 °C): 24 month(s)

Method: High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)
Set-Up Days / TAT: Monday Wednesday Friday 3 days (after set-up)
CPT Code: 80183

Compound Name / Alias	Units	RL
10-Hydroxycarbazepine Licarbazepine; Oxcarbazepine/Eslicarbazepine Acetate Metabolite	mcg/mL	0.5

Reference Comment
Therapeutic serum range: 10 - 35 mcg/mL.

The ratio of whole blood concentration to serum or plasma concentration is approximately 1.2-1.4.

This test is not chiral specific. The reported concentration represents racemic 10-Hydroxycarbazepine in patients who have taken Oxcarbazepine (Trileptal®) and S-10-Hydroxycarbazepine in patients who have taken Eslicarbazepine Acetate (Aptiom®).

87. 52432B PMA Confirmation (Qualitative), Blood (Forensic)

Scope of Analysis:	PMA
Method(s):	High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)
Purpose:	Confirmation of positive Screen; This test is New York State approved.
Category:	NPS
Specimen Requirements:	1 mL Blood
Minimum Volume:	0.7 mL
Special Handling:	None
Specimen Container:	Lavender top tube (EDTA)
Transport Temperature:	Refrigerated
Light Protection:	Not Required
Rejection Criteria:	None
Known Interference(s):	N/A
Stability:	Room Temperature: 30 day(s) Refrigerated: 30 day(s) Frozen (-20 °C): 30 day(s)

Method: High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

Set-Up Days / TAT: Tuesday 5 days (after set-up)

CPT Code: 80371

Compound Name / Alias	Units	RL
PMA para-methoxyamphetamine	ng/mL	10

Reference Comment

PMA is a serotonergic drug of the amphetamine class. It is a potent serotonergic stimulant drug and produces significant toxic effects at recreational doses. Adverse effects are linked to the potent serotonergic properties of the drug and include hyperpyrexia, tachycardia, agitation, shallow labored breathing and hypertension.

88. 52096B Paroxetine Confirmation, Blood (Forensic)

Scope of Analysis:	Paroxetine
Method(s):	High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)
Purpose:	Confirmation of positive Screen; This test is New York State approved.
Category:	Antidepressant
Specimen Requirements:	1 mL Blood
Minimum Volume:	0.4 mL
Special Handling:	None
Specimen Container:	Lavender top tube (EDTA)
Transport Temperature:	Refrigerated
Light Protection:	Not Required
Rejection Criteria:	Received Room Temperature.
Known Interference(s):	N/A
Stability:	Room Temperature: 2 day(s) Refrigerated: 14 day(s) Frozen (-20 °C): 1 month(s)

Method: **High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)**

Set-Up Days / TAT: Tuesday Friday 3 days (after set-up)

CPT Code: 80332

Compound Name / Alias	Units	RL
Paroxetine Paxil®	ng/mL	10

Reference Comment

Paroxetine trough steady-state plasma levels in adult patients have great inter-individual variability.
The following steady-state trough plasma data for paroxetine is reported as mean +/- 1 SD:
20 mg/day: 49 +/- 26 ng/mL;
30 mg/day: 86 +/- 61 ng/mL;
40 mg/day: 129 +/- 86 ng/mL;
50 mg/day: 117 +/- 90 ng/mL.
The blood to plasma ratio of paroxetine is approximately 1.

89. 52423B Perphenazine Confirmation, Blood (Forensic)

Scope of Analysis: Perphenazine

Method(s): High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

Purpose: Confirmation of positive Screen; This test is New York State approved.

Category: Antidepressant

Specimen Requirements: 2 mL Blood

Minimum Volume: 0.7 mL

Special Handling: None

Specimen Container: Lavender top tube (EDTA)

Transport Temperature: Refrigerated

Light Protection: Not Required

Rejection Criteria: None

Known Interference(s): Perphenazine [LC-MS/MS]: Diclofenac

Stability: Room Temperature: 10 day(s)
Refrigerated: 30 day(s)
Frozen (-20 °C): 30 day(s)

Method: **High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)**

Set-Up Days / TAT: Wednesday 3 days (after set-up)

CPT Code: 80342

Compound Name / Alias	Units	RL
Perphenazine Trilafon®	ng/mL	0.2

Reference Comment

Daily regimen of 12 to 48 mg: 0.3 - 30 ng/mL

Substance(s) known to interfere with the identity and/or quantity of the reported result: Diclofenac

90. 50017B Phencyclidine Confirmation, Blood (Forensic)

Scope of Analysis: Phencyclidine

Method(s): High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

Purpose: Confirmation of positive Screen; This test is New York State approved.

Category: N/A
Specimen Requirements: 1 mL Blood
Minimum Volume: 0.3 mL
Special Handling: None
Specimen Container: Gray top tube (Sodium Fluoride / Potassium Oxalate)
Transport Temperature: Refrigerated
Light Protection: Not Required
Rejection Criteria: None
Known Interference(s): N/A
Stability: Room Temperature: 14 day(s)
Refrigerated: 30 day(s)
Frozen (-20 °C): 30 day(s)

Method: High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

Set-Up Days / TAT: Monday Wednesday Friday 3 days (after set-up)
CPT Code: 83992

Compound Name / Alias	Units	RL
Phencyclidine Angel Dust; PCP; Sherm	ng/mL	5.0

91. 52291B Pheniramine Confirmation, Blood (Forensic)

Scope of Analysis: Pheniramine
Method(s): Gas Chromatography (GC)
Purpose: Confirmation of positive Screen; This test is New York State approved.
Category: Antihistamine
Specimen Requirements: 2 mL Blood
Minimum Volume: 0.7 mL
Special Handling: None
Specimen Container: Gray top tube (Sodium Fluoride / Potassium Oxalate)
Transport Temperature: Refrigerated
Light Protection: Not Required
Rejection Criteria: None
Known Interference(s): Pheniramine [GC]: Dimethyltryptamine, Phencyclidine
Stability: Room Temperature: Undetermined
Refrigerated: Undetermined
Frozen (-20 °C): Undetermined

Method: Gas Chromatography (GC)

Set-Up Days / TAT: Tuesday Thursday 3 days (after set-up)
CPT Code: 80375

Compound Name / Alias	Units	RL
Pheniramine	ng/mL	40

Reference Comment

Expected peak level following a single 75 mg oral antihistaminic dose: 190 ng/mL.

Substance(s) known to interfere with the identity and/or quantity of the reported result: Dimethyltryptamine and Phencyclidine.

92. 52105B Phenytoin Confirmation, Blood (Forensic)

Scope of Analysis:	Phenytoin
Method(s):	High Performance Liquid Chromatography(HPLC)
Purpose:	Confirmation of positive Screen; This test is New York State approved.
Category:	Anticonvulsant, Antiepileptic
Specimen Requirements:	2 mL Blood
Minimum Volume:	0.7 mL
Special Handling:	None
Specimen Container:	NMS Labs has no experimental or literature-based data regarding the choice of specific specimen collection containers for this test.
Transport Temperature:	Refrigerated
Light Protection:	Not Required
Rejection Criteria:	None
Known Interference(s):	N/A
Stability:	Room Temperature: 14 day(s) Refrigerated: 14 day(s) Frozen (-20 °C): 14 day(s)

Method: High Performance Liquid Chromatography(HPLC)

Set-Up Days / TAT: Monday Wednesday Friday 3 days (after set-up)
CPT Code: 80185

Compound Name / Alias	Units	RL
Phenytoin Dilantin®	mcg/mL	0.5

Reference Comment
Antiepileptic range: 10 - 20 mcg/mL.

93. 52373B Piperazine Designer Drugs Confirmation, Blood (Forensic)

Scope of Analysis:	BZP; TFMPP; mCPP
Method(s):	Gas Chromatography/Mass Spectrometry (GC/MS)
Purpose:	Confirmation of positive Screen; This test is New York State approved.
Category:	Hallucinogen, NPS
Specimen Requirements:	2 mL Blood
Minimum Volume:	0.7 mL
Special Handling:	None
Specimen Container:	Lavender top tube (EDTA)
Transport Temperature:	Refrigerated
Light Protection:	Not Required
Rejection Criteria:	None
Known Interference(s):	N/A
Stability:	Room Temperature: 30 day(s) Refrigerated: 30 day(s) Frozen (-20 °C): 30 day(s)

Method: Gas Chromatography/Mass Spectrometry (GC/MS)

Set-Up Days / TAT: Wednesday 3 days (after set-up)
CPT Code: 80371

Compound Name / Alias	Units	RL
TFMPP 3-Trifluoromethylphenylpiperazine	ng/mL	10

Reference Comment
TFMPP is a synthetic piperazine derivative categorized as a 'designer drug'. TFMPP is available in tablet and capsule forms and is commonly only present in products that contain N-Benzylpiperazine (BZP). TFMPP is often mixed with BZP in order to mimic the psychoactive effects of methylenedioxymethamphetamine (MDMA) and methylenedioxyamphetamine (MDA).

There is little information concerning blood or plasma concentrations of TFMPP. In one study, serum concentrations of TFMPP in 3 drug abusers were reported to be between 260 and 270 ng/mL. In two autopsy cases, postmortem femoral blood was found to contain 50 and 150 ng/mL of the compound.

Compound Name / Alias	Units	RL
BZP 1-Benzylpiperazine	ng/mL	10

Reference Comment

Mean peak plasma concentration following a 200 mg oral dose was reported to be 262 ng/mL (range 222 - 344 ng/mL), 75 min post dose.

The whole blood to plasma ratio has not been reported for this drug.

mCPP 1-(3-Chlorophenyl)Piperazine; Nefazodone metabolite; Trazodone metabolite	ng/mL	10

Reference Comment

mCPP is an active metabolite of the prescription antidepressants Trazodone and Nefazodone. mCPP is also encountered in illicit tablets sold as Ecstasy. Reported concentrations of mCPP in these tablets range from 2 - 357 mg/tablet. Tablets may contain only mCPP or may be mixed with other drugs such as MDMA, TFMPP or caffeine. mCPP has similar subjective stimulant and hallucinogenic effects as MDMA, but unlike MDMA has not been found to increase blood pressure or heart rate.

Reported adverse effects include nausea, vomiting, dizziness, sweating, induction of migraine-like headache, anxiety, depressive symptoms and paranoia.

A woman reported to have taken 3 tablets containing 30.3 mg mCPP/tablet (total dose = 90.9 mg) had a plasma mCPP concentration of 320 ng/mL.

The blood to serum/plasma ratio of mCPP is not known.

94. 52106B Primidone, Phenobarbital and PEMA Confirmation, Blood (Forensic)

Scope of Analysis:	Phenobarbital; Phenylethylmalonamide (PEMA); Primidone
Method(s):	High Performance Liquid Chromatography(HPLC)
Purpose:	Confirmation of positive Screen; This test is New York State approved.
Category:	Anticonvulsant, Sedative, Anticonvulsant, Antiepileptic
Specimen Requirements:	2 mL Blood
Minimum Volume:	0.7 mL
Special Handling:	None
Specimen Container:	NMS Labs has no experimental or literature-based data regarding the choice of specific specimen collection containers for this test.
Transport Temperature:	Refrigerated
Light Protection:	Not Required
Rejection Criteria:	None
Known Interference(s):	N/A
Stability:	Room Temperature: Undetermined Refrigerated: Undetermined Frozen (-20 °C): Undetermined

Method: High Performance Liquid Chromatography(HPLC)

Set-Up Days / TAT:	Monday Wednesday Friday 3 days (after set-up)
CPT Code:	80184, 80188

Compound Name / Alias	Units	RL
Primidone Mysoline®	mcg/mL	0.5

Reference Comment

Antiepileptic range: 5 - 12 mcg/mL.

Compound Name / Alias	Units	RL
Phenobarbital Primidone Metabolite	mcg/mL	0.5
Reference Comment Patients receiving 1000 mg of primidone daily, showed phenobarbital serum concentrations of 17 - 29 mcg/mL. A blood/plasma ratio of 0.81 has been reported.		
Phenylethylmalonamide (PEMA) Primidone Metabolite	mcg/mL	0.5
Reference Comment Following a 1000 mg Primidone daily regimen: 7 - 10 mcg PEMA/mL.		

95. 52469B Prochlorperazine Confirmation, Blood (Forensic)

Scope of Analysis: Prochlorperazine
Method(s): High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)
Purpose: Confirmation of positive Screen; This test is New York State approved.
Category: Antiemetic, Antipsychotic
Specimen Requirements: 1 mL Blood
Minimum Volume: 0.3 mL
Special Handling: None
Specimen Container: Lavender top tube (EDTA)
Transport Temperature: Refrigerated
Light Protection: Not Required
Rejection Criteria: None
Known Interference(s): Prochlorperazine [LC-MS/MS]: Trimeprazine, Diclofenac
Stability: Room Temperature: 10 day(s)
Refrigerated: 30 day(s)
Frozen (-20 °C): 30 day(s)

Method: High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

Set-Up Days / TAT: Wednesday 3 days (after set-up)
CPT Code: 80342

Compound Name / Alias	Units	RL
Prochlorperazine Compazine®	ng/mL	1.0
Reference Comment Peak plasma concentrations following a single oral dose of 25 mg prochlorperazine averaged 3.4 ng/mL (range 1.6 to 7.6 ng/mL). The blood to plasma ratio for prochlorperazine is not known. Substance(s) known to interfere with the identity and/or quantity of the reported result: Trimeprazine, Diclofenac		

96. 52446B Promazine Confirmation, Blood (Forensic)

Scope of Analysis: Promazine
Method(s): High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)
Purpose: Confirmation of positive Screen; This test is New York State approved.
Category: Antiemetic, Antipsychotic

Specimen Requirements: 1 mL Blood
Minimum Volume: 0.4 mL
Special Handling: None
Specimen Container: Gray top tube (Sodium Fluoride / Potassium Oxalate)
Transport Temperature: Refrigerated
Light Protection: Not Required
Rejection Criteria: None
Known Interference(s): N/A
Stability: Room Temperature: 7 day(s)
Refrigerated: 30 day(s)
Frozen (-20 °C): 30 day(s)

Method: High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

Set-Up Days / TAT: Monday Wednesday Friday 3 days (after set-up)
CPT Code: 80342

Compound Name / Alias	Units	RL
Promazine Sparine®	ng/mL	5.0

Reference Comment
Following a 100 mg oral dose, mean peak plasma concentration was 137 ng/mL at 1.5 hours, declining with an average half-life of 13 hours.

97. 52456B Promethazine Confirmation, Blood (Forensic)

Scope of Analysis: Promethazine
Method(s): High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)
Purpose: Confirmation of positive Screen; This test is New York State approved.
Category: Antihistamine
Specimen Requirements: 1 mL Blood
Minimum Volume: 0.5 mL
Special Handling: None
Specimen Container: Lavender top tube (EDTA)
Transport Temperature: Refrigerated
Light Protection: Not Required
Rejection Criteria: None
Known Interference(s): Promethazine [LC-MS/MS]: Promazine, Chlorpromazine
Stability: Room Temperature: 14 day(s)
Refrigerated: 30 day(s)
Frozen (-20 °C): 30 day(s)

Method: High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

Set-Up Days / TAT: Tuesday Thursday 3 days (after set-up)
CPT Code: 80342

Compound Name / Alias	Units	RL
Promethazine Phenergan®	ng/mL	5.0

Reference Comment
Following a single 50 mg oral dose:
Average 29 ng/mL (serum).
Substance(s) known to interfere with the identity and/or quantity of the reported result:
Promazine, Chlorpromazine.

98. 50018B Propoxyphene and Metabolite Confirmation, Blood (Forensic)

Scope of Analysis:	Norpropoxyphene; Propoxyphene
Method(s):	Gas Chromatography/Mass Spectrometry (GC/MS)
Purpose:	Confirmation of positive Screen; This test is New York State approved.
Category:	Analgesic
Specimen Requirements:	2 mL Blood
Minimum Volume:	0.7 mL
Special Handling:	None
Specimen Container:	Gray top tube (Sodium Fluoride / Potassium Oxalate)
Transport Temperature:	Refrigerated
Light Protection:	Not Required
Rejection Criteria:	None
Known Interference(s):	Propoxyphene [GC/MS]: Amitriptyline
Stability:	Room Temperature: Undetermined Refrigerated: Undetermined Frozen (-20 °C): Undetermined

Method: Gas Chromatography/Mass Spectrometry (GC/MS)

Set-Up Days / TAT: Wednesday 3 days (after set-up)

CPT Code: 80367

Compound Name / Alias	Units	RL
Propoxyphene Darvon®	mcg/mL	0.1

Reference Comment

Average serum concentrations following a daily regimen of 195 mg Propoxyphene: 0.42 mcg Propoxyphene/mL.

Substance(s) known to interfere with the identity and/or quantity of the reported result: Amitriptyline

Norpropoxyphene Propoxyphene Metabolite	mcg/mL	0.1

Reference Comment

Average serum concentrations following a daily regimen of 195 mg Propoxyphene: 1.45 mcg Norpropoxyphene/mL.

99. 52431B Psilocin Confirmation (Qualitative), Blood (Forensic)

Scope of Analysis:	Psilocin
Method(s):	High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)
Purpose:	Confirmation of positive Screen; This test is New York State approved.
Category:	N/A
Specimen Requirements:	3 mL Blood
Minimum Volume:	0.7 mL
Special Handling:	None
Specimen Container:	Lavender top tube (EDTA)
Transport Temperature:	Refrigerated
Light Protection:	Not Required
Rejection Criteria:	Received Room Temperature.
Known Interference(s):	N/A
Stability:	Room Temperature: 1 day(s)

Refrigerated: 14 day(s)

Frozen (-20 °C): 12 month(s)

If this test contains multiple compounds, the reported stability reflects that which is least stable. Stability may vary among compounds included in the test and may be dependent upon matrix, pH, collection tube, and storage temperature. Negative results should be interpreted with caution. For more information on stability of a specific compound please contact the laboratory.

NOTE: If the test contains multiple compounds samples received at room temperature will not be rejected.

Method: High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

Set-Up Days / TAT: Tuesday 5 days (after set-up)

CPT Code: 80323

Compound Name / Alias	Units	RL
Psilocin 4-OH-DMT; 4-hydroxy-dimethyltryptamine	ng/mL	10

100. 52327B Pyrrolidinophenone Confirmation, Blood

Scope of Analysis: MPHP

Method(s): High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

Purpose: Confirmation of positive Screen; This test is New York State approved.

Category: NPS

Specimen Requirements: 1 mL Blood

Minimum Volume: 0.4 mL

Special Handling: None

Specimen Container: Gray top tube (Sodium Fluoride / Potassium Oxalate)

Transport Temperature: Refrigerated

Light Protection: Not Required

Rejection Criteria: None

Known Interference(s): N/A

Stability: Room Temperature: 7 day(s)

Refrigerated: 30 day(s)

Frozen (-20 °C): 30 day(s)

Method: High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

Set-Up Days / TAT: Tuesday 3 days (after set-up)

CPT Code: 80371

Compound Name / Alias	Units	RL
MPHP 4'-methyl-alpha-Pyrrolidinohexiophenone	ng/mL	5.0

Reference Comment

MPHP is a psychoactive stimulant of the pyrrolidinophenone series that is structurally related to pyrovalerone and alpha PVP. In general, psychoactive stimulants have temporary effects on the psychoneurotic system. In addition, they seem to have a much higher tendency to cause side effects such as paranoia, hallucinations, and schizophrenic or psychosis like symptoms.
A 27 year old man who was admitted to the hospital with agitation and concomitant foot fractures from jumping out a window had reportedly snorted a powder believed to be cocaine; MPHP was found to be present in the serum at approximately 100 ng/mL. A blood/plasma ratio has not been established.
Some pyrrolidinophenones are known to have limited stability in biological specimens related to pH, collection tube, and storage temperature. Results are those obtained at the time of analysis. Negative results should be interpreted with caution.

101. 52112B Quetiapine Confirmation, Blood (Forensic)

Scope of Analysis:	Quetiapine
Method(s):	High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)
Purpose:	Confirmation of positive Screen; This test is New York State approved.
Category:	Antipsychotic
Specimen Requirements:	1 mL Blood
Minimum Volume:	0.22 mL
Special Handling:	None
Specimen Container:	Lavender top tube (EDTA)
Transport Temperature:	Refrigerated
Light Protection:	Not Required
Rejection Criteria:	None
Known Interference(s):	N/A
Stability:	Room Temperature: 30 day(s) Refrigerated: 30 day(s) Frozen (-20 °C): 30 day(s)

Method: High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

Set-Up Days / TAT: Tuesday Friday 3 days (after set-up)

CPT Code: 80342

Compound Name / Alias	Units	RL
Quetiapine Seroquel®	ng/mL	50

Reference Comment

Steady-state peak (1.0 to 1.5 hours) plasma levels
following a t.i.d. daily regimen:
286 ng/mL (225 mg/day)
598 ng/mL (450 mg/day)
828 ng/mL (750 mg/day)
The plasma half-life is approximately 6 hours.

102. 52148B Quinidine Confirmation, Blood (Forensic)

Scope of Analysis:	Quinidine
Method(s):	High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)
Purpose:	Confirmation of positive Screen; This test is New York State approved.
Category:	Cardiovascular
Specimen Requirements:	1 mL Blood
Minimum Volume:	0.22 mL
Special Handling:	None
Specimen Container:	Lavender top tube (EDTA)
Transport Temperature:	Refrigerated
Light Protection:	Not Required
Rejection Criteria:	None
Known Interference(s):	N/A
Stability:	Room Temperature: 30 day(s) Refrigerated: 30 day(s) Frozen (-20 °C): 30 day(s)

Method:	High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

Set-Up Days / TAT: Thursday 4 days (after set-up)

CPT Code: 80194

Compound Name / Alias	Units	RL
Quinidine Conquinine	ng/mL	100

Reference Comment

For the treatment of arrhythmia, effective plasma concentrations typically range between 2000 and 5000 ng/mL.
The blood/plasma ratio is not known for quinidine, but concentrations in red blood cells are usually lower than plasma.

103. 52424B Ramelteon and Metabolite Confirmation, Blood (Forensic)

Scope of Analysis: Ramelteon; Ramelteon M-II

Method(s): High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

Purpose: Confirmation of positive Screen; This test is New York State approved.

Category: Sleep Aid

Specimen Requirements: 1 mL Blood

Minimum Volume: 0.4 mL

Special Handling: None

Specimen Container: Gray top tube (Sodium Fluoride / Potassium Oxalate)

Transport Temperature: Refrigerated

Light Protection: Not Required

Rejection Criteria: None

Known Interference(s): N/A

Stability: Room Temperature: 30 day(s)
Refrigerated: 30 day(s)
Frozen (-20 °C): 30 day(s)

Method:	High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

Set-Up Days / TAT: Monday 3 days (after set-up)

CPT Code: 80375

Compound Name / Alias	Units	RL
Ramelteon Rozerem®	ng/mL	1.0
Ramelteon M-II Ramelteon Metabolite	ng/mL	5.0

Reference Comment

Mean peak plasma concentration reported after 8 mg of ramelteon = 73 ng/mL (range, 53 - 104 ng/mL)

Mean peak plasma concentration reported after 64 mg of ramelteon = 460 ng/mL (range, 340 - 650 ng/mL)

The ratio of whole blood concentration to serum or plasma concentration is unknown for this analyte.

104. 52436B Risperidone and Metabolite Confirmation, Blood (Forensic)

Scope of Analysis:	9-Hydroxyrisperidone; Risperidone; Risperidone and 9-Hydroxyrisperidone - Total
Method(s):	High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)
Purpose:	Confirmation of positive Screen; This test is New York State approved.
Category:	Antipsychotic (Neuroleptic)
Specimen Requirements:	1 mL Blood
Minimum Volume:	0.4 mL
Special Handling:	None
Specimen Container:	NMS Labs has no experimental or literature-based data regarding the choice of specific specimen collection containers for this test.
Transport Temperature:	Refrigerated
Light Protection:	Not Required
Rejection Criteria:	None
Known Interference(s):	N/A
Stability:	Room Temperature: 14 day(s) Refrigerated: 14 day(s) Frozen (-20 °C): 7 month(s)

Method: High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

Set-Up Days / TAT: Tuesday 3 days (after set-up)

CPT Code: 80342

Compound Name / Alias	Units	RL
Risperidone Risperdal®	ng/mL	1.0
9-Hydroxyrisperidone Risperidone Metabolite	ng/mL	1.0
Reference Comment Risperidone and 9-Hydroxyrisperidone are approximately equieffective, therefore, the sum of their concentrations is pertinent.		
Risperidone and 9-Hydroxyrisperidone - Total Total Active Moiety	ng/mL	
Reference Comment Mean steady-state plasma levels for the total active moiety following daily regimens: 2 mg/day - 14 ng/mL (Risperidone + Metabolite) 6 mg/day - 45 ng/mL (Risperidone + Metabolite) 10 mg/day - 73 ng/mL (Risperidone + Metabolite) 16 mg/day - 110 ng/mL (Risperidone + Metabolite)		

105. 50001B Salicylate Confirmation, Blood (Forensic)

Scope of Analysis:	Salicylate
Method(s):	High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)
Purpose:	Confirmation of positive Screen; This test is New York State approved.
Category:	Analgesic
Specimen Requirements:	1 mL Blood
Minimum Volume:	0.22 mL
Special Handling:	None
Specimen Container:	Lavender top tube (EDTA)

Transport Temperature: Refrigerated
Light Protection: Not Required
Rejection Criteria: None
Known Interference(s): N/A
Stability: Room Temperature: 30 day(s)
Refrigerated: 30 day(s)
Frozen (-20 °C): 24 month(s)

Method: High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

Set-Up Days / TAT: Friday 3 days (after set-up)
CPT Code: 80329

Compound Name / Alias	Units	RL
Salicylate	mcg/mL	5.0

Reference Comment
Analgesic range: 20 - 100 mcg/mL.
Anti-inflammatory range: 150 - 300 mcg/mL.
Toxic: Greater than 300 mcg/mL.

106. 52116B Sertraline and Desmethylsertraline Confirmation, Blood (Forensic)

Scope of Analysis: Desmethylsertraline; Sertraline
Method(s): High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)
Purpose: Confirmation of positive Screen; This test is New York State approved.
Category: Antidepressant
Specimen Requirements: 1 mL Blood
Minimum Volume: 0.4 mL
Special Handling: None
Specimen Container: Lavender top tube (EDTA)
Transport Temperature: Frozen
Light Protection: Not Required
Rejection Criteria: Received Room Temperature. Received Refrigerated.
Known Interference(s): N/A
Stability: Room Temperature: Not Stable
Refrigerated: Not Stable
Frozen (-20 °C): 14 day(s)

Method: High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

Set-Up Days / TAT: Tuesday Friday 3 days (after set-up)
CPT Code: 80332

Compound Name / Alias	Units	RL
Sertraline Zoloft®	ng/mL	10
Desmethylsertraline Norsertraline; Sertraline Metabolite	ng/mL	20

Reference Comment
Fifteen adults taking 200 mg daily sertraline had mean trough serum concentrations of 29 ng/mL (range 9 - 82 ng/mL) sertraline.
The blood to plasma ratio for sertraline is approximately 1.2.

Reference Comment
Fifteen adults taking 200 mg daily sertraline had mean trough serum concentrations of 87 ng/mL desmethylsertraline (range 40 - 189 ng/mL).
The blood to plasma ratio is not known for desmethylsertraline.

107. 52437B Sildenafil and Metabolite Confirmation, Blood (Forensic)

Scope of Analysis:	N-Desmethylsildenafil; Sildenafil
Method(s):	High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)
Purpose:	Confirmation of positive Screen; This test is New York State approved.
Category:	Antihypertensive, Erectile Dysfunction
Specimen Requirements:	1 mL Blood
Minimum Volume:	0.3 mL
Special Handling:	None
Specimen Container:	Lavender top tube (EDTA)
Transport Temperature:	Refrigerated
Light Protection:	Not Required
Rejection Criteria:	None
Known Interference(s):	N/A
Stability:	Room Temperature: 7 day(s) Refrigerated: 14 day(s) Frozen (-20 °C): 30 day(s)

Method: High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

Set-Up Days / TAT: Wednesday 3 days (after set-up)

CPT Code: 80375

Compound Name / Alias	Units	RL
Sildenafil Viagra®	ng/mL	2.0
N-Desmethylsildenafil Sildenafil Metabolite	ng/mL	2.0

108. 52403B Strychnine Confirmation, Blood (Forensic)

Scope of Analysis:	Strychnine
Method(s):	Gas Chromatography (GC)
Purpose:	Confirmation of positive Screen; This test is New York State approved.
Category:	Poison
Specimen Requirements:	5 mL Blood
Minimum Volume:	2.2 mL
Special Handling:	None
Specimen Container:	Gray top tube (Sodium Fluoride / Potassium Oxalate)
Transport Temperature:	Refrigerated
Light Protection:	Not Required
Rejection Criteria:	None
Known Interference(s):	N/A
Stability:	Room Temperature: Undetermined Refrigerated: Undetermined Frozen (-20 °C): Undetermined

Method: Gas Chromatography (GC)

Set-Up Days / TAT: Monday Wednesday 2 days (after set-up)

CPT Code: 80323

Compound Name / Alias	Units	RL
Strychnine	ng/mL	20

Reference Comment

Potentially lethal concentrations are in excess of 500 ng/mL.

109. 52328B Substituted Cathinone Panel, Blood

Scope of Analysis: Butylone; Dibutylone; Ethylone; N-Ethyl Pentylone; Pentylone

Method(s): High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

Purpose: Confirmation of positive Screen; This test is New York State approved.

Category: NPS

Specimen Requirements: 2 mL Blood

Minimum Volume: 0.7 mL

Special Handling: None

Specimen Container: Gray top tube (Sodium Fluoride / Potassium Oxalate)

Transport Temperature: Refrigerated

Light Protection: Not Required

Rejection Criteria: Received Room Temperature.

Known Interference(s): N/A

Stability: Room Temperature: 2 day(s)

Refrigerated: 28 day(s)

Frozen (-20 °C): 28 day(s)

Method: High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

Set-Up Days / TAT: Tuesday 5 days (after set-up)

CPT Code: 80371

Compound Name / Alias	Units	RL
Pentylone	ng/mL	10

Reference Comment

Pentylone is a substituted cathinone that is sold recreationally as a novel psychoactive substance. Pentylone is a stimulant type drug, with effects similar to that of cocaine, with some additional activity at serotonin receptors. Synthetic cathinone users report psychological, cardiovascular, and neurological sympathomimetic symptoms, with effects ranging from tachycardia, vasoconstriction, seizures, agitation, aggression, and psychosis.
Synthetic cathinones, including pentylone, are increasingly being detected in a range of forensic toxicology cases, including both human performance and postmortem cases.

Ethylone	ng/mL	10

Reference Comment

Ethylone is a substituted cathinone that is sold recreationally as a novel psychoactive substance. Ethylone is a stimulant type drug, with effects similar to that of cocaine, with some additional activity at serotonin receptors. Synthetic cathinone users report psychological, cardiovascular, and neurological sympathomimetic symptoms, with effects ranging from tachycardia, vasoconstriction, seizures, agitation, aggression, and psychosis.
Ethylone is increasingly being detected in a range of forensic toxicology cases, including both human performance and postmortem cases. In nine postmortem cases, ethylone blood concentrations ranged from 38 to >2,500 ng/mL; almost all cases involved additional findings.

Compound Name / Alias	Units	RL
Butylone	ng/mL	10

Reference Comment

Butylone is a substituted cathinone that is sold recreationally as a novel psychoactive substance. Butylone is a stimulant type drug, with effects similar to that of cocaine, with some additional activity at serotonin receptors. Synthetic cathinone users report psychological, cardiovascular, and neurological sympathomimetic symptoms, with effects ranging from tachycardia, vasoconstriction, seizures, agitation, aggression, and psychosis.
Synthetic cathinones, including butylone, are increasingly being detected in a range of forensic toxicology cases, including both human performance and postmortem cases. There is one case report of a 24 year old female who died after ingesting a combination of methylone and butylone which was sold to her as 'Ecstasy'; she died of multi-organ failure stemming from serotonin syndrome.

Dibutylone bk-DMBDB	ng/mL	10

Reference Comment

Dibutylone is a substituted cathinone that is sold recreationally as a novel psychoactive substance. Butylone may be present due to being a potential metabolite of dibutylone; butylone itself is also considered a novel psychoactive substance.
It has been identified in some 'bath salt' or 'research chemical' type products for euphoric and empathogenic effects.
The drug is usually taken orally, but can also be insufflated or vaporized.

N-Ethyl Pentylone	ng/mL	10

Reference Comment

N-Ethyl Pentylone is a substituted cathinone structurally similar to pentylone. It is sold as a novel psychoactive substance. Due to its structural similarities to pentylone, N-Ethyl Pentylone is expected to have stimulant type effects.
N-Ethyl Pentylone was reported as the sole intoxicant in a fatality where an individual was agitated and displayed erratic behavior followed by cardiac arrest; other symptoms included rhabdomyolysis, hypoglycemia, hepatic and renal injury, respiratory failure, and disseminated intravascular coagulation.

110. 52499B Suvorexant Confirmation, Blood (Forensic)

Scope of Analysis:	Suvorexant
Method(s):	High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)
Purpose:	Confirmation of positive Screen; This test is New York State approved.
Category:	Sleep Aid
Specimen Requirements:	1 mL Blood
Minimum Volume:	0.4 mL
Special Handling:	None
Specimen Container:	Lavender top tube (EDTA)
Transport Temperature:	Refrigerated
Light Protection:	Not Required

Rejection Criteria: None
Known Interference(s): N/A
Stability: Room Temperature: 30 day(s)
Refrigerated: 30 day(s)
Frozen (-20 °C): 12 month(s)

Method: High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

Set-Up Days / TAT: Tuesday 3 days (after set-up)
CPT Code: 80375

Compound Name / Alias	Units	RL
Suvorexant Belsomra	ng/mL	20

Reference Comment
Normal adult dosage: 10 - 40 mg daily
Reported therapeutic serum range: 130 - 400 ng/mL

111. 5971B Synthetic Cannabinoids Confirmation Panel 1 (Qualitative), Blood

Scope of Analysis: 5F-ADB-PINACA; 5F-ADBICA; AB-CHMINACA; AB-FUBINACA; AB-PINACA; ADB-CHMINACA; ADB-FUBINACA; ADB-PINACA; ADBICA; APP-CHMINACA (PX3); PX1; PX2
Method(s): High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)
Purpose: Confirmation of positive Screen; This test is New York State approved.
Category: Synthetic Cannabinoid
Specimen Requirements: 2 mL Blood
Minimum Volume: 0.7 mL
Special Handling: None
Specimen Container: Lavender top tube (EDTA)
Transport Temperature: Refrigerated
Light Protection: Not Required
Rejection Criteria: Received Room Temperature.
Known Interference(s): N/A
Stability: Room Temperature: 1 day(s)
Refrigerated: 7 day(s)
Frozen (-20 °C): 30 day(s)

Method: High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

Set-Up Days / TAT: Monday Wednesday 3 days (after set-up)
CPT Code: 80352

Compound Name / Alias	Units	RL
PX1 (S)-N-(1-amino-1-oxo-3-phenylpropan-2-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide; 5F- APP-PICA; SRF-30	ng/mL	0.1

Reference Comment
PX1 is one of many synthetic cannabinoid drugs. The drug is typically sprayed on botanical material and smoked, although it can be ingested in liquid or powder form. No studies have been performed to evaluate the pharmacological effects of this compound.

This analyte has demonstrated instability under certain storage conditions which may be dependent upon matrix, pH, collection tube, and storage temperature.
Negative results should be interpreted with caution.

Compound Name / Alias	Units	RL
5F-ADBICA N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide	ng/mL	1.0
Reference Comment 5F-ADBICA is one of many synthetic cannabinoid drugs. The drug is typically sprayed on botanical material and smoked, although it can be ingested in liquid or powder form. It binds to and demonstrates functional activity at the same brain receptor as THC, the active component of marijuana.		
AB-FUBINACA N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide	ng/mL	1.0
Reference Comment AB-FUBINACA is one of many synthetic cannabinoid drugs. The drug is typically sprayed on botanical material and smoked, although it can be ingested in liquid or powder form. AB-FUBINACA binds to the same brain receptor as THC, the active component of marijuana, and has been shown to produce similar pharmacological effects.		
PX2 (R)-N-(1-amino-1-oxo-3-phenylpropan-2-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide; 5F-APP-PINACA; FU-PX	ng/mL	0.2
Reference Comment PX2 is one of many synthetic cannabinoid drugs. The drug is typically sprayed on botanical material and smoked, although it can be ingested in liquid or powder form. No studies have been performed to evaluate the pharmacological effects of this compound. This analyte has demonstrated instability under certain storage conditions which may be dependent upon matrix, pH, collection tube, and storage temperature. Negative results should be interpreted with caution.		
5F-ADB-PINACA N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(5-Fluoropentyl)-1H-indazole-3-carboxamide	ng/mL	1.0
Reference Comment 5F-ADB-PINACA is one of many synthetic cannabinoid drugs. The drug is typically sprayed on botanical material and smoked, although it can be ingested in liquid or powder form. It binds to and demonstrates functional activity at the same brain receptor as THC, the active component of marijuana. This analyte has demonstrated instability under certain storage conditions which may be dependent upon matrix, pH, collection tube, and storage temperature. Negative results should be interpreted with caution.		
ADB-FUBINACA N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide	ng/mL	1.0
Reference Comment ADB-FUBINACA is one of many synthetic cannabinoid drugs. The drug is typically sprayed on botanical material and smoked, although it can be ingested in liquid or powder form. ADB-FUBINACA binds to the same brain receptor as THC, the active component of marijuana, and has been shown to produce similar pharmacological effects.		
AB-PINACA N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide	ng/mL	0.2
Reference Comment AB-PINACA is one of many synthetic cannabinoid drugs. The drug is typically sprayed on botanical material and smoked, although it can be ingested in liquid or powder form. It binds to and demonstrates functional activity at the same brain receptor as THC, the active component of marijuana.		

Compound Name / Alias	Units	RL
ADBICA N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indole-3-carboxamide	ng/mL	1.0
Reference Comment ADBICA is one of many synthetic cannabinoid drugs. The drug is typically sprayed on botanical material and smoked, although it can be ingested in liquid or powder form. It binds to and demonstrates functional activity at the same brain receptor as THC, the active component of marijuana.		
ADB-PINACA N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide	ng/mL	0.2
Reference Comment ADB-PINACA is one of many synthetic cannabinoid drugs. The drug is typically sprayed on botanical material and smoked, although it can be ingested in liquid or powder form. It binds to and demonstrates functional activity at the same brain receptor as THC, the active component of marijuana.		
AB-CHMINACA N-[(1S)-1-(Aminocarbonyl)-2-methylpropyl]-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide	ng/mL	1.0
Reference Comment AB-CHMINACA is one of many synthetic cannabinoid drugs. The drug is typically sprayed on botanical material and smoked, although it can be ingested in liquid or powder form. It binds to and demonstrates functional activity at the same brain receptor as THC, the active component of marijuana.		
APP-CHMINACA (PX3) N-[(1S)-2-amino-2-oxo-1-(phenylmethyl)ethyl]-1-(cyclohexylmethyl)-1H-Indazole-3-carboxamide; PX3	ng/mL	0.2
Reference Comment APP-CHMINACA is one of many synthetic cannabinoid drugs. The drug is typically sprayed on botanical material and smoked, although it can be ingested in liquid or powder form. It binds to the same brain receptor as THC, the active component of marijuana.		
ADB-CHMINACA MAB-CHMINACA; N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide	ng/mL	0.1
Reference Comment ADB-CHMINACA is one of many synthetic cannabinoid drugs. The drug is typically sprayed on botanical material and smoked, although it can be ingested in liquid or powder form. It binds to the same brain receptor as THC, the active component of marijuana		

112. 5970B Synthetic Cannabinoids Confirmation Panel 2 (Qualitative), Blood

Scope of Analysis: 5F-AB-001; 5F-ADB; 5F-AMB; 5F-APICA; 5F-APINACA (5F-AKB-48); 5F-MN-18; 5F-PB-22; AMB; APICA; APINACA (AKB-48); CUMYL-THPINACA; EG-2201; FUB-144; FUB-AKB-48; FUB-AMB; FUB-JWH-018; FUB-PB-22; MA-CHMINACA; MDMB-CHMCZCA; MDMB-CHMINACA; MDMB-FUBINACA; MMB-CHMICA; MMB-CHMINACA (MDMB-CHMICA); MO-CHMINACA; NM-2201; THJ-018; THJ-2201

Method(s): High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

Purpose: Confirmation of positive Screen; This test is New York State approved.

Category: Synthetic Cannabinoid

v.18

Specimen Requirements:	2 mL Blood
Minimum Volume:	0.7 mL
Special Handling:	None
Specimen Container:	Lavender top tube (EDTA)
Transport Temperature:	Frozen
Light Protection:	Not Required
Rejection Criteria:	Received Room Temperature. Received Refrigerated.
Known Interference(s):	N/A
Stability:	Room Temperature: 1 day(s) Refrigerated: 1 day(s) Frozen (-20 °C): 30 day(s)

Method: High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

Set-Up Days / TAT:	Wednesday Friday 3 days (after set-up)
CPT Code:	80352

Compound Name / Alias	Units	RL
5F-AMB 5F-AMP; N-[[1-(5-fluoropentyl)-1H-indazol-3-yl]carbonyl]-L-valine, methyl ester	ng/mL	0.1
Reference Comment 5F-AMB is one of many synthetic cannabinoid drugs. The drug is typically sprayed on botanical material and smoked, although it can be ingested in liquid or powder form. It binds to and demonstrates functional activity at the same brain receptor as THC, the active component of marijuana. This analyte has demonstrated instability under certain storage conditions which may be dependent upon matrix, pH, collection tube, and storage temperature. Negative results should be interpreted with caution.		
5F-PB-22 1-(5-fluoropentyl)-8-quinolinyl ester-1H-indole-3-carboxylic acid; 5F-QUPIC	ng/mL	0.1
Reference Comment 5F-PB-22 is one of many synthetic cannabinoid drugs. The drug is typically sprayed on botanical material and smoked, although it can be ingested in liquid or powder form. It binds to and demonstrates functional activity at the same brain receptor as THC, the active component of marijuana.		
FUB-AMB AMB-FUBINACA; methyl (1-(4-fluorobenzyl)-1H-indazole-3-carbonyl)-L-valinate	ng/mL	0.1
Reference Comment FUB-AMB is one of many synthetic cannabinoid drugs. The drug is typically sprayed on botanical material and smoked, although it can be ingested in liquid or powder form. It binds to and demonstrates functional activity at the same brain receptor as THC, the active component of marijuana. This analyte has demonstrated instability under certain storage conditions which may be dependent upon matrix, pH, collection tube, and storage temperature. Negative results should be interpreted with caution.		
FUB-PB-22 quinolin-8-yl-1-(4-fluorobenzyl)-1H-indole-3-carboxylate	ng/mL	0.1
Reference Comment FUB-PB-22 is one of many synthetic cannabinoid drugs. The drug is typically sprayed on botanical material and smoked, although it can be ingested in liquid or powder form. It binds to and demonstrates functional activity at the same brain receptor as THC, the active component of marijuana.		

Compound Name / Alias	Units	RL
5F-ADB 5F-MDMB-PINACA; methyl (R)-2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate	ng/mL	0.2
Reference Comment 5F-ADB is one of many synthetic cannabinoid drugs. The drug is typically sprayed on botanical material and smoked, although it can be ingested in liquid or powder form. It binds to and demonstrates functional activity at the same brain receptor as THC, the active component of marijuana.		
FUB-JWH-018 (1-(4-fluorobenzyl)-1H-indol-3-yl)(naphthalen-1-yl)methanone	ng/mL	0.2
Reference Comment FUB-JWH-018 is one of many synthetic cannabinoid drugs. The drug is typically sprayed on botanical material and smoked, although it can be ingested in liquid or powder form. No studies have been performed to evaluate the pharmacological effects of this compound.		
5F-MN-18 1-(5-fluoropentyl)-N-1-naphthalenyl-1H-indazole-3-carboxamide	ng/mL	0.1
Reference Comment 5F-MN-18 is one of many synthetic cannabinoid drugs. The drug is typically sprayed on botanical material and smoked, although it can be ingested in liquid or powder form. No studies have been performed to evaluate the pharmacological effects of this compound.		
AMB AMP; methyl (1-pentyl-1H-indazole-3-carbonyl)-L-valinate	ng/mL	0.1
Reference Comment AMB is one of many synthetic cannabinoid drugs. The drug is typically sprayed on botanical material and smoked, although it can be ingested in liquid or powder form. No studies have been performed to evaluate the pharmacological effects of this compound.		
THJ-2201 (1-(5-fluoropentyl)-1H-indazol-3-yl)(naphthalen-1-yl)methanone; 5-fluoro THJ-018; AM2201 indazole analog; Fluoropentyl-JWH-018 indazole	ng/mL	0.1
Reference Comment THJ-2201 is one of many synthetic cannabinoid drugs. The drug is typically sprayed on botanical material and smoked, although it can be ingested in liquid or powder form. It binds to and demonstrates functional activity at the same brain receptor as THC, the active component of marijuana.		
MMB-CHMINACA (MDMB-CHMICA) methyl (S)-2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3,3-dimethylbutanoate	ng/mL	0.1
Reference Comment MMB-CHMINACA is one of many synthetic cannabinoid drugs. The drug is typically sprayed on botanical material and smoked, although it can be ingested in liquid or powder form. It binds to and demonstrates functional activity at the same brain receptor as THC, the active component of marijuana.		
5F-APICA 5F-JWH-018 Adamantyl Carboxamide; N-(1-adamantyl)-1-(5-fluoropentyl-1H-indole-3-carboxamide; STS-135	ng/mL	1.0
Reference Comment 5F-APICA is one of many synthetic cannabinoid drugs. The drug is typically sprayed on botanical material and smoked, although it can be ingested in liquid or powder form. It binds to and demonstrates functional activity at the same brain receptor as THC, the active component of marijuana.		

Compound Name / Alias	Units	RL
NM-2201 CBL-2201; naphthalen-1-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate	ng/mL	0.1
Reference Comment NM-2201 is one of many synthetic cannabinoid drugs. The drug is typically sprayed on botanical material and smoked, although it can be ingested in liquid or powder form. It binds to and demonstrates functional activity at the same brain receptor as THC, the active component of marijuana.		
FUB-144 (1-(4-fluorobenzyl)-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone; FUB-UR-144	ng/mL	0.1
Reference Comment FUB-144 is one of many synthetic cannabinoid drugs. The drug is typically sprayed on botanical material and smoked, although it can be ingested in liquid or powder form. It binds to and demonstrates functional activity at the same brain receptor as THC, the active component of marijuana.		
MA-CHMINACA AMB-CHMINACA; AMB-N-methylcyclohexyl analog; MAB-AB-CHMINACA; methyl (1-(cyclohexylmethyl)-1H-indazole-3-carbonyl)-L-valinate	ng/mL	0.2
Reference Comment MA-CHMINACA is one of many synthetic cannabinoid drugs. The drug is typically sprayed on botanical material and smoked, although it can be ingested in liquid or powder form. It binds to and demonstrates functional activity at the same brain receptor as THC, the active component of marijuana.		
5F-AB-001 1-(5-Fluoropentyl)-3-(1-adamantoyl)indole; 5F-JWH-018 Adamantyl Analog; AM2201 adamantyl analog	ng/mL	1.0
Reference Comment 5F-AB-001 is one of many synthetic cannabinoid drugs. The drug is typically sprayed on botanical material and smoked, although it can be ingested in liquid or powder form. No studies have been performed to evaluate the pharmacological effects of this compound. This analyte has demonstrated instability under certain storage conditions which may be dependent upon matrix, pH, collection tube, and storage temperature. Negative results should be interpreted with caution.		
5F-APINACA (5F-AKB-48) N-(1-adamantyl)-1-(5-Fluropentyl)-1H-indazole-3-carboxamide	ng/mL	2.0
Reference Comment 5F-APINACA is one of many synthetic cannabinoid drugs. The drug is typically sprayed on botanical material and smoked, although it can be ingested in liquid or powder form. It binds to and demonstrates functional activity at the same brain receptor as THC, the active component of marijuana.		
MDMB-CHMINACA N-[[1-(cyclohexylmethyl)-1H-indazol-3-yl]carbonyl]-3-methyl-L-valine, methyl ester	ng/mL	0.1
Reference Comment MDMB-CHMINACA is one of many synthetic cannabinoid drugs. The drug is typically sprayed on botanical material and smoked, although it can be ingested in liquid or powder form. It binds to and demonstrates functional activity at the same brain receptor as THC, the active component of marijuana.		

Compound Name / Alias	Units	RL
EG-2201 (9-(5-fluoropentyl)-9H-carbazol-3-yl)(naphthalen-1-yl)methanone **Reference Comment** EG-2201 is one of many synthetic cannabinoid drugs. The drug is typically sprayed on botanical material and smoked, although it can be ingested in liquid or powder form. No studies have been performed to evaluate the pharmacological effects of this compound.	ng/mL	0.2
THJ-018 1-naphthalenyl(1-pentyl-1H-indazol-3-yl)-methanone; JWH-018 indazole analog **Reference Comment** THJ-018 is one of many synthetic cannabinoid drugs. The drug is typically sprayed on botanical material and smoked, although it can be ingested in liquid or powder form. It binds to and demonstrates functional activity at the same brain receptor as THC, the active component of marijuana.	ng/mL	0.1
APICA 2NE1; JWH-018 Adamantyl Carboxamide; N-(1-adamantyl)-1-pentyl-1H-indole-3-carboxamide; SDB-001 **Reference Comment** APICA is one of many synthetic cannabinoid drugs. The drug is typically sprayed on botanical material and smoked, although it can be ingested in liquid or powder form. It binds to and demonstrates functional activity at the same brain receptor as THC, the active component of marijuana.	ng/mL	0.2
FUB-AKB-48 AKB-48 N-(4-fluorobenzyl) analog; N-((3s,5s,7s)-adamantan-1-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide **Reference Comment** FUB-AKB-48 is one of many synthetic cannabinoid drugs. The drug is typically sprayed on botanical material and smoked, although it can be ingested in liquid or powder form. It binds to and demonstrates functional activity at the same brain receptor as THC, the active component of marijuana.	ng/mL	0.2
APINACA (AKB-48) N-(1-adamantyl)-1-pentyl-1H-indazole-3-carboxamide **Reference Comment** APINACA is one of many synthetic cannabinoid drugs. The drug is typically sprayed on botanical material and smoked, although it can be ingested in liquid or powder form. No studies have been performed to evaluate the pharmacological effects of this compound. Positive effects reported by users include euphoria, relaxation, and feelings of joy and well being. Reported negative effects include anxiety, paranoia, dry mouth and hunger.	ng/mL	1.0
MO-CHMINACA 1-methoxy-3,3-dimethyl-1-oxobutan-2-yl 1-(cyclohexylmethyl)-1H-indazole-3-carboxylate; MO-AMB **Reference Comment** MO-CHMINACA is one of many synthetic cannabinoid drugs. The drug is typically sprayed on botanical material and smoked, although it can be ingested in liquid or powder form. No studies have been published which evaluate the pharmacological effects of this compound.	ng/mL	0.1

Compound Name / Alias	Units	RL
MDMB-CHMCZCA EGMB-CHMINACA; methyl (S)-2-(9-(cyclohexylmethyl)-9H-carbazole-3-carboxamido)-3,3-dimethylbutanoate	ng/mL	0.1

Reference Comment

MDMB-CHMCZCA is one of many synthetic cannabinoid drugs. The drug is typically sprayed on botanical material and smoked, although it can be ingested in liquid or powder form. No studies have been published which evaluate the pharmacological effects of this compound.

MMB-CHMICA methyl (1-(cyclohexylmethyl)-1H-indole-3-carbonyl)-L-valinate	ng/mL	0.1

Reference Comment

MMB-CHMICA is one of many synthetic cannabinoid drugs. The drug is typically sprayed on botanical material and smoked, although it can be ingested in liquid or powder form. It binds to and demonstrates functional activity at the same brain receptor as THC, the active component of marijuana.

CUMYL-THPINACA N-(1-methyl-1-phenylethyl)-1-[(tetrahydro-2H-pyran-4-yl)methyl]-1H-indazole-3-carboxamide	ng/mL	0.1

Reference Comment

CUMYL-THPINACA is one of many synthetic cannabinoid drugs. The drug is typically sprayed on botanical material and smoked, although it can be ingested in liquid or powder form. No studies have been published which evaluate the pharmacological effects of this compound.

MDMB-FUBINACA FUB-MDMB; MDMB-Bz-F; methyl (S)-2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate	ng/mL	0.1

Reference Comment

MDMB-FUBINACA is one of many synthetic cannabinoid drugs. The drug is typically sprayed on botanical material and smoked, although it can be ingested in liquid or powder form. It binds to and demonstrates functional activity at the same brain receptor as THC, the active component of marijuana.

113. 5960B Synthetic Cannabinoids Confirmation, Blood (Forensic)

Scope of Analysis:	AM-2201; JWH-018; JWH-122; UR-144; XLR-11
Method(s):	High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)
Purpose:	Confirmation of positive Screen; This test is New York State approved.
Category:	Synthetic Cannabinoid
Specimen Requirements:	2 mL Blood
Minimum Volume:	0.4 mL
Special Handling:	None
Specimen Container:	Lavender top tube (EDTA)
Transport Temperature:	Refrigerated
Light Protection:	Not Required

Rejection Criteria: Green top tube (Sodium Heparin).

Known Interference(s): N/A

Stability: Room Temperature: 30 day(s)

Refrigerated: 30 day(s)

Frozen (-20 °C): 7 month(s)

Method: High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

Set-Up Days / TAT: Monday-Sunday 7 days (after set-up)

CPT Code: 80351

Compound Name / Alias	Units	RL
AM-2201 5F-JWH-018; [1-(5-fluoropentyl)-1H-indol-3-yl]-1-naphthalenyl-methanone	ng/mL	0.1
Reference Comment AM-2201, a synthetic cannabinoid, has been identified in products sold as 'herbal incense'. These products may be used as an alternative to cannabis. Whole blood concentrations of 0.31 - 4.6 ng/mL have been reported (N=6).		
XLR-11 (1-(5-fluoropentyl)-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone; 5F-UR-144	ng/mL	0.2
Reference Comment XLR-11 a synthetic cannabinoid, has been identified in products sold as 'herbal incense'. These products may be used as an alternative to cannabis. A serum concentration of 35 ng/mL was reported in a patient admitted to the hospital with nausea, vomiting and abdominal pain. XLR-11 has been associated with acute kidney injury. The whole blood to serum ratio of this analyte is not known.		
JWH-018 (1-pentyl-1H-indol-3-yl)-1-naphthalenyl-methanone; AM-678	ng/mL	0.1
Reference Comment JWH-018, a synthetic cannabinoid, has been identified in products sold as 'herbal incense'. These products may be used as an alternative to cannabis. Two volunteers smoked cigarettes containing 100 mg or 150 mg of an herbal incense containing an unknown amount of JWH-018. Peak serum concentrations were 8.1 and 10.2 ng/mL, respectively, 5 minutes post-dose. Serum concentrations in both volunteers were <0.5 ng/mL 3 hours post dose. The whole blood to serum ratio of this analyte is not known.		
JWH-122 (4-methyl-1-naphthalenyl)(1-pentyl-1H-indol-3-yl)-methanone	ng/mL	0.1
Reference Comment JWH-122, a synthetic cannabinoid, has been identified in products sold as 'herbal incense'. These products may be used as an alternative to cannabis. Eleven patients admitted to emergency departments had JWH-122 serum concentrations of 0.17 - 40 ng/mL; the concentration was less than 1 ng/mL in 6 cases. The whole blood to serum ratio of this analyte is not known.		

Compound Name / Alias	Units	RL
UR-144 1-pentyl-3-[1-(2,2,3,3-tetramethylcyclopropyl)]indole; KM-X1	ng/mL	0.2

Reference Comment

UR-144 a synthetic cannabinoid, has been identified in products sold as 'herbal incense'. These products may be used as an alternative to cannabis.

JWH-081 a synthetic cannabinoid, has been identified in products sold as 'herbal incense'. These products may be used as an alternative to cannabis.

A serum concentration of 6 ng/mL was reported in a patient admitted to the hospital with nausea, vomiting and abdominal pain.

The whole blood to serum ratio of this analyte is not known.

114. 52407B Synthetic Opioids - Free (Unconjugated) Confirmation, Blood (Forensic)

Scope of Analysis: Buprenorphine - Free; Butorphanol - Free; Nalbuphine - Free; Norbuprenorphine - Free
Method(s): High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)
Purpose: Confirmation of positive Screen; This test is New York State approved.
Category: Narcotic Analgesic
Specimen Requirements: 2 mL Blood
Minimum Volume: 0.7 mL
Special Handling: None
Specimen Container: Gray top tube (Sodium Fluoride / Potassium Oxalate)
Transport Temperature: Refrigerated
Light Protection: Not Required
Rejection Criteria: None
Known Interference(s): N/A
Stability: Room Temperature: 14 day(s)
Refrigerated: 30 day(s)
Frozen (-20 °C): 30 day(s)

Method: High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

Set-Up Days / TAT: Tuesday Thursday 3 days (after set-up)
CPT Code: 80348, 80362

Compound Name / Alias	Units	RL
Buprenorphine - Free Buprenex	ng/mL	0.5

Reference Comment

Maximum plasma buprenorphine concentrations in patients maintained on varying buprenorphine doses were:
2 mg/day: 0.3 +/- 0.1 ng/mL
16 mg/day: 6.3 +/- 0.9 ng/mL
32 mg/day: 13 +/- 4.2 ng/mL
The blood to plasma ratio of buprenorphine is approximately 1.0 - 1.4.

Norbuprenorphine - Free Buprenorphine Metabolite	ng/mL	0.5

Reference Comment

Maximum plasma norbuprenorphine concentrations in patients maintained on varying buprenorphine doses were:
2 mg/day: 0.7 +/- 0.2 ng/mL
16 mg/day: 5.4 +/- 1.3 ng/mL
32 mg/day: 14 +/- 2.9 ng/mL
The blood to plasma ratio for norbuprenorphine is not known.

Compound Name / Alias	Units	RL
Butorphanol - Free Stadol	ng/mL	0.5

Reference Comment

Peak plasma concentrations following 1 to 2 mg doses of butorphanol by intravenous, intramuscular or intranasal routes range from 1 to 4 ng/mL.
The blood to plasma ratio of butorphanol is approximately 1.2.

Nalbuphine - Free Nubain	ng/mL	0.5

Reference Comment

The average peak plasma concentration was 53 ng/mL nalbuphine 5 minutes after a 10 mg intravenous dose.
The blood to plasma ratio of nalbuphine is approximately 0.9 to 1.0.

115. 52425B Tadalafil Confirmation, Blood (Forensic)

Scope of Analysis: Tadalafil
Method(s): High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)
Purpose: Confirmation of positive Screen; This test is New York State approved.
Category: Erectile Dysfunction
Specimen Requirements: 2 mL Blood
Minimum Volume: 0.7 mL
Special Handling: None
Specimen Container: Lavender top tube (EDTA)
Transport Temperature: Refrigerated
Light Protection: Not Required
Rejection Criteria: None
Known Interference(s): N/A
Stability: Room Temperature: 30 day(s)
Refrigerated: 30 day(s)
Frozen (-20 °C): 30 day(s)

Method: High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

Set-Up Days / TAT: Wednesday 3 days (after set-up)
CPT Code: 80375

Compound Name / Alias	Units	RL
Tadalafil Cialis®	ng/mL	10

Reference Comment

Following a single 10mg dose, subjects achieved a mean peak plasma concentration of 142 mcg/L (CV 26%) at an average of 3.5 hours. A single oral dose of 20 mg given to healthy males resulted in peak plasma tadalafil concentrations averaging approximately 330 mcg/L at 3 hours.
The ratio of whole blood concentration to serum or plasma concentration is unknown for this analyte

116. 52426B Tapentadol - Free Confirmation, Blood (Forensic)

Scope of Analysis:	Tapentadol - Free
Method(s):	High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)
Purpose:	Confirmation of positive Screen; This test is New York State approved.
Category:	Centrally Acting Analgesic
Specimen Requirements:	1 mL Blood
Minimum Volume:	0.22 mL
Special Handling:	None
Specimen Container:	NMS Labs has no experimental or literature-based data regarding the choice of specific specimen collection containers for this test.
Transport Temperature:	Refrigerated
Light Protection:	Not Required
Rejection Criteria:	None
Known Interference(s):	N/A
Stability:	Room Temperature: 30 day(s) Refrigerated: 30 day(s) Frozen (-20 °C): 30 day(s)

Method: High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

Set-Up Days / TAT: Thursday 4 days (after set-up)

CPT Code: 80372

Compound Name / Alias	Units	RL
Tapentadol - Free Nucynta®	ng/mL	5.0

Reference Comment

Tapentadol is a Schedule II analgesic used in pain management.
Following oral or IV administration of Tapentadol HCl 60 mg:
Cmax was 50.0 +/- 23.1 ng/mL and 299.5 +/- 48.7 ng/mL, respectively.
Tmax was 0.83 +/- 0.13 h and 0.18 +/- 0.03 h, respectively.
Efficacy of Tapentadol for pain relief has been demonstrated in the range of 5 - 300 ng/mL.

117. 52427B Tetrahydrozoline Confirmation, Blood (Forensic)

Scope of Analysis:	Tetrahydrozoline
Method(s):	High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)
Purpose:	Confirmation of positive Screen; This test is New York State approved.
Category:	Occular Vasoconstrictor
Specimen Requirements:	1 mL Blood
Minimum Volume:	0.45 mL
Special Handling:	None
Specimen Container:	Gray top tube (Sodium Fluoride / Potassium Oxalate)
Transport Temperature:	Refrigerated
Light Protection:	Not Required

Rejection Criteria: None
Known Interference(s): N/A
Stability: Room Temperature: 30 day(s)
Refrigerated: 30 day(s)
Frozen (-20 °C): 24 month(s)

Method: High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

Set-Up Days / TAT: Tuesday 3 days (after set-up)
CPT Code: 80375

Compound Name / Alias	Units	RL
Tetrahydrozoline Murine Tears Plus®; Tetryzoline; Tyzine®; Visine®	ng/mL	0.1

Reference Comment
Whole blood concentrations of tetrahydrozoline have not been reported.

118. 52121B Theophylline Confirmation, Blood (Forensic)

Scope of Analysis: Theophylline
Method(s): High Performance Liquid Chromatography(HPLC)
Purpose: Confirmation of positive Screen; This test is New York State approved.
Category: Bronchodilator
Specimen Requirements: 1 mL Blood
Minimum Volume: 0.4 mL
Special Handling: None
Specimen Container: NMS Labs has no experimental or literature-based data regarding the choice of specific specimen collection containers for this test.
Transport Temperature: Refrigerated
Light Protection: Not Required
Rejection Criteria: None
Known Interference(s): N/A
Stability: Room Temperature: 1 month(s)
Refrigerated: 1 month(s)
Frozen (-20 °C): 1 month(s)

Method: High Performance Liquid Chromatography(HPLC)

Set-Up Days / TAT: Monday Thursday 3 days (after set-up)
CPT Code: 80198

Compound Name / Alias	Units	RL
Theophylline Aminophylline	mcg/mL	0.5

Reference Comment
Usual therapeutic range: 10 - 20 mcg/mL.

119. 52283B Thioridazine and Metabolite Confirmation, Blood (Forensic)

Scope of Analysis: Mesoridazine; Thioridazine
Method(s): Gas Chromatography (GC)
Purpose: Confirmation of positive Screen; This test is New York State approved.
Category: Antipsychotic (Neuroleptic)
Specimen Requirements: 2 mL Blood

Minimum Volume: 0.7 mL

Special Handling: None

Specimen Container: NMS Labs has no experimental or literature-based data regarding the choice of specific specimen collection containers for this test.

Transport Temperature: Refrigerated

Light Protection: Not Required

Rejection Criteria: None

Known Interference(s): N/A

Stability: Room Temperature: 8 day(s)

Refrigerated: 8 day(s)

Frozen (-20 °C): 12 month(s)

Method:

Set-Up Days / TAT: N/A

CPT Code: 80369, 80376

Method: Gas Chromatography (GC)

Set-Up Days / TAT: Tuesday Thursday 3 days (after set-up)

CPT Code: 80342

Compound Name / Alias	Units	RL
Mesoridazine Serentil®	ng/mL	200
Reference Comment Therapeutic range: 100 - 1400 ng/mL.		
Thioridazine Mellaril®	ng/mL	200
Reference Comment Steady-state serum concentration during chronic oral administration of 400 mg daily: 140 - 2600 ng/mL. Therapeutic steady-state concentrations may overlap levels associated with toxicity.		

120. 52125B Tiletamine Confirmation, Blood (Forensic)

Scope of Analysis: Tiletamine

Method(s): Gas Chromatography (GC)

Purpose: Confirmation of positive Screen; This test is New York State approved.

Category: Hypnotic, Sedative

Specimen Requirements: 2 mL Blood

Minimum Volume: 0.7 mL

Special Handling: None

Specimen Container: NMS Labs has no experimental or literature-based data regarding the choice of specific specimen collection containers for this test.

Transport Temperature: Refrigerated

Light Protection: Not Required

Rejection Criteria: None

Known Interference(s): N/A

Stability: Room Temperature: Undetermined

Refrigerated: Undetermined

Frozen (-20 °C): Undetermined

Method: Gas Chromatography (GC)

Set-Up Days / TAT: Wednesday 3 days (after set-up)

CPT Code: 80375

Compound Name / Alias	Units	RL
Tiletamine Telazol®	mcg/mL	0.05

Reference Comment
No reference data available.

121. 52127B Topiramate Confirmation, Blood (Forensic)

Scope of Analysis: Topiramate
Method(s): High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)
Purpose: Confirmation of positive Screen; This test is New York State approved.
Category: Anticonvulsant, Antiepileptic
Specimen Requirements: 1 mL Blood
Minimum Volume: 0.25 mL
Special Handling: None
Specimen Container: Lavender top tube (EDTA)
Transport Temperature: Refrigerated
Light Protection: Not Required
Rejection Criteria: None
Known Interference(s): N/A
Stability: Room Temperature: 1 month(s)
Refrigerated: 1 month(s)
Frozen (-20 °C): 6 month(s)

Method: High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

Set-Up Days / TAT: Monday Wednesday Thursday Friday 3 days (after set-up)
CPT Code: 80201

Compound Name / Alias	Units	RL
Topiramate Topamax®	ng/mL	200

Reference Comment
The majority of epileptic patients taking 200 to 400 mg topiramate daily had mean trough serum topiramate concentrations between 2400 and 8000 ng/mL.

The blood to plasma ratio of topiramate varies depending on the concentration, but is typically greater than 2.

122. 52128B Tramadol and Metabolite Confirmation, Blood (Forensic)

Scope of Analysis: O-Desmethyltramadol; Tramadol
Method(s): High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)
Purpose: Confirmation of positive Screen; This test is New York State approved.
Category: Analgesic, Anti-Inflammatory
Specimen Requirements: 1 mL Blood
Minimum Volume: 0.325 mL
Special Handling: None
Specimen Container: Lavender top tube (EDTA)
Transport Temperature: Refrigerated
Light Protection: Not Required

Rejection Criteria: None
Known Interference(s): N/A
Stability: Room Temperature: 14 day(s)
Refrigerated: 14 day(s)
Frozen (-20 °C): 14 day(s)

Method: High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

Set-Up Days / TAT: Monday Wednesday Friday 3 days (after set-up)
CPT Code: 80373

Compound Name / Alias	Units	RL
Tramadol Ultram®; Ultrex®	ng/mL	20
Reference Comment Peak plasma levels following a single 100 mg oral dose: 230 - 380 ng/mL. Steady-state plasma levels following a 100mg 4 times daily regimen: 420 - 770 ng/mL.		
O-Desmethyltramadol Tramadol Metabolite	ng/mL	20
Reference Comment Peak plasma concentration following a single 100 mg oral dose: 35 - 75 ng O-Desmethyltramadol/mL. Steady-state plasma concentration following a 100 mg 4 times daily regimen: 80 - 140 ng O-Desmethyltramadol/mL. The ratio of whole blood concentration to serum or plasma concentration is unknown for this analyte.		

123. 52295B Trazodone Confirmation, Blood (Forensic)

Scope of Analysis: Trazodone
Method(s): Gas Chromatography (GC)
Purpose: Confirmation of positive Screen; This test is New York State approved.
Category: Antidepressant
Specimen Requirements: 2 mL Blood
Minimum Volume: 0.7 mL
Special Handling: None
Specimen Container: Lavender top tube (EDTA)
Transport Temperature: Refrigerated
Light Protection: Not Required
Rejection Criteria: None
Known Interference(s): N/A
Stability: Room Temperature: 14 day(s)
Refrigerated: 14 day(s)
Frozen (-20 °C): 14 day(s)

Method:

Set-Up Days / TAT: N/A
CPT Code: 80362, 80376

Method: Gas Chromatography (GC)

Set-Up Days / TAT: Monday-Friday 3 days (after set-up)

CPT Code: 80338

Compound Name / Alias	Units	RL
Trazodone Desyrel®	mcg/mL	0.2

Reference Comment

Therapeutic range: 0.3 - 1.5 mcg/mL.

124. 52470B Trifluoperazine Confirmation, Blood (Forensic)

Scope of Analysis: Trifluoperazine

Method(s): High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

Purpose: Confirmation of positive Screen; This test is New York State approved.

Category: Antipsychotic (Neuroleptic)

Specimen Requirements: 5 mL Blood

Minimum Volume: 2.1 mL

Special Handling: None

Specimen Container: Lavender top tube (EDTA)

Transport Temperature: Refrigerated

Light Protection: Not Required

Rejection Criteria: None

Known Interference(s): Trifluoperazine [LC-MS/MS]: Trimeprazine, Diclofenac

Stability: Room Temperature: 30 day(s)

Refrigerated: 30 day(s)

Frozen (-20 °C): 30 day(s)

Method: High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

Set-Up Days / TAT: Wednesday 3 days (after set-up)

CPT Code: 80342

Compound Name / Alias	Units	RL
Trifluoperazine Stelazine®	ng/mL	0.2

Reference Comment

Peak plasma concentrations ranging from 0.9 - 4.0 ng/mL were reported three to six hours following a single 20 mg oral dose.

The blood to plasma ratio of trifluoperazine is not known.

Substance(s) known to interfere with the identity and/or quantity of the reported result: Trimeprazine, Diclofenac

125. 52415B Trihexyphenidyl Confirmation, Blood (Forensic)

Scope of Analysis: Trihexyphenidyl

Method(s): Gas Chromatography (GC)

Purpose: Confirmation of positive Screen; This test is New York State approved.

Category: Antiparkinson

Specimen Requirements: 5 mL Blood

Minimum Volume: 2.2 mL

Special Handling: None
Specimen Container: Gray top tube (Sodium Fluoride / Potassium Oxalate)
Transport Temperature: Refrigerated
Light Protection: Not Required
Rejection Criteria: None
Known Interference(s): N/A
Stability: Room Temperature: 7 day(s)
Refrigerated: 14 day(s)
Frozen (-20 °C): 12 month(s)

Method: Gas Chromatography (GC)

Set-Up Days / TAT: Tuesday Friday 3 days (after set-up)
CPT Code: 80375

Compound Name / Alias	Units	RL
Trihexyphenidyl	ng/mL	1.0

126. 52280B Trimipramine and Metabolite Confirmation, Blood (Forensic)

Scope of Analysis: Desmethyltrimipramine; Trimipramine
Method(s): Gas Chromatography (GC)
Purpose: Confirmation of positive Screen; This test is New York State approved.
Category: Antidepressant
Specimen Requirements: 2 mL Blood
Minimum Volume: 0.7 mL
Special Handling: None
Specimen Container: Lavender top tube (EDTA)
Transport Temperature: Refrigerated
Light Protection: Not Required
Rejection Criteria: None
Known Interference(s): N/A
Stability: Room Temperature: 7 day(s)
Refrigerated: 14 day(s)
Frozen (-20 °C): 17 month(s)

Method: Gas Chromatography (GC)

Set-Up Days / TAT: Tuesday Thursday 3 days (after set-up)
CPT Code: 80335

Compound Name / Alias	Units	RL
Trimipramine Surmontil®	ng/mL	20
Reference Comment Observed levels during chronic oral antidepressant doses of 75 to 150 mg/day: 10 - 240 ng/mL.		
Desmethyltrimipramine Trimipramine Metabolite	ng/mL	20
Reference Comment Observed concentrations during chronic antidepressant doses of 75 to 150 mg/day: 3 - 380 ng/mL.		

127. 52297B Triprolidine Confirmation, Blood (Forensic)

Scope of Analysis:	Triprolidine
Method(s):	Gas Chromatography (GC)
Purpose:	Confirmation of positive Screen; This test is New York State approved.
Category:	Antihistamine, Decongestant
Specimen Requirements:	2 mL Blood
Minimum Volume:	0.7 mL
Special Handling:	None
Specimen Container:	Lavender top tube (EDTA)
Transport Temperature:	Refrigerated
Light Protection:	Not Required
Rejection Criteria:	None
Known Interference(s):	N/A
Stability:	Room Temperature: Undetermined
	Refrigerated: Undetermined
	Frozen (-20 °C): Undetermined

Method:

Set-Up Days / TAT: N/A

CPT Code: 80369, 80376

Method: Gas Chromatography (GC)

Set-Up Days / TAT: Tuesday Thursday 3 days (after set-up)

CPT Code: 80375

Compound Name / Alias	Units	RL
Triprolidine Actidil®	ng/mL	60

128. 52428B Vardenafil and Metabolite Confirmation, Blood (Forensic)

Scope of Analysis:	Desethylvardenafil; Vardenafil
Method(s):	High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)
Purpose:	Confirmation of positive Screen; This test is New York State approved.
Category:	Phosphodiesterase #5 Inhibitor
Specimen Requirements:	1 mL Blood
Minimum Volume:	0.4 mL
Special Handling:	None
Specimen Container:	Lavender top tube (EDTA)
Transport Temperature:	Refrigerated
Light Protection:	Not Required
Rejection Criteria:	None
Known Interference(s):	N/A
Stability:	Room Temperature: 14 day(s)
	Refrigerated: 14 day(s)
	Frozen (-20 °C): 14 day(s)

Method: High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

Set-Up Days / TAT: Wednesday 3 days (after set-up)

CPT Code: 80375

Compound Name / Alias	Units	RL
Vardenafil Levitra®	ng/mL	5.0
Reference Comment Following administration of a 20 mg oral dose to 12 healthy males, peak plasma concentrations of 44 (+/- 36) ng/mL were achieved at an average Tmax of 0.75 hours. Vardenafil has a half-life of about 4 hours. The ratio of whole blood concentration to plasma concentration is unknown for this analyte.		
Desethylvardenafil Vardenafil Metabolite	ng/mL	5.0
Reference Comment Following administration of a 20 mg oral dose of vardenafil to 12 healthy males, peak plasma concentrations were 38 (+/- 17) ng/mL at a Tmax of 0.75 hours. The ratio of whole blood concentration to plasma concentration is unknown for this analyte.		

129. 52132B Venlafaxine and Metabolite Confirmation, Blood (Forensic)

Scope of Analysis: O-Desmethylvenlafaxine; Venlafaxine

Method(s): High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

Purpose: Confirmation of positive Screen; This test is New York State approved.

Category: Antidepressant

Specimen Requirements: 1 mL Blood

Minimum Volume: 0.325 mL

Special Handling: None

Specimen Container: NMS Labs has no experimental or literature-based data regarding the choice of specific specimen collection containers for this test.

Transport Temperature: Refrigerated

Light Protection: Not Required

Rejection Criteria: None

Known Interference(s): N/A

Stability: Room Temperature: 14 day(s)

Refrigerated: 14 day(s)

Frozen (-20 °C): 5 month(s)

Method: High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

Set-Up Days / TAT: Monday Wednesday Friday 3 days (after set-up)

CPT Code: 80338

Compound Name / Alias	Units	RL
Venlafaxine Effexor®	ng/mL	20
Reference Comment Steady-state peak plasma levels following a daily regimen occur at 2 hours for Venlafaxine: 35 - 79 ng/mL (75 mg/day), 93 - 334 ng/mL (150 mg/day), 68 - 265 ng/mL (225 mg/day), 196 - 597 ng/mL (450 mg/day). Steady-state trough plasma concentrations following a 150 mg per day regimen: 0 - 141 ng/mL.		

Compound Name / Alias	Units	RL
O-Desmethylvenlafaxine Desvenlafaxine; Pristiq®; Venlafaxine Metabolite	ng/mL	20

Reference Comment

Steady-state peak plasma levels following a daily regimen of Venlafaxine occur at approximately 2.5 hours for O-Desmethylvenlafaxine:
94 - 200 ng/mL (75 mg/day),
85 - 472 ng/mL (150 mg/day),
243 - 515 ng/mL (225 mg/day),
390 - 1096 ng/mL (450 mg/day).

Steady-state trough plasma levels following a 150 mg per day regimen:
65 - 300 ng O-Desmethylvenlafaxine/mL.

130. 52298B Verapamil Confirmation, Blood (Forensic)

Scope of Analysis:	Verapamil
Method(s):	Gas Chromatography (GC)
Purpose:	Confirmation of positive Screen; This test is New York State approved.
Category:	Calcium Channel Blocker
Specimen Requirements:	2 mL Blood
Minimum Volume:	0.7 mL
Special Handling:	None
Specimen Container:	NMS Labs has no experimental or literature-based data regarding the choice of specific specimen collection containers for this test.
Transport Temperature:	Refrigerated
Light Protection:	Not Required
Rejection Criteria:	None
Known Interference(s):	N/A
Stability:	Room Temperature: 14 day(s) Refrigerated: 30 day(s) Frozen (-20 °C): 18 month(s)

Method:

Set-Up Days / TAT: N/A
CPT Code: 80362, 80376

Method: Gas Chromatography (GC)

Set-Up Days / TAT: Monday-Friday 3 days (after set-up)
CPT Code: 80375

Compound Name / Alias	Units	RL
Verapamil Calan®; Isoptin®	ng/mL	20

Reference Comment

Probable therapeutic range: 70 - 350 ng/mL.
Two to three fold greater plasma Verapamil concentrations are required after oral dosing, as compared to I.V. dosing, to elicit the same increase in a-v conduction time.

131. 52135B Xylazine Confirmation, Blood (Forensic)

Scope of Analysis:	Xylazine
Method(s):	Gas Chromatography (GC)
Purpose:	Confirmation of positive Screen; This test is New York State approved.
Category:	Analgesic, Muscle Relaxant
Specimen Requirements:	2 mL Blood
Minimum Volume:	0.45 mL
Special Handling:	None
Specimen Container:	NMS Labs has no experimental or literature-based data regarding the choice of specific specimen collection containers for this test.
Transport Temperature:	Refrigerated
Light Protection:	Not Required
Rejection Criteria:	None
Known Interference(s):	N/A
Stability:	Room Temperature: Undetermined Refrigerated: Undetermined Frozen (-20 °C): Undetermined

Method: Gas Chromatography (GC)

Set-Up Days / TAT: Wednesday 3 days (after set-up)

CPT Code: 80375

Compound Name / Alias	Units	RL
Xylazine Rompun®	mcg/mL	0.4

Reference Comment

No reference data available.

132. 52136B Yohimbine Confirmation, Blood (Forensic)

Scope of Analysis:	Yohimbine
Method(s):	High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)
Purpose:	Confirmation of positive Screen; This test is New York State approved.
Category:	Anti-Impotence Drug
Specimen Requirements:	1 mL Blood
Minimum Volume:	0.5 mL
Special Handling:	None
Specimen Container:	Lavender top tube (EDTA)
Transport Temperature:	Refrigerated
Light Protection:	Not Required
Rejection Criteria:	None
Known Interference(s):	N/A
Stability:	Room Temperature: 30 day(s) Refrigerated: 30 day(s) Frozen (-20 °C): 30 day(s)

Method: High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

Set-Up Days / TAT: Tuesday Thursday 3 days (after set-up)

CPT Code: 80375

Compound Name / Alias	Units	RL
Yohimbine Actibine®; Aphrodyne®; Yocon®; Yohimex®; Yomax®	ng/mL	4.0

Reference Comment

Ten healthy men given a single oral 8 mg dose had average peak plasma concentrations of 37 ng/mL (range, 3.4 - 171) at 1.2 hours, declining with an average elimination half-life of 1.5 hours

133. 52137B Zaleplon Confirmation, Blood (Forensic)

Scope of Analysis:	Zaleplon
Method(s):	High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)
Purpose:	Confirmation of positive Screen; This test is New York State approved.
Category:	Sleep Aid
Specimen Requirements:	1 mL Blood
Minimum Volume:	0.5 mL
Special Handling:	None
Specimen Container:	Lavender top tube (EDTA)
Transport Temperature:	Refrigerated
Light Protection:	Not Required
Rejection Criteria:	None
Known Interference(s):	N/A
Stability:	Room Temperature: 30 day(s) Refrigerated: 30 day(s) Frozen (-20 °C): 30 day(s)

Method: High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

Set-Up Days / TAT:	Tuesday Thursday 3 days (after set-up)
CPT Code:	80368

Compound Name / Alias	Units	RL
Zaleplon Sonata®	ng/mL	4.0

Reference Comment

Zaleplon is a short-acting hypnotic agent used for the treatment of insomnia. Peak plasma levels 1 hour following a single 10 or 20 mg oral dose are 26 and 49 ng/mL, respectively. The drug has an elimination half-life of approximately 1 hour.

134. 52429B Ziprasidone Confirmation, Blood (Forensic)

Scope of Analysis:	Ziprasidone
Method(s):	High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)
Purpose:	Confirmation of positive Screen; This test is New York State approved.
Category:	Antipsychotic
Specimen Requirements:	1 mL Blood
Minimum Volume:	0.4 mL
Special Handling:	None
Specimen Container:	Lavender top tube (EDTA)
Transport Temperature:	Frozen
Light Protection:	Not Required

Rejection Criteria: Received Room Temperature. Received Refrigerated.

Known Interference(s): N/A

Stability: Room Temperature: Not Stable

Refrigerated: Not Stable

Frozen (-20 °C): 30 day(s)

Method: High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

Set-Up Days / TAT: Tuesday 3 days (after set-up)

CPT Code: 80342

Compound Name / Alias	Units	RL
Ziprasidone Geodon®; Zeldox®	ng/mL	2.0

Reference Comment

In clinical trials, the following mean Plasma concentrations (+/- 1 sd) were reported in non-fasting subjects at steady-state:
14.8 +/- 6.7 ng/mL (10 mg/day),
44.6 +/- 48 ng/mL (40 mg/day),
118 +/- 80 ng/mL (80 mg/day),
139 +/- 81 ng/mL (120 mg/day).
Steady-state concentrations occurred 1 to 3 days following initialization of dosing.

135. 52138B Zolazepam Confirmation, Blood (Forensic)

Scope of Analysis: Zolazepam

Method(s): Gas Chromatography (GC)

Purpose: Confirmation of positive Screen; This test is New York State approved.

Category: Hypnotic, Sedative

Specimen Requirements: 2 mL Blood

Minimum Volume: 0.7 mL

Special Handling: None

Specimen Container: NMS Labs has no experimental or literature-based data regarding the choice of specific specimen collection containers for this test.

Transport Temperature: Refrigerated

Light Protection: Not Required

Rejection Criteria: None

Known Interference(s): N/A

Stability: Room Temperature: Undetermined

Refrigerated: Undetermined

Frozen (-20 °C): Undetermined

Method: Gas Chromatography (GC)

Set-Up Days / TAT: Wednesday 3 days (after set-up)

CPT Code: 80368

Compound Name / Alias	Units	RL
Zolazepam Flupyrazapon®	mcg/mL	0.05

Reference Comment

No reference data available.

136. 52139B Zolpidem Confirmation, Blood (Forensic)

Scope of Analysis:	Zolpidem
Method(s):	High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)
Purpose:	Confirmation of positive Screen; This test is New York State approved.
Category:	Hypnotic, Sedative
Specimen Requirements:	1 mL Blood
Minimum Volume:	0.25 mL
Special Handling:	None
Specimen Container:	Lavender top tube (EDTA)
Transport Temperature:	Refrigerated
Light Protection:	Not Required
Rejection Criteria:	None
Known Interference(s):	N/A
Stability:	Room Temperature: 30 day(s) Refrigerated: 30 day(s) Frozen (-20 °C): 30 day(s)

Method: High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

Set-Up Days / TAT: Monday Wednesday Friday 3 days (after set-up)

CPT Code: 80368

Compound Name / Alias	Units	RL
Zolpidem Ambien®	ng/mL	4.0

Reference Comment

Plasma concentrations following single oral 5 mg and 10 mg immediate release doses range from 29 - 110 ng/mL (mean, 59 ng/mL) and 58 - 270 ng/mL (mean, 120 ng/mL), respectively, occurring at a mean time of 1.6 hrs. Peak plasma concentrations following a single oral 12.5 mg extended release dose ranged from 69 - 190 ng/mL (mean = 130 ng/mL) occurring at a mean time of 1.5 hrs.

The ratio of whole blood concentration to serum or plasma concentration is unknown for this analyte.

137. 52140B Zonisamide Confirmation, Blood (Forensic)

Scope of Analysis:	Zonisamide
Method(s):	High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)
Purpose:	Confirmation of positive Screen; This test is New York State approved.
Category:	Anticonvulsant, Antiepileptic
Specimen Requirements:	1 mL Blood
Minimum Volume:	0.25 mL
Special Handling:	None
Specimen Container:	Gray top tube (Sodium Fluoride / Potassium Oxalate)
Transport Temperature:	Refrigerated
Light Protection:	Not Required

Rejection Criteria: None

Known Interference(s): N/A

Stability: Room Temperature: 30 day(s)

Refrigerated: 30 day(s)

Frozen (-20 °C): 24 month(s)

Method: High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

Set-Up Days / TAT: Monday Wednesday Friday 3 days (after set-up)

CPT Code: 80203

Compound Name / Alias	Units	RL
Zonisamide Zonegran®	mcg/mL	0.5

Reference Comment

Antiepileptic range: 10 - 40 mcg/mL.